Tobacco product-derived aldehydes: effects on circulating angiogenic cells & implications for cardiovascular disease. by Lynch, Jordan B.
University of Louisville 
ThinkIR: The University of Louisville's Institutional Repository 
Electronic Theses and Dissertations 
5-2020 
Tobacco product-derived aldehydes: effects on circulating 
angiogenic cells & implications for cardiovascular disease. 
Jordan B. Lynch 
University of Louisville 
Follow this and additional works at: https://ir.library.louisville.edu/etd 
 Part of the Cardiovascular Diseases Commons, Environmental Health Commons, and the Toxicology 
Commons 
Recommended Citation 
Lynch, Jordan B., "Tobacco product-derived aldehydes: effects on circulating angiogenic cells & 
implications for cardiovascular disease." (2020). Electronic Theses and Dissertations. Paper 3395. 
Retrieved from https://ir.library.louisville.edu/etd/3395 
This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's 
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized 
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of 
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu. 
TOBACCO PRODUCT-DERIVED ALDEHYDES: EFFECTS ON CIRCULATING 
ANGIOGENIC CELLS & IMPLICATIONS FOR CARDIOVASCULAR DISEASE 
By 
Jordan B. Lynch 
B.S., McKendree University, 2011 
M.S., Southern Illinois University Edwardsville, 2013 
M.S., University of Louisville, 2016 
A Dissertation 
Submitted to the Faculty of the 
School of Medicine of the University of Louisville 
in Partial Fulfillment of the Requirements 
for the Degree of 
Doctor of Philosophy 
in Pharmacology and Toxicology 
Department of Pharmacology and Toxicology 






TOBACCO PRODUCT-DERIVED ALDEHYDES: EFFECTS ON CIRCULATING 
ANGIOGENIC CELLS & IMPLICATIONS FOR CARDIOVASCULAR DISEASE 
By 
Jordan B. Lynch 
B.S., McKendree University, 2011 
M.S., Southern Illinois University Edwardsville, 2013 
M.S., University of Louisville, 2016 
Dissertation Approved on 
April 17th, 2020 
by the Following Dissertation Committee: 
_____________________________ 
Daniel J. Conklin, Ph.D. 
_____________________________ 
Aruni Bhatnagar, Ph.D., F.A.H.A. 
_____________________________ 
Gary W. Hoyle, Ph.D. 
_____________________________ 
Rachel Keith, Ph.D. 
_____________________________ 





This dissertation is dedicated to Shelby and Lorene Lashley, 




I would like to thank my mentor, Daniel J. Conklin, Ph.D., for all his advice and 
direction during my time in his lab.  I would also like to thank my committee members for 
their insight and assistance.  Additional thanks to Dr. Andrew DeFilippis, Karen Beatty, 
and Jessica Nystoriak for their advice and assistance in the Louisville Healthy Heart study; 
Gregg Shirk, Whitney Theis, and Lexi Hand for assistance with the murine exposures; and 
Dan Riggs for assistance on statistics.  Thanks also to the National Institutes of Health for 
my funding (ES019217, GM127607, HL122676, HL149351, U54HL120163, 
T32ES011564). 
Many thanks also to my fellow students for their assistance in the lab, but more 
importantly, for their friendship and advice during my time here.  In particular, I would 
like to thank Dr. Stacey Konkle, Andre Richardson, and Dr. Lexiao Jin for their 
encouragement and for commiserating with me over the struggles of graduate school. 
I would be remiss if I did not thank my parents, Kevin and Lisa Finch.  I would 
never have made it this far without their unfailing support throughout my entire education 
and especially through these last few years as I worked towards my doctorate.  Their 
examples of dedication and perseverance proved to me that I could succeed, and the fact 
that they rarely complained about having to hear stories about urine collections proved that 
they’re just the best.  And finally, I’d like to thank my husband, Blake, whom I met as a 
result of said urine collections and who has always believed I could do anything I wanted.  
It’s thanks to him that I’ve had the courage and optimism to pursue my dreams. 
v 
ABSTRACT 
TOBACCO PRODUCT-DERIVED ALDEHYDES: EFFECTS ON CIRCULATING 
ANGIOGENIC CELLS & IMPLICATIONS FOR CARDIOVASCULAR DISEASE 
Jordan B. Lynch 
April 17, 2020 
Cardiovascular disease (CVD) is the leading cause of death worldwide.  Tobacco 
smoke is the most significant modifiable risk factor in CVD development and contains 
numerous toxic compounds, including aldehydes, which have been linked to CVD.  
Formaldehyde, acetaldehyde, acrolein, and crotonaldehyde have been identified as 
significant contributors to cigarette-induced health effects, but the mechanism of these 
effects is not well understood.  These aldehydes are also found in aerosols produced by e-
cigarettes (e-cigs).  The goal of this dissertation was to explore the systemic, hematological, 
and endothelium-related effects of exposure to tobacco products and constituent aldehydes 
and to identify potential mechanisms of injury.  In the Louisville Healthy Heart Study, 
hematological measures and circulating angiogenic cells (CACs) were assessed against 
tobacco product use categories.  In murine studies, male and female C57BL/6J, transient 
receptor potential ankyrin 1 (TRPA1)-null, and/or extracellular superoxide dismutase-
transgenic (ecSOD-Tg) mice were exposed to mainstream cigarette smoke (MCS), e-cig 
aerosol, humectants, or constituent aldehydes for varying durations and concentrations.  
Hematological measures, plasma biomarkers, and levels of CACs were assessed.  Chapter 
III of this dissertation describes findings from the Louisville Healthy Heart Study.  E-cig
vi 
or dual users showed significantly increased levels of leukocytes and of CAC-3, an early 
endothelial progenitor cell population, compared with never smokers.  Chapter IV 
describes systemic and vascular changes induced by exposure to MCS, e-cig aerosol, or 
humectants, finding significant decreases in leukocytes after all exposures and decreases 
in CACs in female mice exposed to JUUL Mango aerosol.  Chapter V describes effects of 
exposure to formaldehyde and acetaldehyde, finding that formaldehyde induces significant 
hematological and vascular changes.  Chapter VI describes effects of exposure to acrolein 
and crotonaldehyde, presenting novel evidence implicating chronic crotonaldehyde 
exposure as a risk factor for CVD.  Finally, chapter VII explores the roles of ecSOD and 
TRPA1 in tobacco product-related CVD, demonstrating that the effects of unsaturated 
aldehydes are mediated by TRPA1.  This dissertation presents novel data investigating 
associations between CACs and e-cigs in a human cohort, examining the role of tobacco 
products and individual constituent aldehydes in the development of CVD, and 
demonstrating the role of TRPA1 in the CVD effects related to tobacco products.
vii 
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A. Background and Rational 
1. Cardiovascular Disease and Air Pollution
Cardiovascular disease (CVD) is the leading cause of death both nationally (1) and 
globally (2).  In 2016, the World Health Organization reported that approximately 27% of 
the 56.9 million deaths worldwide were due to ischemic heart disease and stroke; these 
diseases have been the leading causes of death globally for the last 20 years (2).  In the 
United States, the American Heart Association reports that approximately 1 of every 3 
deaths is due to CVD, with about 2,300 daily deaths related to some form of CVD (1).  On 
a local level, between 2014-2016, Kentucky had a CVD mortality rate of 258.5 per 100,000 
people, exceeding the national CVD mortality rate of 220.7 per 100,000 people by 
approximately 17% and ranking the state as the fifth highest in the nation for CVD 
mortality (1).  The American Heart Association projects that CVD prevalence will continue 
to increase, with approximately 45.1% of the United States population expected to have 
some form of CVD by 2035 (1).  In terms of cost, the average annual direct and indirect 
cost of CVD-related care in the United States in 2014 to 2015 was $351,200,000,000, an 
amount which accounted for 14% of the total health expenditures for the county in that
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year (1).  As CVD prevalence increases, the cost of CVD-related health care is also 
expected to increase, with estimates of total direct CVD-related costs of approximately
$749,000,000,000 per year by 2035 (1). 
Although there are many risk factors for the development of CVD (3), a better 
understanding of the relationship between environmental factors and health outcomes has 
led to the hypothesis that environmental exposures to air pollutants contribute to CVD 
development.  Over the past 30 years, a number of clinical and epidemiological studies 
have established the damaging effects of air pollution on human health.  The majority of 
this damage is found in the pulmonary and cardiovascular systems, leading to an increased 
risk of heart disease or stroke (4-13).  Many of these health effects are linked to different 
forms of air pollution, including ambient air pollution and diesel and gasoline engine 
exhausts.  Ambient air pollution is composed of a gaseous suspension of aerosolized 
particles, known as particulate matter (PM), that typically have an aerodynamic diameter 
<10 µm (14, 15); this range is classified into specific particle sizes: ultrafine (<0.1 µm), 
fine (PM2.5, 0.1-2.5 µm), and coarse (PM10, >2.5-10 µm).  General exposure to ambient air 
pollution has been shown to be a significant trigger for heart attacks (4), and there is strong 
evidence linking increased levels of PM2.5 with increased cardiovascular effects (15-17).  
A 10 µg/m3 increase in PM2.5 levels is associated with an increased risk of heart failure 
hospitalization (18) and with long-term all-cause mortality (5-9). 
Additional studies of specific types of air pollutants further strengthen the link 
between exposure and cardiovascular events.  PM2.5 exposure significantly increases left 
ventricular mass (10) and systolic (11, 19, 20) and mean ambulatory arterial (21) blood 
pressures.  Changes in PM2.5 are associated with the onset of heart attacks (22) and 
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increased intima media thickness progression (12, 13), with accelerated carotid intima 
media thickness (CIMT) progression of up to 5.5 µm (per 10 µg/m3) per year (23).  
Similarly, exposure to diesel exhaust and traffic-related pollution increases arterial 
stiffness (24) and systolic blood pressure (25) and is associated with both increased 
mortality hazard ratio and increased risk of dying after hospital discharge (26).  
Collectively, these pathogenic changes (e.g., increased CIMT, increased blood pressure) 
suggest that an underlying vascular alteration or dysfunction is responsible, and thus, there 
is a need to explore mechanisms consistent with these vascular manifestations.   
Brook et al. (16) propose three likely mechanisms by which air pollutants may 
contribute to the development of CVD: 1) an imbalance in the autonomic nervous system; 
2) translocation of particles, specifically ultrafine particulate matter, into the circulation; 
and, 3) the development of systemic oxidative stress and inflammation within the 
vasculature.  These hypothetical pathways are generally accepted (17, 21, 24, 27-32).  A 
primary outcome of each of these mechanisms is the initiation of endothelium dysfunction, 
which appears central (perhaps as a result of or in combination with oxidative stress and 
inflammation) to further development of CVD.  Evidence suggests a strong association 
between endothelium dysfunction and cardiovascular events, leading to high morbidity and 
mortality from CVD (33) as well as other disease states (34-39).  Nonetheless, more 
research is required in order to ultimately improve pollutant-related health outcomes.  
Based on the health and financial burden of CVD, it is necessary from medical, legislative, 
and economic standpoints to continue working towards decreased air pollutant exposures 
in an effort to collectively reduce morbidity and mortality and to reveal the biological 
mechanism(s) by which air pollutants cause and/or exacerbate CVD. 
4 
 
2. Reactive Oxygen Species 
 Oxidative stress as proposed by Brook et al. (16) is the result of excessive 
production of reactive oxygen species (ROS) (40-42).  ROS are oxygen-containing, highly 
reactive molecules, many of which are endogenously produced by normal cellular 
metabolism (42, 43).  At normal levels, ROS have been shown to have a number of 
beneficial aspects, serving as signaling molecules (43, 44) and playing roles in gene 
expression, cell growth, and apoptosis (42, 43).  However, stressors such as pollutants or 
toxicants can lead to increased production of ROS (32, 45, 46), overcoming the body’s 
ability to clear these oxidizing compounds and leading to the development of oxidative 
stress (40-42, 44, 47).  Increased ROS and the resulting oxidative stress have been linked 
to a number of negative health outcomes (42, 47, 48), including CVD (42, 48-52). 
Increased ROS and oxidative stress have been linked to downstream health 
outcomes via changes in the production and bioavailability of nitric oxide (NO), a potent 
vasodilator (40-42, 49).  Excess levels of the anion superoxide in particular have been 
directly implicated in disease development via the development of endothelium 
dysfunction (40-42).  These excess levels can occur when superoxide dismutase (SOD), 
the antioxidant enzyme that catalyzes the dismutation of superoxide, is inactivated or 
mutated (53).  The free superoxide molecule can then bind with NO to form peroxynitrite, 
a powerful oxidant that can subsequently cause dysfunction of endothelial nitric oxide 
synthase (eNOS), one of the enzymes responsible for synthesizing NO (40, 41, 49, 50).  By 
disrupting eNOS function, NO levels are further decreased, leading to an imbalance in the 
vasoactive factors in the vasculature and resulting in endothelium dysfunction (40, 41).  
This dysfunction has been noted as one of the earliest vascular changes in a number of 
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disease states, including atherosclerosis (54-56) and both systemic (57) and pulmonary (58) 
hypertension.  Although a number of therapeutic strategies specifically targeting the 
production of ROS and the development of endothelium dysfunction have been developed 
for the treatment of CVD (59-61), the relationship between these endothelial and vascular 
changes and downstream disease development is complex, and more research is needed to 
fully understand these connections. 
3. Circulating Angiogenic Cells 
Once endothelium dysfunction develops, repair is at least partially mediated by 
circulating angiogenic cells (CACs) (62, 63).  CACs are sensitive indicators of both 
vascular health and pollution exposure, and they play an important role in proper 
endothelial function and overall endothelial health (63-66).  These cells are recruited from 
the bone marrow to sites of endothelial damage where they contribute to repair of the 
vasculature (62, 67-69).  Vasa et al. (70) found that the number of atherosclerotic risk 
factors, such as hypertension, diabetes, and hypercholesterolemia, was inversely correlated 
with CAC levels and CAC function.  Similarly, Hill et al. (66) demonstrated a strong 
correlation between an individual’s Framingham Risk Score, the 10-year risk score for 
nonfatal heart attack or sudden cardiac death, and their CAC levels, with higher risk scores 
associated with diminished CAC levels.  Furthermore, the group showed a significant 
relationship between endothelial function as measured by flow-mediated brachial 
reactivity and CACs (66). 
Based on these results, Hill et al. concluded that CACs were a better predictor of 
vascular reactivity than the presence or absence of conventional risk factors and that CACs 
may serve as a surrogate biologic marker for vascular function and cumulative 
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cardiovascular risk (66).  This concept has been evaluated in a number of studies examining 
the relationship between CVD and air pollution.  Consistent with Hill’s theory, these 
studies show that exposure to air pollution causes a decrease in CAC levels that correlates 
with an increased CVD risk (67, 71-74).  Therefore, it is imperative for any research 
concerning CVD and air pollution to assess CAC levels and function in relation to 
endothelium dysfunction and as an indicator of vascular homeostasis. 
4. Tobacco Smoke and Cardiovascular Disease 
It is also important to consider personal sources of pollutant exposures when 
conducting CVD research.  While some level of exposure to ambient air pollution is 
inevitable (4), exposure to indoor air pollutants can be controlled to a degree; one indoor 
air pollutant that is of particular health concern is tobacco smoke.  Tobacco smoke is the 
most significant modifiable risk factor in the development of CVD (1, 14, 75-77).  
Cigarettes contains numerous toxic compounds, many of which could contribute to disease 
development (30, 78-82).  The Centers for Disease Control and Prevention (CDC) reports 
that although cigarette use has been declining for a number of years, reaching an all-time 
low of 13.7% in 2018 (83), tobacco use still remains the leading cause of preventable death 
both globally and nationally, with overall mortality for American smokers three times that 
of their fellow non-smokers (1).  Furthermore, secondhand smoke (SHS) has also been 
shown to cause a large number of negative health effects.  The CDC reports that since 
1964, approximately two and a half million nonsmokers have died from health problems 
caused by exposure to SHS (84).  The Surgeon General’s report estimates more than 33,000 
nonsmokers die every year in the United States from coronary heart disease caused by 
exposure to SHS (80).  It has also been shown that SHS exposure can cause heart attacks 
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and strokes in nonsmokers (80, 84), and a variety of health consequences in both children 
and adults have been linked to SHS exposure as well, including cardiovascular, respiratory, 
and reproductive effects (80, 84).  Much as with ambient air pollutant exposure, the 
development of oxidative stress and endothelium dysfunction likely contributes to this 
disease development, as both mainstream cigarette smoke (MCS) (85, 86) and SHS (87, 
88) exposures have been linked to increased production of ROS.   
5. Aldehydes 
Aldehydes, one class of compounds known as volatile organic compounds (VOCs), 
are compounds with a terminal carbonyl group (-CHO), and they can be classified as 
saturated, unsaturated, or aromatic.  Unsaturated aldehydes contain one or more carbon-
carbon double bond, which increase their reactivity compared with saturated aldehydes 
(89).  These compounds are generally ubiquitous in the natural environment, and many are 
found in foods and drinks, including meats, cheeses, fried foods, bread, and beer and other 
alcohols (90).  However, the majority of environmental aldehydes are generated from 
anthropogenic sources, including combustion sources (e.g., diesel and gasoline exhaust, 
industrial emissions, MCS, and SHS) and also various consumer products and building 
materials that leach aldehydes (90).  Additionally, as they have been linked to a number of 
negative health effects (91-94), aldehydes from both ambient and personal exposure 
sources (e.g., MCS, SHS, occupational exposures, personal hobby exposures) present 
potential health risks.  Because of their pervasiveness and their documented toxicity, four 
specific aldehydes have been identified as significant contributors to disease risk and 
development: formaldehyde, acetaldehyde, acrolein, and crotonaldehyde. 
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a. Formaldehyde and Acetaldehyde 
The cigarette- and pollutant-related development of CVD may in part be 
attributable to saturated aldehydes such as formaldehyde (FR) and acetaldehyde (AA).  
Both of these aldehydes have been officially established by the United States Food and 
Drug Administration as harmful constituents in tobacco products and tobacco smoke, with 
FR listed as a respiratory toxicant and a carcinogen and AA listed as a carcinogen, a 
respiratory toxicant, and an addictive component (82, 93, 95).  Furthermore, the Institute 
of Medicine ranked AA and FR as two of the most significant toxins in tobacco smoke in 
relation to CVD (96).  There is some level of natural exposure to both of these products, 
both exogenously and endogenously.  FR, the smallest aldehyde, is naturally produced in 
the cells of humans and other mammals by amino acids and via the demethylation of 
various endogenous metabolites (93, 97, 98).  It is swiftly degraded via FR dehydrogenase 
and S-formylglutathione hydrolase to form formic acid (93, 97, 99) and does not therefore 
accumulate in the blood, with a half-life of approximately 1.5 minutes (99, 100), 
contributing to a basal concentration of 2-3 mg/L (93, 97, 99).  In terms of exogenous 
sources, FR is released as a combustion product, both of biomass (101) and fuel (102, 103).  
Combustion accounts for the majority of FR released in the environment (102).  FR is also 
used in many consumer products, including carpets, manufactured wood products, paints 
and varnishes, and preservatives, which may lead to increased exposure (102).  However, 
levels of FR in the air are typically low, (100, 102, 104), with natural concentrations less 
than 1 µg/m3 (93, 99), although some variation is seen between rural, suburban, and urban 
locations (93, 99, 102).   
AA, the second smallest aldehyde, is pervasive in the ambient environment and is 
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widely used in different industries as an intermediate in the production of other chemicals 
(105, 106).  It is produced due to the incomplete combustion of wood from both personal 
and industrial use (105, 106), and it is also naturally found in dairy, meats, and plants 
commonly consumed by humans (105).  Alcohol consumption is another common source 
of exposure (105, 106), as AA is formed from the breakdown of ethanol via alcohol 
dehydrogenases.  The concentration in ambient air is typically between 5 and 10 µg/m3 
(92, 107).  Like FR, AA has a short half-life in the blood—again, approximately 90 seconds 
(108, 109)—and does not typically accumulate in the blood; Lynch et al. report the 
concentration of AA in the whole blood of fasted subjects to be less than 0.1 mg/L (110). 
Although some exposure to both FR and AA is common for all individuals, those 
exposed to MCS or SHS are exposed to much higher levels of these compounds, greatly 
increasing their risk of morbidity and mortality (92, 93, 95, 99, 111-113).  The World 
Health Organization reports that, on average, a person is naturally exposed to 
approximately 1 mg of FR per day; smoking 20 cigarettes per day will increase that 
exposure, raising levels of inhaled FR by an additional 0.9-2.0 mg/day (99).  Direct analysis 
of MCS has measured levels of FR between 12-29 µg/cigarette (114-117), and additional 
exposure from SHS can increase FR exposure by 0.2-3.5 mg/day taking into account 
exposure possible in both the workplace and at home (99).   
Typical exposure to AA, although ubiquitous, occurs via food intake, particularly 
alcohol consumption (105-107).  Therefore, any significant level of exposure via inhalation 
can significantly increase overall exposure, and tobacco smoke is one of the most common 
modifiable forms of exposure to AA (107, 118).  Based on the mean ambient 
concentrations of AA in both indoor and outdoor environments,  Bruinen de Bruin et al. 
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(107) estimate that an individual is exposed to 0.321 mg of AA a day.  The current literature 
repots a range of AA within cigarettes, but most data suggest between 0.5-3 mg/cigarette 
(107, 109, 114, 117, 118).  Based on 2016 data showing that American daily smokers 
consume an average of 14 cigarettes per day—a level that is down from the estimated 17 
cigarettes per day in 2005—this increases the average smoker’s exposure to AA by 7-42 
mg/day (119).  Exposure to AA via SHS may be equivalent or even greater than that from 
MCS (107, 118), with reported levels ranging from 2-3 mg/cigarette (107). 
Some cardiovascular and hematopoietic effects of FR or AA exposure are 
documented, but there remain questions regarding the mechanisms through which these 
aldehydes cause cardiovascular effects.  Exposure to FR has been shown to cause 
hematotoxicity, significantly decreasing total leukocyte count (93, 120-122) as well as 
platelets and red blood cell counts (93, 120, 122).  Progenitor cell lines were additionally 
seen to be decreased with exposure (120, 122).  FR has also been shown to cause decreases 
in blood pressure; in rats, inhalation of formalin, a saturated solution of FR in water, 
produced a significant drop in arterial blood pressure (123), and in vitro studies also note 
a concentration-dependent relaxation in response to FR (124-127).  Hypotension has also 
been noted in individuals who have attempted suicide via ingestion of FR (128).  
Furthermore, occupational exposures in industries associated with increased exposure to 
FR (embalmers, undertakers, perfumery workers) have been associated with increased 
incidence of heart disease (129-131).   
Human studies of the cardiovascular effects of AA typically revolve around 
aldehyde dehydrogenase (ALDH2), the fast-acting enzyme that metabolizes AA, and 
specifically the mutation in the enzyme that prevents AA metabolism and allows for 
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increased blood levels of AA (132).  This mutation is present in 35-45% of Asians and 
causes facial flushing and nausea after alcohol consumption, presumably due to high levels 
of AA in the blood (133).  The resulting increase in AA has been linked to several negative 
cardiovascular outcomes, including increased risk of hypertension (134, 135), coronary 
heart disease (136, 137), and heart attack (136), as well as alterations in heart rhythm (132, 
138) and overall cardiac toxicity (132, 135).  Other studies have observed that prolonged 
exposure to AA can cause decreases in both leukocytes and red blood cells (139), and the 
formation of hemoglobin-AA adducts decreases the amount of free hemoglobin available 
in the blood, which could contribute to anemia (139-142). 
b. Acrolein 
Unsaturated aldehydes, aldehydes that contain at least one carbon-carbon double 
bond, have also been linked to the development of CVD (71, 74, 86, 143-145).  Unsaturated 
aldehydes are more reactive than their saturated counterparts as a result of the polarization 
of their carbon-carbon double bond by the aldehyde group, which increases the potential 
for nucleophilic addition (146).  One unsaturated aldehyde that has been extensively 
researched is acrolein.  Acrolein is a combustion air pollutant associated with tobacco 
smoke, vehicular exhaust, open fires, and industrial emissions (94).  Although acrolein can 
be found in the environment, levels are typically low, and the highly reactive nature of the 
compound gives acrolein a half-life of roughly one day (94).  Exposure more commonly 
occurs via ingestion of foods such as beer, cheese, bread, coffee, and fried or burnt foods, 
and some level of endogenous production of acrolein occurs via lipid peroxidation (94).  
Although both ambient and indoor levels of acrolein are typically low, ranging between <1 
and 12 ppb, indoor levels can become significantly increased by tobacco smoke.  MCS is 
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known to be a significant source of acrolein, with between 18-98 µg/cigarette or 50-70 ppm 
of acrolein generated per puff in MCS (90, 114, 117, 147); this level is significantly higher 
than the 4-8 ppm generated by exhaust from gasoline and diesel engines (148).   
The Agency for Toxic Substances and Disease Registry classifies acrolein as an 
eye, nose, skin, and respiratory irritant, and the United States Department of Health and 
Human Services notes that acrolein may be a possible human carcinogen (94).  Acrolein 
has been shown to also contribute to the development of CVD.  Haussmann (145) reports 
that almost 90% of the non-cancer health risk associated with smoking, particularly the risk 
of cardiovascular and pulmonary diseases, is thought to be due to acrolein, and Stabbert et 
al. (149) have shown that the majority of the cytotoxicity related to the gas vapor phase 
constituents of MCS is due to acrolein.  Furthermore, exposure to acrolein has been linked 
to increases in CVD risk in both humans and mice (71, 74, 150-153); inhalation of acrolein 
even at levels low enough to not induce a respiratory response showed changes in cardiac 
performance (154).  Inhalation of acrolein has also been shown to cause endothelium 
dysfunction in mice (150) and to decrease levels of CACs in both humans (71) and murine 
models (74, 151), while ingestion of acrolein promotes pro-atherosclerotic changes (152, 
153). 
c. Crotonaldehyde 
Crotonaldehyde (CR) is another unsaturated aldehyde found in high levels in MCS 
and linked to CVD.  CR is found in many foodstuffs, including meat, fruits, vegetables, 
milk, and bread (155, 156), and there is some endogenous production of CR via lipid 
peroxidation and the metabolism of 1,3-butadiene (157).  However, most exposure to CR 
occurs through anthropogenic sources such as industry emissions, engine exhaust, wood 
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smoke, and tobacco smoke (155-157).  Because CR is a ubiquitous compound, low levels 
of exposure via ingestion or inhalation are expected on a day-to-day basis (158), but most 
exposure occurs via cigarette smoke (156, 159).  The concentration of CR in MCS is 
estimated to be between 1-53 µg/cigarette, although this level may vary somewhat based 
on the type of cigarette (160).  However, a recent study by Jaccard et al. (117) reported a 
CR yield of approximately 10 µg/cigarette in 3R4F Kentucky reference cigarettes, which 
are commonly used as standard cigarettes for non-clinical tobacco research (161). 
CR, like acrolein, is classified as an eye, nose, skin, and respiratory irritant, and 
inhalation of even low levels of CR has been reported to cause extreme respiratory irritation 
(157).  The United States Environmental Protection Agency further classifies CR as a 
possible human carcinogen (162).  Additionally, CR has been linked to the production of 
oxidative stress (163, 164), the dysfunction of cardiomyocyte contractility (164), and the 
development of atherosclerosis in African-American men occupationally exposed to 1,3-
butadiene, the parent compound of CR (165, 166).  Similarly, inhalation of 1,3-butadiene 
was shown to accelerate the development of arteriosclerotic lesions in cockerels (167).  
However, despite these findings and despite the physical and chemical similarities between 
CR and acrolein, more research is needed to further elucidate the role of CR in the 
development of CVD. 
6. Electronic Cigarettes 
A recent report by the CDC found that smoking rates among American adults were 
down to 13.7% in 2018, an all-time low set by the continuing decline in smoking rates over 
the past few decades (83).  However, a new class of nicotine-delivery devices has recently 
been introduced, giving traditional tobacco users a new route for their nicotine 
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consumption.  Electronic nicotine delivery systems (ENDS) deliver an inhalable aerosol 
created by heating a solution known as an e-liquid.  Liquids in ENDS are composed of a 
humectant such as propylene glycol (PG) and/or vegetable glycerin (VG) and typically 
contain nicotine (168-171); many users also use flavor additives (96, 172-174).  The most 
commonly used ENDS are electronic cigarettes (e-cigs) (173, 175-177).  Although the first 
patent for a smokeless non-tobacco cigarette was first filed in the United States in 1965 
(178), e-cigs did not become widely available until the early 2000s (173).  E-cigs are simply 
designed, consisting of a battery, a cartridge to contain the e-liquid, and a heating element 
to vaporize the e-liquid and produce the aerosol (96, 173, 175, 179).  Different generations 
of e-cigs vary somewhat in appearance, but these basic elements are all still present (175, 
180). 
Usage of ENDS devices has increased dramatically over the past several years, with 
a significant rise in the use of e-cigs.  The 2018 National Health Interview Survey estimated 
that 49.1 million American adults used any tobacco product, with approximately of 3.2% 
(8.1 million) of individuals reporting use of a tobacco product other than traditional 
cigarettes reporting use of e-cigs (83).  Among total tobacco product users, 42.6% reported 
daily use of e-cigs, and of the 9.3 million current dual-use tobacco product users, more than 
30% report using both traditional cigarettes and e-cigs (83).  In another national sampling 
of adults in the United States, 84.5% of e-cig users reported usage as a smoking cessation 
tool or a healthier alternative (181).  Because the long-term health effects of e-cigs are still 
unknown, the increased use of e-cigs among adults may beget worrisome health conditions 
in the future, but more alarming is the trend in e-cig use among youth.  E-cigs have been 
the most commonly used tobacco product among American middle (grades 6-8) and high 
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school (grades 9-12) students since 2014 (182).  The 2018 National Youth Tobacco Survey 
estimated that 20.8% of high school students and 4.9% of middle school students were 
current e-cig users, with current use defined as usage on one or more day(s) during the past 
month, with exclusive use of e-cigs reported by 42.0% and 42.7% of high school and 
middle school students e-cig users, respectively (182).  Further analysis of these data 
showed that although there was no significant change in use of any tobacco product overall 
among high school and middle school students during 2011-2018, there were significant 
nonlinear increases in e-cig use specifically among both age groups (182); a 77.8% increase 
among high school students and a 48.5% increase among middle school students were 
reported in 2017-2018 alone despite no other significant changes in the use of other tobacco 
products occurring during this time period (182).  The 2019 National Youth Tobacco 
Survey showed that usage has further increased, with an estimated 27.5% of high school 
students and 10.5% of middle school students reporting current use of e-cigs, with the 
majority of e-cig only users using flavored e-cigs (183). 
As previously mentioned, e-cig use is commonly cited as a means of smoking 
cessation or as a healthier alternative to traditional tobacco smoking (173-175, 177, 181, 
184).  This latter claim is largely due to the fact that e-cigs do not contain actual tobacco 
leaf, nor does their use involve combustion (175, 180).  However, the true health effects of 
these devices are currently unknown.  Early studies of the health effects of e-cigs have 
shown increased reports of cracked teeth and tongue and/or inside-cheek pain in adolescent 
e-cig users (185), increased reports of dry mouth, sore throat, and acute cough in never-
smokers and of acute cough in smokers with and without a history of respiratory disease 
(186), significantly increased airway resistance (187, 188), and impaired mesenchymal 
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stem cell differentiation (189).  Studies in humans have also shown increases in markers 
of oxidative stress after vaping (190, 191), and levels of ROS have been measured in e-cig 
aerosol (192).   
In mice, a two week exposure to e-cigs significantly increased levels of oxidative 
stress and impaired pulmonary anti-microbial defenses, leading to enhanced influenza A-
induced illness and mortality (174).  A similarly impaired pulmonary response to an 
infectious challenge was seen in mice exposed for four months to 60%:40% PG:VG alone 
(193).  Other studies in mice link chronic e-cig exposure with aortic stiffness and impaired 
aortic endothelial function in female C57BL/6 mice (194) and to cardiac dysfunction, 
atherosclerotic development, and increased oxidative stress in apolipoprotein-E knockout 
mice (195).  In rats, acute exposure to e-cig aerosol from either a JUUL device or from an 
earlier generation e-cig showed impaired endothelium function as measured by flow 
mediated dilation in both males and females (196).  Furthermore, female rats exposed to e-
cigs during pregnancy show decreased circulation in both the maternal uterine and fetal 
umbilical cords, indicating potential development of negative health effects in the next 
generation related to maternal e-cig use while pregnant, an outcome similar to that seen 
with the use of traditional cigarettes during pregnancy (197). 
More studies have focused on the potential toxicity of the components within the 
aerosol produced by e-cigs.  These analyses have revealed that the aerosol, like MCS, 
contains many harmful or potentially harmful components, including particulates (184, 
198-202), metals (184, 203-205), and VOCs, including many aldehydes, (199, 201, 206-
208), although possibly at lower levels than found in traditional cigarette smoke.  Specific 
aldehydes, including FR, AA, and acrolein, have also been detected in e-cig aerosol (96, 
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180, 207-213).  PG and VG, whether individually or together, have been shown to be 
responsible for some of this aldehyde generation (168, 214-216).  Generated levels of 
unsaturated aldehydes, however, are much lower than those found in MCS and much lower 
compared with generated levels of saturated aldehydes, with CR showing little if any 
generation in different e-cig flavorings and humectants (96, 168).   
However, the flavorings themselves could also be contributing to negative health 
outcomes, a concern on its own but even more so as most youths report using flavored e-
cigs (183).  In 2014, Zhu et al. (217) reported that there were at least 7,764 unique flavors 
of e-cig liquids sold by 466 distinct e-cig brands.  This number has grown as the popularity 
of e-cigs has increased and as individuals have begun creating and using their own flavors.  
This wide variety of flavors may pose a health risk that is only beginning to be recognized.  
Many of the flavorings used to make flavored e-cig liquids come from food flavorings that 
are deemed by the Flavor and Extract Manufacturers Association as safe for ingestion but 
not necessarily for inhalation (218).  Historically, the inhalation of aerosolized diacetyl, a 
flavoring that had been evaluated as safe for ingestion, lead to the development of 
bronchiolitis obliterans in a number of microwave popcorn production plant workers (219), 
and many in the healthcare industry are fearful of the development of similar pulmonary 
diseases in response to the use of flavored e-cig liquids (220-223).   
These fears seem to be founded, as, over the past year, a number of lung injury 
cases have been associated with e-cig use (224-230).  The CDC reports that as of February 
18, 2020, (the date of the last online update) more than 2,800 cases of e-cigarette, or vaping, 
product use associated lung injury (EVALI) have been reported from all 50 states, the 
District of Columbia, and 2 U.S. territories, and 68 EVALI deaths have been confirmed 
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(230).  Of the admitted patients, approximately 76% are under the age of 35, with 15% 
aged under 18 years old (230), the age group most likely to be using e-cigs based on the 
appeal of the flavors rather than as a cessation aid (231, 232).  Vitamin E acetate, a 
thickening agent used in many tetrahydrocannabinol (THC)-containing e-cig liquids, has 
been identified as the primary cause of EVALI (225, 230, 233), and many states have taken 
steps to prevent further e-cig-related illnesses, especially among youths, by placing 
temporary statewide bans on all or some flavored e-cigs and other ENDS (234-240).   
In terms of cardiovascular outcomes, early studies of flavorings in endothelial cell 
lines have shown that flavors can pose a cardiovascular health threat through the 
development of endothelium dysfunction (241, 242), but more research is needed to better 
clarify the vascular toxicities that may be induced by e-cigs.  There is also a need to 
determine how the presence of nicotine in these devices may contribute to adverse health 
effects.  The cardiovascular effects of nicotine have been studied extensively in relation to 
traditional cigarettes, showing increased heart rate (243-245), blood pressure (243, 244, 
246, 247), platelet aggregation (248, 249), and atherosclerotic development (250, 251).  
However, the amount of nicotine in e-liquids can vary substantially (252-255), which could 
have an impact on the use of e-cig devices as a harm reduction or cessation tool for 
traditional smokers and on new use from never-smoking individuals, particularly 
adolescents (256-259) 
Regardless, it is clear that e-cigs are contributing to the development of disease in 
individuals with an otherwise low risk of disease, and although the specific cause of these 
illnesses has yet to be definitively identified, it is possible that the presence of saturated 
and unsaturated aldehydes, either alone or in combination with other constituents, in e-cig 
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aerosol may be contributing to the growing health threat posed by these devices. 
7. Transient Receptor Potential Ankyrin 1 Channel 
Unsaturated aldehydes such as acrolein have been shown to work through 
activation of the transient receptor potential ankyrin 1 (TRPA1) channel.  The TRPA1 
channel is a member of the TRP superfamily of cation channels and the only member of 
the ankyrin subfamily (260).  TRPA1 is a non-selective cation (calcium) channel and 
promiscuous sensory receptor concentrated in sensory fibers that mediates pain 
reception/transmission as well as irritant-related pulmonary reflexes including cough, 
respiratory braking (slowing rate and depth of breathing), and bronchoconstriction (261).  
TRPA1 has been shown to be activated by a number of stimuli, including temperature (260, 
262), pressure (262), and ROS (263-266), as well as by noxious compounds including 
diesel exhaust (267), cigarette smoke (261), acrolein (260, 262, 268, 269), cinnamaldehyde 
(260, 262, 266, 268, 270), and FR (127).  The activation of the channel by the unsaturated 
aldehydes or compounds containing these aldehydes is proposed to occur through aldehyde 
conjugation with the TRPA1 N-terminal free cysteines (271). 
Although TRPA1 was initially identified in sensory neurons (272), the channel has 
since been found in non-neuronal locations, including the endothelium (260, 263, 270, 
272), urothelium (273, 274), vasculature (275, 276), and heart (277, 278).  TRPA1 is 
known to primarily play a role in inflammatory and pain responses, likely through the 
release of vasoactive peptides such as substance P and calcitonin gene-related peptide that 
increase blood flow, vascular permeability, and leukocyte binding—a collective process 
referred to as ‘neurogenic inflammation’ (262, 272, 279-285).  TRPA1 is also important in 
respiratory irritant responses (262, 279, 280, 286-288), and some studies have shown that 
20 
 
the channel helps mediate vasodilation though calcium influx (127, 265, 266, 270, 272, 
275).  Despite data showing that the negative cardiovascular effects of inhaled acrolein are 
TRPA1-dependent (261, 269, 289, 290), the role of TRPA1 in potential cardiovascular 
toxicity of other aldehydes and mixtures (e-cig aerosol) is not well known. 
8. Statement of Goals 
Early studies of e-cig aerosol exposure have shown the development of 
endothelium dysfunction similar to that seen with tobacco smoke.  Many of these studies 
hypothesize that this dysfunction is related to shared constituents between MCS and e-cig 
aerosols, including acrolein, FR, and AA. Although previous research has linked acrolein 
with cardiovascular toxicity in both humans and mice, the effects of other aldehydes on 
endothelium function and repair are unknown.  Therefore, the objective of this project is 
to evaluate the mechanism of tobacco product-induced CVD via the development of 
endothelium-related changes, as well as systemic and hematological effects.   
B. AIMS AND PROPOSALS 
1. Measure hematological and endothelium-related changes in humans in 
response to tobacco-product related pollutant exposures.   
Both ambient and personal air pollutant exposures have been linked to decreased 
CAC levels in humans, but the health outcomes vary with different forms and durations of 
exposure.  Thus, we will examine the response of CACs and other biomarkers of 
hematological change to personal exposures (tobacco use, e-cig use, dual product use) in a 
low to medium-risk heart disease human cohort.  Measures of urinary metabolites will also 
be measured to determine whether VOCs found in MCS are generated in similar levels in 
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e-cigs and to establish the potential cardiovascular health risk of these compounds. 
2. Measure systemic, hematological, and endothelium-related changes in 
mice in response to tobacco products and constituent aldehydes. 
Exposures to both tobacco smoke and e-cig aerosol have been linked to the 
development of endothelium dysfunction and downstream CVD.  Using C57BL/6J (wild 
type, WT) male mice, we will measure concentration- and duration-dependent changes in 
CACs and other hematological biomarkers as well as markers of systemic change 
following exposure to MCS, e-cig aerosol, and aldehydes (FR, AA, acrolein, and CR) 
found in tobacco smoke and/or e-cig aerosol as well as humectants (PG:VG) used in e-cig 
devices.  We will also exposure female WT mice to determine whether exposure-induced 
effects are sex-dependent. 
3. Test the roles of ecSOD and TRPA1 in the development of hematological, 
systemic, and endothelium-related changes contributing to CVD. 
The use of ecSOD-transgenic mice has been shown to reduce levels of ROS in 
response to ambient exposures, but these mice have not been extensively used to relate 
exposure to downstream vascular injury and disease.  Likewise, mice lacking expression 
of the TRPA1 gene have been used to examine cardiopulmonary toxicity in response to 
direct exposure to unsaturated aldehydes, but these mice have not been extensively used to 
relate exposure to specific markers of downstream endothelium dysfunction and to changes 
in hematological and systemic biomarkers.  We will thus use extracellular superoxide 
dismutase transgenic (ecSOD-Tg) mice—mice overexpressing extracellular superoxide 
dismutase in the lungs—and mice lacking expression of TRPA1 (TRPA1-null mice) to test 
the roles of ecSOD and TRPA1 in the mechanism of cardiovascular-related outcomes 
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resulting from in vivo aldehyde exposures.  
C. Overall Aim of this Dissertation 
This dissertation aims to address the significant and global problem of CVD.  In 
particular, this research seeks to investigate the relationship between CVD and air pollutant 
exposures.  The proposed studies will focus on the role of personal exposures to MCS and 
e-cig aerosols, as well as shared constituents, on systemic, hematological, and 
endothelium-related outcomes that have been linked to the development of CVD and will 
seek to identify the mechanism through which these compounds act.  These studies will 
also work to determine whether these effects differ between male and females.  The results 
of this research will contribute to the growing knowledge of CACs and their role in the 
development of CVD as well as to the field of environmental cardiology in relation to 
personal pollutant exposures.  Furthermore, the results of this research have the potential 
to contribute to regulation regarding harmful and potentially harmful constituents of 
tobacco-based products and their contribution to cardiovascular toxicity.  
The focus of this study is the relationships between CACs, systemic and 
hematological biomarkers, and exposure to pollutants, specifically tobacco-based aerosols 
and specific aldehydes found in MCS and/or e-cig aerosols.  Chapter 3 explores the 
relationship between CACs and tobacco product-related exposures in a human cohort.  
Chapter 4 investigates the effects of MCS, e-cig aerosol, and PG:VG on CACs and 
biomarkers in murine models, while chapters 5 and 6 examine exposure-related changes 
from saturated and unsaturated aldehyde exposures, respectively.  Chapter 7 examines the 
roles of ecSOD and the TRPA1 channel in the cardiovascular toxicity related to tobacco 
product use.  Together, these data will provide novel insight into the cardiovascular impact 
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of traditional and emerging tobacco products and provide new understanding of the 





A. Human Studies 
1. Study Populations
To test the research hypothesis, a cohort of 143 participants with varying types of 
tobacco exposure was recruited for the Louisville Healthy Heart Study (LHHS) from 
September 2015 to April 2018.  Participants were recruited through locally-placed 
advertisements, by word of mouth, or from nearby cardiovascular disease (CVD) clinics. 
Clinic enrollment was specific to adults undergoing primary or secondary preventative 
treatment for cardiovascular disease at University of Louisville and KentuckyOne Health 
hospitals clinic systems.  Enrollment outside the clinic was focused on individuals currently 
using tobacco products, with a specific focus on individuals who were e-cigarette (e-cig) 
only users.  All advertisements, study consent forms, and research protocols were approved 
through the University of Louisville’s Institutional Review Board (IRB 09.0174). 
2. Eligibility
Eligibility was determined based on age (≥ 18 years of age at the time of 
enrollment) and, when available, medical records in the general and preventative 
cardiology and family medicine clinics of the KentuckyOne Health hospitals located in and 
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around the University of Louisville’s Health Science Campus in downtown Louisville, KY 
and from the Department of Public Health & Wellness screening database (set up 
previously under the direction of Drs. Troutman and Zahn by the Louisville Metro Health 
Department).  Exclusion criteria included: 1) persons unwilling or unable to provide 
informed consent; 2) persons with significant and/or severe co-morbidities including the 
following conditions: significant chronic lung, liver, kidney, hematological, or neoplastic 
disease; chronic neurological or psychiatric illness; chronic infectious disease such as HIV 
or hepatitis; severe coagulopathies; drug/substance abuse; and chronic cachexia; 3) 
pregnant women; and 4) prisoners and other vulnerable populations.   
3. Case Definition 
For this study, primary prevention cases were defined as individuals who have 
known heart disease risk factors (e.g., hypertension, hypercholesterolemia, obesity, 
diabetes) but no evident coronary artery disease; secondary prevention individuals were 
those with evident heart disease in addition to heart disease risk factors that require 
treatment.  Specifically, these latter individuals had a clinical manifestation of coronary 
artery disease and were being treated for risk factors.  Fundamentally, the designation of a 
patient as a primary or secondary preventative case was based on the absence or presence 
of coronary artery disease. 
4. Recruitment 
Study participants had no restriction on geographic location of residence.  
Recruitment took place through local print and electronic advertisements, by word of 
mouth, and at nearby cardiovascular clinics.  If recruitment occurred at a clinic, patients 
were approached during their clinic visit.  Interested individuals were fully informed as to 
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the purpose of the study and their eligibility confirmed.  Individuals willing to participate 
were either recruited immediately following their clinic visit or required to schedule a 
separate appointment at their convenience.  At this recruitment appointment, individuals 
were asked to sign informed consent forms and administered a brief questionnaire to obtain 
demographic information, exposure history, and baseline clinical characteristics.   
5. Questionnaire  
All study participants were administered a questionnaire during their enrollment.  
This questionnaire was designed to collect relevant demographic and medical information 
and has been used in other human studies, both as originally written (71) and as modified 
(291).  If previous medical history was available, the questionnaire was used to either 
confirm or to add to the clinically-indicated standard medical history, physical 
examination, and laboratory evaluation of traditional CVD risk factors preformed in the 
clinic.  Additional questions sought information regarding the individual’s demographic 
information, residential address, smoking history and current status, secondhand smoke 
(SHS) exposure, alcohol consumption, physical activity status, use of CVD medications, 
and CVD history including heart attack, heart failure, angina, high blood pressure, high 
cholesterol, diabetes, stroke, peripheral artery disease, aortic aneurism, and bleeding 
disorders.  Affirmative answers for the presence of CVD risk factors were based on a 
professional diagnosis as reported by the patient.  Answers were recorded in an electronic 
format, with the REDCap system (Research Electronic Data Capture; Vanderbilt 
University Medical Center, Nashville, TN) serving as an electronic database.   
6. Biological Sample Collection and Processing 
After informed consent was given, biological samples (blood and urine) were 
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obtained.  A random catch urine sample was collected by the participant in the clinic or in 
the human studies laboratory when enrollment occurred outside the clinic.  The urine 
samples were separated as follows: four 4.5 aliquots, four 2 mL aliquots, and two 4.5 mL 
aliquots with 45 µL butylated hydroxytoluene as a preservation additive.  Aliquots were 
stored at -80°C until the time of testing.  A blood sample of approximately 25 mL was 
obtained via venipuncture by a licensed nurse or other medically-trained individual using 
standard procedures and precautions to ensure the safety of the participant and the nurse.  
If any participant became ill or uncomfortable, sample collection was discontinued until 
the participant recovered, and if the participant wished to withdraw from the study, they 
were allowed to do so at any time.  Approximately 8 mL of blood was collected in a 
Vacutainer® CPT Mononuclear Cell Preparation Tube (Becton Dickinson; Franklin Lakes, 
NJ) for CAC analysis, 2.6 mL in a Vacutainer® ACD tube for platelet mononuclear cell 
aggregate analysis, and 6 mL total into a Vacutainer® Serum Tube, a Vacutainer® 
K2EDTA Tube, and a Vacutainer® Citrate Tube for analysis of plasma components.   
7. Complete Blood Cell Count (CBC) 
A complete blood cell count (CBC) was performed on a Coulter Ac•T diff2 
Hematology Analyzer (Beckman Coulter; Brea, CA).  18 µL of collected blood from the 
Vacutainer® K2EDTA tube were used for this analysis.   
8. Circulating Angiogenic Cell (CAC) Quantification 
Circulating angiogenic cell (CAC) populations in blood samples were characterized 
via fluorescence-activated cell sorting (FACS; FACSDiva v6.0 software; BD Biosciences; 
San Jose, CA) flow cytometry using established markers: CD34+ (endothelial progenitor), 
CD45+/- (hematopoietic/non-hematopoietic), CD31+ (endothelial cells), and CD133+ (early 
28 
 
stem cell).  Duda et al. (292) first described this method for defining populations of 
circulating endothelial and progenitor cells in human peripheral blood; a modified version 
of this protocol has been used in our laboratory to measure populations of human CACs 
(71, 73).  Within 30 minutes of the blood draw, blood cells were separated in the CPT 
mononuclear separator tube by centrifugation at 1,600xg for 30 minutes at room 
temperature and then stored in an upright position at room temperature overnight.  The 
following day, the upper layers of the sample were decanted into phosphate-buffered saline 
(PBS) and centrifuged at 500xg for five minutes at room temperature.  The pelleted cells 
were then washed twice with 1% BSA/PBS buffer and then incubated with human FcR 
Blocking Reagent (Miltenyi Biotec) and a panel of fluorescently-conjugated antibodies on 
ice for 30 minutes.  Fluorescent antibodies used included PE-labeled anti-CD34 (BD 
Biosciences), APC-labeled anti-AC133 (Miltenyi Biotec; Bergisch Gladbach, Germany), 
PE-Cy5.5-labeled anti-CD14 (Abcam; Cambridge, United Kingdom), APC-AlexaFluor 
750-labeled anti-CD45 (Invitrogen; Carlsbad, CA), PE-Cy7-labeled anti-CD16 (BD 
Biosciences), FITC-labeled anti-CD31 (BD Biosciences), anti-CD41a (BD Biosciences), 
anti-CD235a (BD Biosciences), Pacific Blue (Pacific Blue monoclonal antibody labeling 
kit; Invitrogen), and a marker for dead cells (LIVE/DEAD fixable dead cell stain; 
Invitrogen).  The cells were then washed again with 1% bovine serum albumin (BSA)/PBS, 
centrifuged at 500xg for five minutes at room temperature, and resuspended in 1% 
BSA/PBS.   
Immediately following resuspension, events were collected by FACS using an LSR 
II flow cytometer (BD Biosciences) for a period of two minutes.  Positive and negative 
boundaries for gating were determined using unstained controls, and sequential gating was 
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performed based on antigenic marker groupings.  CAC counts were normalized to sample 
volume for analysis (71, 73).   
9. Platelet Mononuclear Cell Aggregate (PMA) Quantification 
A portion of the blood sample was collected in an ACD tube.  One mL of this 
sample was fixed with a mixture of PBS and 4% paraformaldehyde and incubated on ice 
for 30 minutes.  Red blood cells were then lysed with the addition of 24 mL of water and 
the sample centrifuged at 400xg for 10 minutes at room temperature.  Following 
centrifugation, the pelleted cells were resuspended in Tyrode’s buffer and stored at 4°C 
overnight.  The following day, 800 µL of the sample was centrifuged at 1,000xg for 5 
minutes at room temperature then incubated on ice with BSA/Tyrode’s buffer and FcR 
Blocking Reagent (Miltenyi Biotec) for 10 minutes.  A second 30-minute incubation with 
a panel of fluorescently-conjugated antibodies followed, and finally the cells were 
centrifuged, washed, and resuspended in BSA/Tyrode’s buffer.  FACS was used to count 
platelet mononuclear cell aggregates (PMAs) on an LSR II flow cytometer as events that 
are both FITC (CD41+) and PerCP-Cy5.5 (CD45+) positive, with the final count calculated 
as the percentage of double-positive cells per total events (71). 
10. Urine Metabolite Quantification 
Collected urine was used to quantify levels of creatinine and volatile organic 
compounds (VOCs) and tobacco alkaloid metabolites as described below. 
a. Creatinine 
Concentrations of creatinine were measured on a Cobas Mira Plus Clinical 
chemistry Autoanalyzer (Roche; Basel, Switzerland) with Infinity Creatinine Reagent 
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(ThermoFisher Scientific; Waltham, MA).  Urine was diluted 1:10 with deionized water 
up to 200 µL for testing. 
b. Volatile Organic Compounds (VOCs) and Tobacco Alkaloids 
Urinary levels of volatile organic compound (VOC) metabolites, including the 
urinary metabolites of acrolein (3-hydroxypropylmercapturic acid, 3-HPMA) and 
crotonaldehyde (CR) (3-hydroxy-1-methylpropylmercapturic acid, HPMMA), and tobacco 
alkaloids metabolites were measured by ultra-performance liquid chromatography tandem 
mass spectrometry (UPLC-MS/MS) as previously described with slight modifications 
(293).  Briefly, 50 µL of sample urine was combined with 400 µL ammonium acetate (15 
mM, pH 6.8) and 50 µL internal standard and applied to an ACQUITY UPLC core system 
(Acquity UPLC HSS T3 column (150 mm x 2.1 mm, 1.8 µM)) and a Quattro Premier XE 
triple quadrupole MS coupled with an electrospray source (Waters Corporation; Milford, 
MA).  Ammonia acetate and acetonitrile were used as mobile phase for chromatographic 
separation. The peak areas of analytes were quantified using at least 12 data points across 
the measurement peaks, and TargetLynx 4.1 (Waters Corporation) was used for peak 
integration, calibration, and quantification of analyze concentrations.  All values were 
normalized to urinary creatinine (mg/dL).  
11. Statistical Analyses 
Descriptive statistics were computed to describe the LHHS cohort and are presented 
as mean ± SE for continuous variables and as n (%) for categorical variables.  Population 
demographics, CVD history, medication use, markers of systemic injury, markers of 
thrombosis, and urinary VOC and tobacco alkaloid metabolites were compared across the 
tobacco product use categories based on self-reported product use and confirmed by 
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urinary cotinine levels.  The tobacco product use categories used were never smokers, 
former smokers, sole cigarette users (CIG only), and sole e-cig users or dual users (E-cig 
or Dual users).  Demographic characteristics were compared using one-way analysis of 
variance (ANOVA) with the Bonferroni post-hoc test for continuous variables and using 
χ-squared analysis with Fisher’s Exact Test for categorical variables.  Two participants 
were excluded from all analyses for misclassification based on inconsistencies between 
self-report of tobacco use and urinary cotinine levels. 
Differences in CBC results between tobacco product use categories were tested 
using one-way ANOVA with the Bonferroni post-hoc test.  Differences in levels of urinary 
VOC and tobacco alkaloid metabolites between tobacco product use categories were tested 
on log-transformed urinary VOC data using one-way ANOVA with the Bonferroni post-
hoc test. 
Relationships in the levels of CACs between tobacco product use categories were 
assessed on log-transformed CAC measures using multivariable-adjusted linear regression 
models with never smokers as the reference group.  These models utilized the normal 
probability distribution and the identity link function.  Models were initially adjusted for 
variables found to be potential confounders from the demographic analysis; these variables 
were age, sex, CVD history, use of CVD medications, family history of CVD, and SHS 
exposure.  Models were also initially adjusted for socioeconomic status (SES) using annual 
household income as a proxy variable as previously reported (294, 295).  A random forest 
model was subsequently used to determine which of the variables used in the fully adjusted 
model were most likely to have an effect on CAC levels independent of tobacco product 
use categories.  The resulting relative feature importance plot indicated age and SES as 
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potential confounders, and a second model examining the relationship between CACs and 
tobacco product use categories was adjusted only for these two variables.   
Analyses of demographic, CBC, and urinary VOC and tobacco alkaloid metabolite 
data by tobacco product use categories was performed using IBM SPSS Statistics V26 
(IBM; Armonk, NY).  Multivariable-adjusted linear regression modeling and random 
forest modeling were performed using R V3.6.1 (The R Foundation for Statistical 
Computing; Vienna, Austria) and utilizing the following packages: tidyverse V1.3.0 (296), 
forcats V0.4.0 (297), and randomForest V4.6.14 (298).  Statistical significance assumed at 
p<0.05.  Data are expressed as indicated. 
B. Murine Studies 
1. Animals and Treatment  
Male and female C57BL/6J (wild type, WT) mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). Male extracellular superoxide dismutase transgenic 
(ecSOD-Tg) mice (on a WT background) mice and male transient receptor potential 
ankyrin 1 (TRPA1)-null mice (on a WT background) were obtained from breeding colonies 
at the University of Louisville (Louisville, KY) (269, 299).  All mice were treated 
according to the Guiding Principles for the Care and Use of Animals in Research and 
Teaching as adopted by the American Physiological Society, and all protocols were 
approved by the University of Louisville Institutional Animal Care and Use Committee 
(IACUC 16624).  Before and during the exposures, mice were housed in the University of 
Louisville vivarium under pathogen-free conditions, controlled temperatures, and a 
12h:12h light:dark cycle.  Mice were maintained on a standard chow diet (Rodent Diet 




a. Mainstream Cigarette Smoke (MCS) 
Male WT, male ecSOD-Tg, and male TRPA1-null mice were exposed to high-
efficiency particulate air- (HEPA) and charcoal-filtered air (control) or mainstream 
cigarette smoke (MCS) for 4 days (6h/day) and euthanized immediately after the last 
exposure.  MCS was generated in a state-of-the-art, 4-chamber inExpose system with a 
software-controlled cigarette smoking robot (Flexiware Software, SCI-REQ; Montreal, 
Canada) housed in the University of Louisville Inhalation Facility with a separate HVAC 
system to maintain barrier, temperature and humidity conditions.  To generate MCS, a 
single reference cigarette (3R4F; University of Kentucky, Center for Tobacco Reference 
Products) was burned at a time (9 puffs, 35 ml/puff, 2 s/puff; 9 min/cigarette, 1 cigarette 
every 30 minutes) for a total of 12 cigarettes burned during the exposure period.  
Humidified cigarettes (60% 2-way humidity packet) (Boveda, Inc.; Wayzata, MN) were 
reloaded between each 2h session.  The exposure chamber (5 L) had continuous air flow 
(3 LPM), and a MicroDust Pro (Casella; Bedford, United Kingdom) continuously 
measured smoke total suspended particulate (TSP) upstream of chamber.  Post-chamber 
thimble filter collection provided gravimetric TSP data.  Mice did not have access to food 
or water during the exposure. 
b. Electronic Cigarettes (E-cigs) 
Male and female WT mice were exposed to either HEPA- and charcoal-filtered air 
(control) or e-cigarette (e-cig) aerosol for a single 6h period or 4 days (6h/day) and 
euthanized immediately after the last exposure.  A custom e-cig holder (SCI-REQ; 
Montreal, Canada) connected to a fully programmable, software-controlled (Flexiware 
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Software, SCI-REQ) exposure system was used to produce the e-cig aerosol.  Blu Plus+ e-
cigs with Classic Tobacco flavoring (BLU Products; Doral, FL) were used for the blu Plus+ 
exposure, and the accompanying blu Plus+ batteries and cartridges were purchased locally.  
JUUL e-cig liquids with Virginia (VA) Tobacco, Mango, and Menthol flavorings (Juul 
Labs, Inc.; San Francisco, CA) with blu Plus+ batteries were used for JUUL exposures.  
The blu Plus+ e-cigs exposure was performed under the following conditions: 1) 
battery charged overnight; 2) new cartridge each day; 3) Classic Tobacco flavor (16 mg 
nicotine); 4) vaping protocol of 4s puff, 50-60 mL puff, 2 puffs/min x 9 min = 18 puffs = 
1 session; 5) each 6h exposure had 20 sessions (1 session = 9 min vaping followed by 9 
min bias air flow); and, 6) blu Plus+ LED lights during each puff (or is rapidly replaced 
with charged battery).   
The JUUL e-cig exposures were performed under the following conditions: 1) 
battery charged overnight; 2) e-liquids placed in Mistic bridge cartomizer (Mistic 
Electronic Cigarettes; Charlotte, NC); 3) new cartomizer used each day; 4) VA Tobacco 
(5% nicotine), Mango, or Menthol flavor; 5) vaping protocol of 4s puff, 91 mL puff, 2 
puffs/min x 9 min = 18 puffs = 1 session; 6) each 6h exposure had 20 sessions (1 session 
= 9 min vaping followed by 9 min bias air flow); and, 7) bias air flow continued for at least 
15 min post-exposure to clear chamber. 
Real-time monitoring (computer data logging) of TSP was done with an inline (pre-
chamber) Microdust Pro near infrared detector (Casella; Bedford, United Kingdom), and 
humidity equilibrated gravimetric filters (post-chamber) were used throughout the 
exposure.  Mice did not have access to food or water during the exposure. 
c. Propylene Glycol and Vegetable Glycerin (PG:VG) 
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Male and female WT mice were exposed to either HEPA- and charcoal-filtered air 
(control) or 50%/50% or 30%/70% propylene glycol:vegetable glycerin (PG:VG) for a 
single 6h period or 4 days (6h/day).  Aerosol from the PG:VG mixtures were generated 
using a refillable, clear tank (approximately 5 mL) atomizer with a coil resistance of 1.8 
Ohm (Mistic Electronic Cigarettes; Charlotte, NC) coupled with a rechargeable battery 
from a blu Plus+ e-cig (3.7 V).  The atomizer tank was weighed before and after the 
exposure session to determine solution consumption.  The vaping protocol of the 
aerosolized 50%/50% PG:VG consisted of a 4s puff, 50-60 ml puff, 2 puffs/min x 9 min = 
18 puffs = 1 session; each 6h exposure period has 20 sessions (1 session = 9 min vaping 
followed by 9 min bias air flow).  The vaping protocol of the aerosolized 30%/70% PG:VG 
consisted of 4s puff, 91 ml puff, 2 puffs/min x 9 min = 18 puffs = 1 session; each 6h 
exposure period has 20 sessions (1 session = 9 min vaping followed by 9 min bias air flow).  
Mice did not have access to food or water during the exposures. 
d. Formaldehyde (FR) 
Male and female WT mice were exposed to either HEPA- and charcoal-filtered air 
(control) or formaldehyde (FR) for 4 days (2 or 5 ppm, 6h/day) or 2 weeks (5 ppm; 6h/day, 
7 days/week) using a custom exposure system and certified permeation tubes (Kin-Tek; 
LaMarque, TX) as previously described (151).  FR vapor was diluted with HEPA-filtered 
room air, and the FR concentration was continuously monitored using an in-line 
photoionization detector (MultiRae, Rae Industries; Sunnyvale, CA) upstream of a 
polycarbonate cage (about 31 L).  Air or FR was delivered through a fine mesh screen at 
8-10 L per minute via a custom cyclone-type top that distributed gas within 10% of the 
mean concentration at six locations in the cage (Teague Enterprises; Woodland, CA).  Mice 
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did not have access to food or water during the exposure.   
e. Acetaldehyde (AA) 
Male and female WT mice were exposed to either HEPA- and charcoal-filtered air 
(control) or acetaldehyde (AA) for 4 days (5 ppm, 6h/day) or 2 weeks (5 ppm; 6h/day, 7 
days/week) and euthanized immediately following exposure on the final day.  The 
experimental protocol for the exposure is the same as described for FR above with the 
substitution of AA vapor. 
f. Acrolein 
Male WT mice were exposed to either HEPA- and charcoal-filtered air (control) or 
acrolein for 4 days (1 ppm, 6h/day) and euthanized immediately following exposure on the 
final day.  The experimental protocol for the exposure is the same as described for FR 
above with the substitution of acrolein vapor. 
g. Crotonaldehyde (CR) 
Male and female WT mice and male TRPA1-null mice were exposed to either 
HEPA- and charcoal-filtered air (control) or crotonaldehyde (CR) for 4 days (1 or 3 ppm, 
6h/day) or 12 weeks (1 ppm; 6h/day, 5 days/week) and euthanized immediately following 
exposure on the final day.  The experimental protocol for the exposure is the same as 
described for FR above with the substitution of CR vapor. 
3. Urine Collection 
For each type of exposure, urine was collected using rodent metabolic chambers 
(Nalgene, Lab Products Inc.; Seaford, DE).  After exposure, mice were placed singly per 
metabolic cage (Harvard Apparatus; Cambridge, MA) with 3% glucose/0.125% saccharin 
solution drinking water but without food to collect urine (in graduated cylinders in 4°C 
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water-jacketed organ baths) in 1h increments up to 3h post-exposure followed by a 3-16h 
(overnight, O/N; mice given food) urine collection (151, 300).  Collected urine samples 
were centrifuged (1800xg, 5 min; to pellet any feces or food particles) in cold immediately 
after collection before being decanted and stored at -80°C.   
4. Urine Metabolite Quantification 
Collected urine was used to quantify levels of volatile organic compound (VOC) 
metabolites and metabolites of saturated aldehydes as described below.   
a. Formate and Acetate 
Urinary levels of formate and acetate, the metabolites of formaldehyde (FR) and 
acetaldehyde (AA), respectively, were measured by gas chromatography-mass 
spectrometry (GC-MS) as adapted and modified from previous reports (301, 302).  In short, 
20 µL of collected urine was mixed with 20 µL sodium phosphate (0.5 M, pH 8.0) 
containing 13C-formate (2.3 mM) and 13C1-acetate (0.23 mM) internal standards, and 
pentafluorobenzyl bromide (130 µL, 0.1 M).  The mixture was vortexed for 1 minute and 
then incubated at 60°C for fifteen minutes, and the resulting reaction products were 
extracted using hexane (300 µL) before being transferred to glass tubes for GC-MS 
analysis.  The peak areas of analytes were quantified using at least 12 data points across 
the measurement peaks, and TargetLynx 4.1 (Waters Corporation) was used for peak 
integration, calibration, and quantification of analyze concentrations.  Measured formate 
and acetate sample concentrations were corrected for the natural abundance of 13C isotopes. 
b. Volatile Organic Compounds (VOCs) and Tobacco Alkaloids 
Urinary levels of volatile organic compound (VOC) metabolites, including the 
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urinary metabolites of acrolein (3-HPMA) and crotonaldehyde (CR) (HPMMA), and 
tobacco alkaloids metabolites were measured by ultra-performance liquid chromatography 
tandem mass spectrometry (UPLC-MS/MS) as previously described with slight 
modifications (293, 303).  Briefly, 10 µL of sample urine was combined with 440 µL 
ammonium acetate (15 mM, pH 6.8) and 50 µL internal standard and filtered through a 0.2 
µm PTFE membrane into a 2 mL UPLC vial.  The samples were then applied to an 
ACQUITY UPLC core system (Acquity UPLC HSS T3 column (150 mm x 2.1 mm, 1.8 
µM)) and a Quattro Premier XE triple quadrupole MS coupled with an electrospray source 
(Waters Corporation).  Ammonia acetate (15 mM, pH 6.8) and acetonitrile were used as 
mobile phase for chromatographic separation. The peak areas of analytes were quantified 
using at least 12 data points across the measurement peaks, and TargetLynx 4.1 (Waters 
Corporation) was used for peak integration, calibration, and quantification of analyze 
concentrations.  
5. Tissue Collection and Storage 
Immediately following the final exposure, mice were anesthetized with sodium 
pentobarbital (≈150 mg/kg, i.p.) followed by ventral thoracotomy and exsanguination via 
cardiac puncture for blood collection in EDTA-coated syringes.  Whole blood was taken 
for complete blood cell count (CBC) analysis (50 µL) and circulating angiogenic cell 
(CAC) analysis (300 µL).  The remaining blood was collected for additional tests or 
immediately centrifuged (4.6 rpm, 20 min, 4°C) to separate plasma; plasma was 
subsequently stored at -80°C for further analysis.  Collected tissues (heart, lung, kidney, 
liver, pancreas, spleen, fat pad, and/or skeletal muscle) were frozen in liquid nitrogen and 
stored at -80°C for further analysis. 
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6. Complete Blood Cell Count (CBC) 
Complete blood cell counts (CBCs) were measured (20 µL blood) with a 
hematology analyzer calibrated with multispecies hematological reference controls 
(Hemavet 950FS; Drew Scientific, Inc.; Miami Lakes, FL) as described (151).  
7. Plasma Biomarkers Quantification 
Plasma total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein 
(LDL), triglycerides, albumin, total protein, aspartate transaminase (AST), alanine 
transaminase (ALT), lactate dehydrogenase (LDH), creatine kinase (CK), and creatinine 
were measured on a Cobas Mira Plus clinical chemistry Autoanalyzer (Roche Diagnostics; 
Indianapolis, IN) as previously described (151) or on a Vet Axcel clinical chemistry system 
(Alfa Wassermann Diagnostic Technologies, LLC; West Caldwell, NJ). 
8. Circulating Angiogenic Cell (CAC) Quantification 
A 300 µL sample of whole blood was lysed (3 mL BD PharmLyse, BD 
BioSciences, San Jose, CA; 10 min, RT), and after centrifugation (5 min, 500xg, RT), the 
supernatant was aspirated.  The cell pellet was vortexed and resuspended in 1% BSA/PBS 
and divided into 2 equal fractions (i.e., isotype control or Flk-1/Sca-1 labeling). After 
another centrifugation (5 min, 500xg, RT), mononuclear cells were re-suspended in 1% 
BSA/PBS with 5 µL anti-mouse CD16/CD32 Fc Block (0.5 µg; BD Biosciences), and the 
samples incubated for on ice. After 10 minutes, 5 µL of staining cocktail containing anti-
Sca-1 (FITC; BD BioSciences) and anti-Flk-1 (APC, BD BioSciences) antibodies was 
added to each sample and the samples incubated on ice for 30 minutes.  Cells were then 
washed with 1% BSA/PBS and centrifuged (5 min, 500xg, RT).  After being resuspended 
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in 250 µL of 1% BSA/PBS, 5 µL of propidium iodide stock staining solution 
(ThermoFisher Scientific) was added to each tube, and cells were analyzed using a LSRII 
flow cytometer (BD BioSciences).  Based on forward and side scatter, small non-debris 
events in a sub-lymphocyte population (3-5 µm; sized using calibrated beads, Invitrogen, 
Carlsbad, CA, USA) were gated electronically and displayed in a two-color dot plot.  Data 
were analyzed using FlowJo software (FlowJo LLC; Ashland, OR), and double positive 
events were normalized per 1 µl of whole blood.  
9. Leukocyte Subpopulation Quantification 
A 100 µL sample of whole blood was lysed (1 mL BD PharmLyse, BD 
BioSciences, San Jose, CA; 10 min, RT) and after centrifugation (5 min, 500xg, RT), the 
supernatant was aspirated.  The cell pellet was vortexed and resuspended with 1 mL 1% 
BSA/PBS and again centrifuged (5 min, 500xg, RT), aspirated, and vortexed.  This process 
was repeated a third time before the addition of 5 µL anti-mouse CD16/CD32 Fc Block 
(50 µg/mL; BD Biosciences) and incubation on ice. After 10 minutes, the cells were 
incubated on ice for 30 minutes with a cocktail containing FITC-anti-Nk1.1 (0.5 µg), PE-
anti-Ly6C (0.125 µg), PerCPe710-anti-CD8 (0.125 µg), PECy7-anti-CD62 (0.25 µg), 
APC-anti-CD19 (0.125 µg), Alexa 700-antiGr-1 (0.125 µg), APCe780-anti-CD3 (1 µg), 
eVolve605-CD11b (1 µg), and e650-anti-CD4 (1 µg).  The stained cells were once again 
centrifuged (5 min, 500xg, RT), aspirated, and vortexed before resuspension in 250 µL 1% 
BSA/PBS before analysis on an LSR II flow cytometer (high speed, 90 seconds) (BD 
BioSciences).  Cell numbers were analyzed using the FlowJo software (FlowJo LLC) and 
normalized per 1 µl of whole blood.  Monocytes double positive for Ly6C and CD62L 
were defined as a Ly6Chigh subpopulation. 
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10. Statistical Analyses 
Statistical analyses of flow cytometry data were performed using FlowJo V10 
(FlowJo LLC; Ashland, OR) and SigmaPlot 12.5 (Systat Software, Inc.; San Jose, CA).  
Analyses of changes in body and tissue parameters as well as analyses of the results of 
CBC, plasma biomarker, and urine metabolite testing were performed using Excel 2016 
(Microsoft; Redmond, WA) and SigmaPlot 12.5 (Systat Software, Inc.).  Rank sum tests 
with Bonferroni’s post-test were used to determine statistical significance when comparing 
two groups.  Two-way ANOVA with Dunn’s post-test was used when comparing multiple 
groups.  Statistical significance assumed at p<0.05 or as indicated.  Data are expressed as 




ASSOCIATIONS BETWEEN CIRCULATING ANGIOGENIC CELLS AND USE 
OF TRADITIONAL AND EMERGING TOBACCO PRODUCTS 
A. Introduction 
According to the World Health Organization, ischemic heart disease and stroke 
have been the leading causes of death worldwide since 2000, accounting for almost 27% 
of reported global deaths (2).  In the United States, cardiovascular disease (CVD) 
constitutes a significant health and economic burden.  The American Heart Association 
estimates that by 2035, more than 45% of the adult US population will have some form of 
CVD, and costs for medical care related to CVD will reach almost $1 trillion (304).  The 
development of CVD has been linked to the development of endothelium dysfunction; 
endothelium function is a balance of injury and repair, in part attributed to circulating 
angiogenic cells (CACs), wherein CAC levels are associated with endothelium health (62-
66).  Many studies have linked decreased levels of CACs with well-known CVD risk 
factors, including hypertension (70, 305), total (66) and low-density lipoprotein (LDL) (70, 
306) cholesterol, diabetes (307, 308), flow-mediated brachial reactivity (66), and an 
increased Framingham Risk Score (66, 309, 310).  Furthermore, levels of CACs have been
shown to be decreased in individuals with more severe CVD (311-314), and Hill et al. (66) 
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have proposed that CACs may serve as a surrogate biomarker for vascular health and 
overall CVD risk. 
Smoking has also been associated with CACs (315, 316).  Smoking reduction and 
cessation have been linked to increased endothelium function attributed to greater levels or 
function of CACs (317-319), and specific components of traditional cigarettes and other 
tobacco products have been directly shown to alter levels of CACs (151, 320, 321).  
Although the effects of electronic cigarettes (e-cigs) on CACs are still debated (322-324), 
the many shared components between mainstream cigarette smoke (MCS) and e-cigs may 
contribute to changes in the number and function of CACs in a way that is likely to 
contribute to CVD development.  Thus, the goal of this study was to examine the effects 
of personal exposures, specifically exposures to MCS and/or secondhand cigarette smoke 
(SHS) and e-cig aerosol, on hematological and endothelium-related changes in a human 
cohort. 
B. Experimental Procedures 
1. Study Population
Participants were recruited for the Louisville Healthy Heart Study (LHHS) as 
described in Chapter II, Section A.1.  
2. Eligibility
Interested individuals were questioned regarding the eligibility requirements 
outlined in Chapter II, Section A.2.  Individuals who met the eligibility requirements were 
enrolled in the study. 
3. Case Definition
Study participants who were enrolled through the University of Louisville and 
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KentuckyOne Health hospitals cardiovascular clinic systems were defined as undergoing 
primary or secondary treatment based on the criteria outlined in Chapter II, Section A.3. 
4. Recruitment
Details of participant recruitment are given in Chapter II, Section A.4. 
5. Questionnaire
Each participant was administered a questionnaire as described in Chapter II, 
Section A.5.  The questionnaire was designed to collect relevant information regarding the 
participant’s demographics, medical history, and product use. 
6. Biological Sample Collection and Processing
Upon confirming eligibility and obtaining written consent, blood and urine samples 
were collected, aliquoted, and stored as described in Chapter II, Section A.6.  
7. Complete Blood Cell Count (CBC)
A sample of collected blood from the Vacutainer® K2EDTA tube was used for a 
complete blood cell count (CBC) as described in Chapter II, Section A.7. 
8. Circulating Angiogenic Cell (CAC) Quantification
Florescence-activated cell sorting (FACS) flow cytometry was used to analyze the 
number of CACs in blood samples collected in the Vacutainer® CPT Mononuclear Cell 
Preparation Tube as described in Chapter II, Section A.8.  The gating scheme for this 
analysis is shown in Figure 3.1.  The 15 CAC populations are described in Table 3.1. 
9. Peripheral Blood Mononuclear Cell Aggregate (PMA) Quantification
FACS flow cytometry was used to analyze the number of platelet mononuclear cell 
aggregates (PMAs) in blood samples collected in the Vacutainer® ACD tube as described 







Fig. 3.1.  Flow cytometry gating scheme for circulating angiogenic cell (CAC) 




Table 3.1.  Antigenic identity of circulating angiogenic cells (CACs). 
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10. Urine Metabolite Quantification
Collected random catch urine samples were used to quantify levels of creatinine 
and volatile organic compound (VOC) and tobacco alkaloids metabolites using analytical 
methods as described in Chapter II, Section A.10. 
11. Statistical Analyses
Differences between demographics, measures of systemic injury, urinary 
metabolites, and CACs were assessed as described in Chapter II, Section A.11. 
C. Results 
1. Baseline Characteristics by Tobacco Product Use Categories
Overall, the mean (SE) age of the Louisville Healthy Heart study population was 
49 (±1) years, and the majority of participants were women (66%) (Table 3.2).  E-cig or 
dual users were significantly younger than never or former smokers and cigarette only 
smokers (Table 3.2).  There were not notable sex differences, with similar levels of 
cigarette only and e-cig or dual use between males and females, and both cigarette only 
and e-cig or dual users were predominately white (68% and 71%, respectively), although 
these differences were not statistically significant (Table 3.2).  Current nonusers of tobacco 
were more educated and had higher annual income than current users of tobacco products 
(Table 3.2).  Never smokers reported higher prevalence of high blood cholesterol and 
hypertension in their family history, while former smokers reported a lower family 
prevalence of diabetes (Table 3.2).  Current tobacco product users reported more 
secondhand smoke exposure, but reports of alcohol consumption and regular exercise were 






Table 3.2.  Demographic characteristics by tobacco product use categories.   









E-Cig or Dual 
(n=28) 
p-value 
Age 49 (1) 53 (2) 53 (2) 49 (2) 40 (1) <0.001 
BMI 30 (1) 30 (1) 30 (1) 29 (1) 30 (1) 0.263 




Former Smokers CIG Only E-Cig or Dual p-value 
Sex 
     Female     



















     Caucasian 
     African American 






















Family Medical History 
     Diabetes 
     High Blood Cholesterol 
     Hypertension  
































     Secondhand Smoke 
     Regular Exercise 


























     < HS 
     Some HS/HS Grad 
     Some College 
     2-4 Year Degree 









































Annual Household Income 
     <$20,000 
     $20,000-$45,000 
     $45,000-$89,999 





































Two-thirds of participants (n=94, 66%) reported some form of CVD history, with 
almost half of those individuals reporting a diagnosis of hypertension (n=69, 49%) and 
approximately one-third reporting a diagnosis of high blood cholesterol (n=47, 33%) 
(Table 3.3).  Additionally, over half of the participants reported taking some form of CVD 
medication (n=76, 53%) (Table 3.3).  By tobacco product use category, fewer e-cig or dual 
users reported significant CVD history than both never and former smokers as well as less 
use of CVD medication than all other use categories (Table 3.3).  E-cig or dual users were 
also less likely to have high blood cholesterol and hypertension than all other use categories 
and to use aspirin or beta-blockers than former smokers, while never smokers were less 
likely to have hypertension and to use beta blockers than former smokers (Table 3.3).  
Former smokers and cigarette only users showed similar likelihoods of having some form 
of CVD and using CVD medication (Table 3.3).  
2. Tobacco Product Use Categories and Hematological Measures  
E-cig or dual users had significantly higher levels of leukocytes than never smokers, 
driven by a significant increase in granulocytes, as well as an increased level of hemoglobin 
(Table 3.4).  Cigarette only users had an increased red cell distribution width compared 
with both never smokers and e-cig or dual users (Table 3.4).  Although platelets levels 
(measured by CBC) were unchanged between the groups, platelet monocyte aggregates 
(PMAs; measured by flow cytometry) were significantly different between the categories, 
with e-cig or dual users showing significantly lower levels of PMAs compared with never 
smokers, former smokers, and cigarette only users (Table 3.4).  Never smokers and former 
smokers showed no significant differences between any of the hematological measures 






Table 3.3.  Medical history and medication use by tobacco product use categories. 
















     CVD History 
        Angina 
        Atrial Fibrillation/Flutter 
        Blood Clot 
        CABG/PCI/Stents 
        Heart Failure 
        Heart Valve Disease 
        High Blood Cholesterol 
        Hypertension 
        Heart Attack 
        Peripheral Artery Disease 
        Stroke         
     Other Significant Medical Condition(s) 
        Diabetes 


































































































     CVD Medication 
        ACE Inhibitor 
        Angiotensin-receptor Blocker 
        Aspirin 
        Beta-blocker 
        Calcium-channel Blocker 
        Diuretics 




























































     Other Medication 














Values = mean ± SE.  Abbr.: ACE, angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; 







Table 3.4.  Hematological measures by tobacco product use categories. 
Complete Blood Cell Count – 










E-Cig or Dual 
(n=27) 
p-value 
White Blood Cell (K/µL) 6.43 ± 0.17 5.82 ± 0.20 6.10 ± 0.37 7.05 ± 0.42 7.49 ± 0.42 0.002 
Lymphocytes (%) 30.89 ± 0.62 32.17 ± 1.02 30.19 ± 1.10 31.81 ± 1.52 27.68 ± 1.19 0.098 
Monocytes (%) 6.90 ± 0.16 7.12 ± 0.25 7.46 ± 0.33 6.41 ± 0.35 6.41 ± 0.42 0.049 
Granulocytes (%) 62.27 ± 0.65 60.49 ± 1.05 63.21 ± 0.93 61.78 ± 1.58 65.93 ± 1.37 0.016 
Red Blood Cell (M/µL) 4.68 ± 0.05 4.6 ± 0.06 4.68 ± 0.12 4.52 ± 0.09 4.92 ± 0.14 0.107 
Hemoglobin (g/dL) 14.1 ± 0.1 13.8 ± 0.2 13.9 ± 0.3 13.9 ± 0.4 15.0 ± 0.4 0.029 
Hematocrit (%) 42.0 ± 0.5 41.4 ± 0.5 41.7 ± 1.0 41.3 ± 1.2 44.4 ± 1.3 0.171 
Mean Corpuscular Volume (fL) 89.8 ± 0.5 89.2 ± 0.6 89.3 ± 0.9 91.1 ± 1.6 90.2 ± 1.1 0.621 
Mean Corpuscular Hemoglobin (pg) 30.3 ± 0.3 29.8 ± 0.3 30.0 ± 0.5 30.9 ± 0.8 30.9 ± 1.0 0.534 
Mean Corpuscular Hemoglobin 
Concentration (g/dL) 
33.7 ± 0.3 33.4 ± 0.2 33.6 ± 0.5 34.0 ± 0.8 34.3 ± 1.1 0.831 
Red Cell Distribution Width (%) 14.8 ± 0.1 14.5 ± 0.1 15.0 ± 0.3 15.6 ± 0.4 14.2 ± 0.4 0.008 
Platelets (K/µL) 263 ± 6 256 ± 8 270 ±  16 259 ± 16 276 ± 13 0.551 
PMAs (%) 23.3 ± 0.8 23.9 ± 1.1 22.8 ± 1.8 23.7 ± 2.2 21.6 ± 1.7 <0.001 
Mean Platelet Volume (fL) 8.4 ± 0.1 8.3 ± 0.2 8.7 ± 0.4 8.4 ± 0.3 8.4 ± 0.2 0.787 
 





3. Tobacco Products Use Categories and Urinary VOC Metabolites 
Analysis of urinary VOC and tobacco alkaloid metabolites showed that never and 
former smokers had lower mean levels of most VOC and tobacco alkaloid metabolites 
compared with current users of tobacco products (Table 3.5).  Never smokers and former 
smokers showed no significantly different levels of measured VOC or tobacco alkaloid 
metabolites (Table 3.5).  All measured metabolites except N-acetyl-S-(benzyl)-L-cysteine 
(BMA) showed significant differences between the tobacco product use categories, and the 
majority of VOC metabolites were higher in cigarette only users and/or e-cig or dual users 
than in never or former smokers (Table 3.5).  Almost one-third of the VOC metabolites 
were significantly different between cigarette only users and e-cig or dual users, with levels 
of cyanoethyl mercapturic acid (CEMA), 3-hydroxypropylmercapturic acid (3HPMA), N-
acetyl-S-(2-carbamoylethyl)-L-cysteine (AAMA), N-acetyl-S-(4-hydroxy-2-buten-1-yl)-
L-cysteine (3MHBMA), N-acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine (HPMMA), 
N-acetyl-S-(N-methylcarbamoyl)-L-cysteine (AMCC), and anatabine (ANTB) 
significantly higher in cigarette only users compared with e-cig or dual users (Table 3.5).  
Interestingly, while never smokers showed significantly lower levels of AMCC, N-acetyl-
S-(2-hydroxypropyl)-L-cysteine (2HPMA), 2-methylhippuric acid (2MHA), and 3-
methylhippuric acid + 4-methylhippuric acid (3MHA + 4MHA), compared with both 
cigarette only users and e-cig or dual users, levels of these metabolites in former smokers 
were not significantly different compared with e-cig or dual users (Table 3.5).  
Additionally, former smokers had levels of anabasine (ANB) that were not significantly 
different from either e-cig or dual users or cigarette only users, although levels were also 






Table 3.5.  Mean urinary volatile organic compound (VOC) metabolite levels by tobacco product use categories (ng/mg). 














167.8 ± 17.3 
822.8 ± 107.6 
72.0 ± 14.0 
313.8 ± 67.5 
71.4 ± 13.6 
267.1 ± 38.7 
365.0 ± 39.7 
1,837.9 ± 280.6 
228.9 ± 33.6 
1,222.0 ± 280.7 
<0.001 
<0.001 
Acrylamide AAMA 103.9 ± 8.7 67.8 ± 6.0 69.0 ± 10.5 192.3 ± 25.9 109.5 ± 16.0 <0.001 
1,3-Butadiene DHBMA 
3MHBMA 
422.0 ± 20.1 
25.1 ± 3.5 
343.4 ± 17.3 
5.8 ± 0.6 
410.9 ± 53.2 
4.6 ± 0.5 
573.0 ± 56.5 
65.7 ± 8.6 
427.0 ± 37.3 
37.5 ± 7.9 
0.001 
<0.001 
Crotonaldehyde HPMMA 606.3 ± 70.5 240.3 ± 32.3 256.6 ± 50.5 1,347.0 ± 185.2 838.7 ± 168.2 <0.001 
N,N-
Dimethylformamide 
AMCC 284.8 ± 22.3 154.2 ± 13.2 227.5 ± 34.0 526.1 ± 52.9 336.8 ± 51.5 <0.001 
Ethylbenzene, 
styrene 
PGA 290.6 ±15.5 234.0 ± 17.2 220.2 ± 27.7 407.9 ± 36.5 337.2 ± 37.0 <0.001 
Propylene Oxide 2HPMA 61.8 ± 8.8 50.3 ± 17.8 57.4 ±21.8 87.9 ± 10.0 60.3 ± 10.4 <0.001 
Styrene MA 261.0 ± 16.5 171.9 ± 14.9 180.0 ± 21.0 391.5 ± 40.2 371.6 ± 33.8 <0.001 








56.4 ± 7.7 
 
403.9 ± 46.1 
22.2 ± 4.5 
 
250.1 ± 76.3 
41.8 ± 13.4 
 
275.9 ± 85.3 
131.6 ± 24.5 
 
725.5 ± 90.2 
56.0 ± 12.0 
 





Anabasine ANB 4.7 ± 0.4 2.8 ± 0.3 4.5 ± 1.1 7.5 ± 1.0 5.6 ± 0.9 <0.001 




657.2 ± 130.4 
527.0 ± 91.6 
1,716.0 ± 258.2 
11.3 ± 2.4 
2.3 ± 0.3 
9.5 ± 3.1 
13.9 ± 2.9 
2.6 ± 0.6 
11.7 ± 3.7 
1,350.4 ± 287.6 
1,413.8 ± 242.4 
4,234.2 ± 453.8 
1,795.5 ± 443.8 
1,081.3 ± 215.7 











cysteine; ANB, anabasine; ANTB, anatabine; BMA, N-acetyl-S-(benzyl)-L-cysteine; CEMA, N-acetyl-S-(2-carboxyethyl)-L-cysteine; 
CIG, cigarette; COT, cotinine; DHBMA, N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine; E-cig, electronic cigarette; 3HC, trans-3’-
hydroxycotinine; 2HPMA,  N-acetyl-S-(2-hydroxypropyl)-L-cysteine; 3HPMA,  N-acetyl-S-(3-hydroxypropyl)-L-cysteine; HPMMA, 
N-acetyl-S-(3-hydroxypropyl-1-methyl)-L-cysteine;  MA, mandelic acid; 2MHA, 2-methylhippuric acid; 3MHA, 3-methylhippuric 








 metabolites of tobacco alkaloids (nicotine (NIC), cotinine (COT), and trans-3’-
hydroxycotinine (3HC)) were significantly increased in cigarette only users and e-cig or 
dual users compared with never or former smokers, but levels were not significantly 
different between the two current product use categories (Table 3.5). 
4. Tobacco Product Use Categories and CACs 
In the fully adjusted (adjusted for age, sex, CVD history, use of CVD medications, 
family history of CVD, SHS exposure, and SES (income category used as proxy indicator)) 
multivariable-linear regression model testing the association between tobacco product use 
categories and log-transformed CAC levels, levels of CAC-12 (CD45+) were significantly 
decreased in e-cig or dual users compared with never smokers (-6.6%; p=0.008) (Table 
3.6).  There were no significant differences in the levels of the other fourteen measured 
CAC populations between any of the tobacco product use categories (Table 3.6).  In order 
to explore dimension reduction of the demographic adjustments used in the fully adjusted 
model, a random forest model was used to select the demographic variables that varied the 
most across the four tobacco product use categories independently of smoking status.  
Based on the resulting variable importance plot (Fig. 3.3), multivariable-adjusted linear 
regression models were again used to assess the relationship between log-transformed CAC 
measures and tobacco product use categories adjusting for age and SES.  When the model 
was adjusted only for age and SES,  levels of CAC-12 (CD45+) remained decreased in e-
cig or dual users compared with never smokers (-6.4%; p=0.004), and CAC-3 
(CD31+/CD34+/AC133+/CD45dim) was also found to be significantly different between 
never smokers and e-cig or dual users, with e-cig or dual users showing significantly 






Table 3.6.  Percent change in levels of circulating angiogenic cells (CACs) comparing tobacco product use categories with never 




% (95% CI) 
CIG Only, 
% (95% CI) 
E-cig or Dual User, 
% (95% CI) 
CAC-1 (CD31+/CD34+/CD45dim) 15.5 (-20.2 to 67.0) -5.8 (-33.2 to 32.8) 4.3 (-30.7 to 56.9) 
CAC-2 (CD45+/CD34+/CD31+) 2.3 (-29.9 to 49.4) -1.3 (-30.6 to 40.4) -15.4 (-44.3 to 28.6) 
CAC-3 (CD31+/CD34+/AC133+/CD45dim) 44.0 (-29.0 to 192.1) 8.0 (-44.1 to 108.6) 75.8 (-19.6 to 284.4) 
CAC-4 (AC133+/CD34+/CD31+/CD45+) -15.9 (-50.0 to 41.2) -14.9 (-47.5 to 37.9) -7.0 (-47.6 to 65.0) 
CAC-5 (AC133+/CD31+) 8.0 (-32.6 to 73.1) -17.3 (-46.7 to 28.2) -25.9 (-56.0 to 24.8) 
CAC-6 (CD31+/CD34+) -3.9 (-40.0 to 54.0) -20.0 (-48.4 to 24.1) -30.2 (-58.6 to 17.6) 
CAC-7 (CD31+/CD34+/AC133-/CD45dim) 13.9 (-21.2 to 64.7) -5.9 (-33.2 to 32.6) 1.9 (-32.2 to 53.2) 
CAC-8 (CD45+/CD34+/CD31+/AC133-) 5.1 (-27.9 to 53.2) 0.9 (-29.0 to 43.2) -16.1 (-44.7 to 27.3) 
CAC-9 (CD34+) -6.3 (-32.8 to 30.6) -8.8 (-33.0 to 24.2) -7.9 (-36.2 to 32.9) 
CAC-10 (CD31+) 17.8 (-10.5 to 55.1) 8.3 (-16.1 to 39.8) -8.7 (-32.6 to 23.7) 
CAC-11 (AC133+) 25.3 (-13.7 to 81.9) -1.9 (-30.6 to 38.8) -24.1 (-49.8 to 14.7) 
CAC-12 (CD45+) 1.3 (-3.1 to 5.9) -2.8 (-6.7 to 1.3) -6.6 (-11.1 to -1.9) 
CAC-13 (CD34+/ACC133+) -6.0 (-38.5 to 43.7) -0.3 (-32.8 to 48.0) 18.8 (-25.7 to 89.9) 
CAC-14 (AC133+/CD34+/CD45+) -10.0 (-40.3 to 35.7) -12.5 (-40.2 to 28.2) 14.7 (-27.2 to 80.6) 






Estimates were derived using the formula (еβ − 1) × 100%, where β represents the β-coefficient of the multivariable-adjusted association 
between product use categories and ln (CAC levels). Models adjusted for age, sex, cardiovascular disease history, use of cardiovascular 
medications, family history of CVD, secondhand smoke exposure, and socioeconomic status (income category used as proxy indicator). 
Bolded values are statistically significant at p<0.05. Abbr.: CAC, circulating angiogenic cell; CI, confidence interval; CIG, cigarette; 










Fig. 3.2.  Relative feature importance of demographic variables on levels of circulating angiogenic cells (CACs).  A random forest 
model was used to determine the most important demographic variables influencing levels of CACs independently of tobacco product 
use category.  Importance was calculated by reduction of gini impurity at relevant branchings.  Abbr.: CAC, circulating angiogenic 






Table 3.7.  Percent change in levels of circulating angiogenic cells (CACs) comparing tobacco product use categories to never 




% (95% CI) 
CIG Only, 
% (95% CI) 
E-cig or Dual User, 
% (95% CI) 
CAC-1 (CD31+/CD34+/CD45dim) 23.7 (-13.3 to 76.4) -4.6 (-31.4 to 32.8) 10.8 (-22.6 to 58.7) 
CAC-2 (CD45+/CD34+/CD31+) 4.7 (-26.8 to 49.9) -1.4 (-29.4 to 37.7) -13.3 (-39.7 to 24.6) 
CAC-3 (CD31+/CD34+/AC133+/CD45dim) 38.5 (-29.8 to 173.2) 24.5 (-33.8 to 134.2) 120.3 (10.8 to 337.8) 
CAC-4 (AC133+/CD34+/CD31+/CD45+) -20.2 (-51.2 to 30.6) -8.3 (-42.0 to 44.9) 11.3 (-32.4 to 83.1) 
CAC-5 (AC133+/CD31+) 7.2 (-31.5 to 67.8) -15.8 (-44.5 to 27.7) -19.1 (-48.6 to 27.2) 
CAC-6 (CD31+/CD34+) 0.6 (-35.6 to 57.4) -18.9 (-46.5 to 23.0) -28.0 (-54.2 to 13.2) 
CAC-7 (CD31+/CD34+/AC133-/CD45dim) 23.1 (-13.7 to 75.7) -5.7 (-32.3 to 31.2) 6.9 (-25.4 to 53.1) 
CAC-8 (CD45+/CD34+/CD31+/AC133-) 8.6 (-24.1 to 55.3) 0.0 (-28.3 to 39.5) -15.1 (-40.9 to 21.9) 
CAC-9 (CD34+) -3.9 (-29.9 to 31.7) -8.9 (-32.0 to 22.2) -8.8 (-33.7 to 25.5) 
CAC-10 (CD31+) 19.2 (-8.4 to 55.1) 9.1 (-14.6 to 39.4) -2.2 (-25.1 to 27.6) 
CAC-11 (AC133+) 21.5 (-15.0 to 73.6) 0.7 (-27.7 to 40.4) -17.4 (-42.4 to 18.5) 
CAC-12 (CD45+) 0.5 (-3.7 to 4.9) -2.4 (-6.2 to 1.5) -6.4 (-10.3 to -2.2) 
CAC-13 (CD34+/ACC133+) -7.0 (-38.1 to 39.5) 5.4 (-27.8 to 53.7) 35.5 (-10.1 to 104.3) 
CAC-14 (AC133+/CD34+/CD45+) -13.6 (-41.5 to 27.4) -9.8 (-37.2 to 29.5) 25.4 (-15.4 to 85.8) 






Estimates were derived using the formula (еβ − 1) × 100%, where β represents the β-coefficient of the multivariable-adjusted association 
between product use categories and ln (CAC levels). Models adjusted for age and socioeconomic status (income category used as proxy 
indicator). Bolded values are statistically significant at p<0.05. Abbr.: CAC, circulating angiogenic cell; CI, confidence interval; CIG, 









Fig. 3.3.  Interrelationships between circulating angiogenic cells (CACs) associated with e-cig or dual use compared with never 
smokers.  Levels of 15 antigenetically defined populations of CACs were measured in 103 participants and examined for their 
association with tobacco product use categories adjusted for age and socioeconomic status.  Associations were only found between e-





The Louisville Healthy Heart Study represents one of the first human cohort studies 
to examine the associations between a large number of CAC populations, urinary VOC and 
tobacco alkaloid metabolites, and specific types of tobacco product use, including e-cig or 
dual e-cig and traditional cigarette users.  Although many adults are using e-cigs as an 
alternative to traditional cigarettes (325), there has been a marked increase in e-cig use 
among youths (83, 182, 183).  Although the current study cohort did not include any 
individuals under the age of 18 (based on exclusion criteria), this trend in the use of e-cig 
devices is reflected in our cohort, as e-cig or dual users were significantly younger than 
never and former smokers and cigarette only users.  The use of e-cigs by younger 
individuals—and especially individuals who may not have previously been using tobacco 
products—is a cause for concern as e-cigs have the potential to create a new generation of 
individuals addicted to nicotine (326).  The current cohort also contained a greater number 
of females than males (66% vs 34%), although this ratio was not statistically significant.  
As males are more likely than women to be smokers (83), there may exist relationships 
between tobacco product users and the measured outcomes that were not noted due to the 
imbalance of sex in the participants in the current cohort.  Use of tobacco products has also 
previously been associated with lower education levels and lower household incomes, as 
was seen in our cohort (83). 
Likely due to their younger age, e-cig or dual users were found to have a lower 
prevalence of high blood cholesterol and hypertension than never smokers, former 
smokers, or cigarette only users and to have a lower usage of CVD medicines.  Increased 




unsurprising that the youngest participants on average in this study have less prevalence of 
major cardiovascular conditions.  Perhaps also unsurprising is the significantly lower 
prevalence of hypertension in never smokers than in former smokers as well as the lower 
use of beta-blockers, which are generally prescribed to help lower blood pressure.  
Although several epidemiological studies have paradoxically shown decreased blood 
pressure in smokers compared with nonsmokers or former smokers (329-332), smoking is 
still considered a risk factor for hypertension (333-335).  However, there is evidence 
associating previous smoking with increased blood pressure, as former smokers have been 
shown to have increased blood pressure and hypertension compared with never smokers 
(331, 336).  This may be due to the development of arterial stiffness, which is closely linked 
with the development of hypertension (337) and which has been shown to be exacerbated 
by smoking (338-341).  Although this increased arterial stiffness has been shown to be 
reversible, it may take more than a decade to achieve levels of stiffness similar to those 
found in never smokers (342).  This persistent stiffness even after smoking cessation may 
be an important factor in the lower prevalence of hypertension seen in our never-smoking 
participants compared with those who had formerly smoked. 
Hematological measures showed significantly increased leukocytes in e-cig or dual 
users compared with never smokers, driven by an increase in granulocytes, although the 
specific type(s) of granulocyte being affected—neutrophils, eosinophils, or basophils—is 
unknown.  It is likely, however, that this increase is at least in part due to increased 
neutrophils, an increase that has been associated with the use of cigarettes (343-347), as 
neutrophils serve as mediators of inflammation (348-350).  Although leukocytes were 




smokers.  Several epidemiological studies have found increased levels of leukocytes in 
cigarette smokers (345, 351-355), a change likely indicative of the persistent inflammation 
induced by MCS (345, 354, 356-358), and while the effects of e-cigs on hematological 
measures are still not well defined, a small study of cigarette smokers and never-smokers 
compared CBC markers after cigarette and e-cig use and found that although leukocytes, 
lymphocytes, and granulocytes were increased after cigarette smoking, they were 
unchanged after e-cig use (359).  It is therefore likely that the increase in leukocytes seen 
in our e-cig or dual use group is mostly contributable to increased levels of leukocytes in 
individuals using both traditional and emerging tobacco products. 
Measures by CBC also showed increased hemoglobin in e-cig or dual users.  
Although some prior studies have shown increases in hemoglobin in smokers (339, 349, 
354), these changes were not seen in the current study.  As previously mentioned, there are 
few studies of the hematological impacts of e-cig use, but Okuni-Watanabe et al. (360) 
report a case study showing that hemoglobin, as well as hematocrit, was initially increased 
in an e-cig user but decreased upon the cessation of e-cig use.  Although this case report 
was based on a single individual—an individual who was also a former heavy smoker—it 
does suggest the potential for e-cig-related changes in erythrocytic measures.  Additional 
studies are needed to better clarify the effects of e-cig use on hematological measures in 
both e-cig only users and in dual users. 
Red blood cell distribution width (RDW) was found to be significantly higher in 
cigarette only users compared with both never smokers and e-cig or dual users.  Elevated 
RDW has been previously seen in smokers (361-363) and has been associated with 




RDW and subsequent morbidity and mortality has not been clarified, this finding in our 
study may be predictive of future cardiovascular events in the cigarette-smoking 
participants.  Contrastingly, platelet mononuclear cell aggregates (PMAs), a marker of 
increased thrombosis, were found to be significantly decreased in e-cig or dual users 
compared with all other groups.  Smoking has been long been known to increase platelet 
aggregation (368), as well as platelet leukocyte aggregation (369), and studies of e-cig 
exposure have shown similar outcomes (370-372).  However, although our e-cig or dual 
user participants showed no significant difference in platelet count (as measured by CBC) 
compared with any other use group, they showed decreased PMAs.  The reason for this 
decrease is unknown, and future studies of cigarette only, e-cig only, and dual users should 
continue to measure PMAs and measure additional markers of thrombosis to better 
understand this finding. 
Unsurprisingly, most urinary VOC metabolites showed higher levels in current 
tobacco product users compared with never and/or former smokers.  Cigarettes are a known 
source of VOCs (160) as well as one of the leading sources of nicotine (373), and both 
cigarette only users and e-cig or dual users also showed increased levels of tobacco 
alkaloids compared with both never and former smokers.  Concentrations of nicotine can 
vary in e-cigs, as different flavorings can contain different levels of nicotine (374), as can 
levels of VOCs in relation to varying power outputs (96, 375), making measurements of 
these compounds in e-cig aerosols difficult.  However, several studies have shown that, as 
in the current study, levels of VOCs generated by e-cig devices are lower than levels 
generated by MCS but still increased compared with levels in nonsmokers (180, 207, 211, 




significantly lower in e-cig or dual users compared with cigarette only smokers, including 
both metabolites of acrolein (CEMA and 3HPMA) and the metabolite of crotonaldehyde 
(HPMMA), despite similar levels of urinary cotinine.  Although these data support the 
hypothesis that e-cigs may be less harmful than traditional cigarettes, they also contribute 
to the growing body of evidence against the claims that e-cigs are harmless (227, 376-378).  
More studies are needed to better clarify levels of VOCs and tobacco alkaloids generated 
by e-cigs compared with traditional cigarettes and to determine whether or not any 
differences in levels between the two types of products indicate a decreased risk of tobacco 
product-related CVD.   
CACs were also examined in relation to tobacco product use categories.  Previous 
research has shown associations between MCS and CACs (72, 316, 318, 320) as well as 
between acrolein, one of the major constituents of tobacco smoke, and CACs (71, 74, 151).  
In our models, age and SES were identified as variables affecting levels of CACs 
independent of tobacco product use categories.  Age is a known risk factor for CVD and is 
included as a variable in a number of CVD risk score calculations (379-382).  Age is also 
associated with decreased endothelium function (383-385), likely through decreased levels 
and function of CACs (385, 386).  Likewise, SES has been shown to have a significant 
impact on CVD health (387), with this impact thought to be the result of factors such as 
poor diet (388), decreased access to health care (389), increased presence of roadways 
(294), and decreased levels of greenness (295) or some combination of these factors and/or 
others.  Both greenness (295) and presence of roadways (294) have previously been 
associated with changes in the levels of CACs.  




significant associations with any of the tobacco product use categories compared with 
never smokers after adjustment for age and SES: CAC-12 (45+) and CAC-3 
(31+/34+/133+/45dim).  CAC-12 is a circulating hematopoietic cell which expresses the 
leukocyte antigen CD45.  In our cohort, e-cig or dual users had significantly lower levels 
of these cells than never smokers.  Although exposure to MCS is associated with decreased 
levels of CACs, there are still gaps in our understanding of the effect of e-cigs on CACs, 
particularly populations such as CAC-12, which is a hematopoietic cell but not a 
hematopoietic stem cell (CD45+/CD34+/CD31+) or an endothelial progenitor cell 
(CD45dim/CD34+/CD31+).  In a previous study, Yeager et al. (295) found that CAC-12, 
among many of the measured CAC populations, was inversely associated with greenness 
while other CAC populations derived from CAC-12 (CAC-14 and CAC-4) were positively 
associated.  The presence of the CD45 antigen appeared to contribute to the reparative 
capacity of the cells positively associated with nearby greenness, as cells displaying the 
same endothelial and stem cell markers (CD31+/CD34+/133+) but not displaying the CD45 
antigen (CD45- or CD45dim) did not show the same response (295).  Additional research is 
needed in order to better understand the true significance of the CD45 antigen in CACs and 
its potential contribution to the regenerative and reparative capacities of hematopoietic 
stem cells. 
Conversely, the results of our study showed an increase in CAC-3 in e-cig or dual 
use compared with no product use, past or present.  Although smoking has been found to 
decrease level of CACs, it may be that, as seen with higher levels of roadway proximity 
(294), the increased levels of CAC-3 measured in e-cig or dual users are indicative of a 




progenitor cell population for repair of the endothelium.  This insult may be mild enough 
to induce increased production of CAC-3 without affecting cell mobilization from the bone 
marrow, an outcome noted in response to exposure to PM2.5 (67) and acrolein (74).  
Regardless, as levels of the CAC populations that give rise to CAC-3 were not significantly 
affected by the use of cigarettes and/or e-cigs, the changes noted in CAC-3 may indicate 
that this population is particularly sensitive to some component to which e-cig or dual users 
are exposed. 
Interestingly, a study of CACs in type 2 diabetics showed that of the CAC 
populations measured, only CAC-3 was associated with peripheral endothelium function 
as measured by reactive hyperemia index (RHI), with individuals with higher levels of 
CAC-3 showing better endothelium function (390).  CAC-3 was thus considered the CAC 
most reflective of endothelium health and was suggested as a specifically sensitive 
predictor of CVD risk (390).  These data also seem to support the hypothesis that the 
increased levels of CAC-3 in e-cig or dual users compared with never smokers is reflective 
of increased endothelium function as the vasculature works to repair low levels of injury.  
Similar increases in CACs are noted in response to acute exposure to e-cig aerosol (322) 
as well as to MCS (315) and PM (73, 391), while chronic exposures to MCS or PM cause 
decreases in CACs as endothelium damage overwhelms repair capabilities.  As e-cig use 
is still a fairly acute phenomenon—that is, the majority of users have not been using e-cigs 
long enough to develop any potential adverse health outcomes that may be associated with 
chronic use—the increased levels of CAC-3 noted in our study may be reflective of the 
increase in CACs related to acute exposure, while the increase in dual users may be 




studies of more chronic e-cig and dual use would help clarify whether this increase persists 
or whether, as with MCS and PM, the levels of CAC-3 decrease.  
Given that both these cell populations were only associated with the e-cig or dual 
use group, we cannot definitively say whether these changes were induced by sole e-cig 
use or by the combined use of cigarettes and e-cigs.  However, as no significant differences 
were seen in the level of these CACs between cigarette only smokers and never smokers, 
it is likely that the changes seen in CAC-3 and CAC-12 are related more so to the use of e-
cigs.  Additional studies with a larger population of e-cig users are needed to better 
understand these relationships, particularly the relationship with CAC-3, which may 
specifically have the potential to serve as a biomarker for endothelial function and disease 
development as previously suggested (390). 
The Louisville Healthy Heart Study represents a cross-sectional study examining 
associations between the use of tobacco products and fifteen antigenetically distinct CAC 
populations.  Although our small number of e-cig only users required their inclusion in an 
‘e-cig or dual use’ group and thus somewhat limited our capability of thoroughly assessing 
the effect of these devices on CACs as well as on urinary VOC and tobacco alkaloid 
metabolites and hematological measures, a number of significant differences were noted 
between this group and the group of individuals smoking cigarettes alone.  These 
differences suggest that e-cig use may produce harmful effects in these outcomes that are 
distinct from those seen in response to use of cigarettes in addition to the outcomes showing 
similar responses, such as increased leukocytes.  Furthermore, as most e-cig users are 
actually dual users (392, 393), the results of our combined e-cig or dual use group may be 




cig or dual user group was significantly younger than other use groups, supporting national 
studies reporting increased use of e-cigs among younger generations (182, 183, 394), and 
reported less prevalence of CVD, likely related to their age.  Because a number of 
participants were recruited from CVD clinics at nearby hospitals, the prevalence of CVD 
and use of CVD medications were unsurprisingly similar between never smokers, former 
smokers, and cigarette smokers.   
Also unsurprising were the significantly higher levels of urinary VOC metabolites 
in both groups of current tobacco product use compared with never and former smokers, 
as tobacco products are known to be a significant source of VOCs (160).  However, 
comparison of urinary VOC metabolite levels between cigarette only smokers and e-cig or 
dual users showed that the use of cigarettes alone resulted in significantly higher levels of 
several metabolites (CEMA, 3HPMA, AAMA, 3MHBMA, HPMMA, AMCC, and 
ANTB).  Nonetheless, the levels of these metabolites were still significantly higher in e-
cig or dual users compared with never or former smokers, so a decreased but continued use 
of traditional cigarettes in combination with the use of e-cigs will likely still result in levels 
of VOC exposure that are capable of contributing to CVD development.  Likewise, because 
e-cigs are often considered to be safer than traditional cigarettes (173, 175, 181), e-cig only 
users may not be aware of the high levels of VOCs to which they are being exposed and 
the associated health risks.   
 Analysis of CACs revealed that two cell populations were significantly different 
between e-cig or dual users and never smokers.  CAC-3, an early endothelial progenitor 
cell population, was significantly increased in e-cig or dual users, while CAC-12, a 




reflective of a repair mechanism in response to a low but persistent level of injury in the 
endothelium.  The cause in the decrease in levels of CAC-12, despite being strongly 
associated with e-cig or dual use as evidenced by its significance in all tested models, is 
less clear and will require additional, more specific studies to better understand.  That both 
these differences were significant despite a small sample in our e-cig or dual use group 
speaks to their importance and potentially to their relevance in other CVD effects induced 
by the use of e-cigs alone or in combination with traditional cigarettes. 
With the increasing use of e-cigs and other ENDS, it is essential to understand the 
health risks associated with their use.  Although few studies have examined the risks of e-
cigs on cardiovascular health, the changes noted in hematological measures and in CACs 
in the LHHS and in other human cohorts (322) demonstrate the potential for these devices 
to contribute to increased CVD risk, as does the evidence of high levels of VOCs in e-cig 
aerosol both in our study and in others (395).  Additional research is needed to clarify the 
results of these early e-cig studies and to explore the specific findings shown in the current 
study.  Furthermore, more studies focusing on e-cig and dual users would help elucidate 
how the combined use of e-cigs and traditional cigarettes may change CVD risk, that is, 
whether combined use is healthier or safer than use of cigarettes alone.  A better 
understanding of the impacts of e-cigs on overall health would help medical professionals 
develop better methods of care for both acute and chronic adverse effects resulting from 






SYSTEMIC, HEMATOLOGICAL, AND ENDOTHELIUM-RELATED EFFECTS OF 
MAINSTREAM CIGARETTE SMOKE, E-CIGARETTE AEROSOL, AND 
PROPYLENE GLYCOL:VEGETABLE GLYCERIN IN MICE 
A. Introduction 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide (1, 2).  In 2016, more than one-fourth of the almost 57 million global deaths 
were attributed to CVD, and ischemic heart disease and stroke have been classified as the 
two leading causes of death for the last 20 years (2).  In the United States alone, on average, 
an individual dies of CVD every 38 seconds; this means that more than 2,000 individuals 
die every day from some form of CVD (1).  Although a number of physical, behavioral, 
and socioeconomic factors have been linked to CVD (3), tobacco smoke has been 
characterized as the most significant modifiable risk factors in CVD development (14, 75).  
Tobacco smoke contains thousands of compounds, including up to 100,000 unidentified 
compounds (396), and many of these can contribute to disease development even in very 
small quantities (82, 396).  Extensive evidence demonstrates that exposure to both 
mainstream (MCS) (80, 82) and secondhand (SHS) (80, 84) cigarette smoke increase the 
risk for CVD.  Smoking has been shown to increase the risk of heart attack, coronary artery 
disease, atherosclerosis, and stroke (85).  Smoking has also been linked to endothelium 
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dysfunction (85), a sine qua non for CVD.  However, the pathophysiological mechanisms
through which tobacco smoke mediates and promotes CVD are not well understood.  
Although American smoking rates are decreasing (1, 119), the number of 
individuals using electronic cigarettes (e-cigs) is increasing, especially among youths and 
never smokers (1, 182, 183, 325, 397), and although e-cigs are promoted as being healthier 
than traditional cigarettes (173-175, 177, 184), their true health effects are not yet known.  
Early studies of e-cigs have shown that the generated aerosol can contain many harmful or 
potentially harmful components, including particulates (184, 198-202), metals (184, 203-
205), and volatile organic compounds (VOCs) including aldehydes (96, 180, 199, 201, 
206-213).  The potential health effects of the liquid components are also causing growing 
concern, as humectants including propylene glycol (PG) and vegetable glycerin (VG) have 
been linked to aldehyde generation (168, 214-216) and as many of the flavoring additives 
used to make flavored e-cig liquids have been deemed safe for ingestion but not necessarily 
for inhalation (218).  As the morbidity and mortality from e-cigarette, or vaping, product 
use associated lung injury (EVALI) has increased in the United States over the past year 
(225-229), it has become imperative to study the health effects of e-cigs and their various 
components.  Thus, the goal of these experiments was to determine the effects of MCS, e-
cig aerosol, and PG:VG on CACs as well as systemic and hematological biomarkers. 
B. Experimental Procedures 
1. Exposures
Animals were exposed to mixtures or humectants via full-body inhalation as 
described in Chapter II, Sections B.2.  Upon completion of the exposure, mice were 
euthanized and tissues collected as described in Chapter II, Section B.5. 
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2. Urine Collection
Urine samples were collected post-exposure as described in Chapter II, Section B.3. 
3. Urine Metabolite Quantification
Collected urine was used to quantify levels of VOC and tobacco alkaloid 
metabolites using analytical methods as described in Chapter II, Section B.4. 
4. Complete Blood Cell Count (CBC)
A sample of whole blood was collected after the final day of exposure for a 
complete blood cell count (CBC) as described in Chapter II, Section B.6. 
5. Plasma Biomarkers Quantification
Plasma was prepared from each sample for an analysis of a number of biomarkers 
as described in Chapter II, Section B.7. 
6. Circulating Angiogenic Cell (CAC) Quantification
Flow cytometry was used to analyze the number of circulating angiogenic cells 
(CACs) in each sample as described in Chapter II, Section B.8. 
7. Statistical Analyses
Statistical analyses were performed as described in Chapter II, Section B.10. 
C. Results 
1. Urinary Metabolites in MCS-Exposed Mice
The use of tobacco products is the leading cause of preventable death both 
nationally and worldwide (1).  Mainstream cigarette smoke (MCS) has been shown to 
contain thousands of compounds (396), and many of these have been implicated in disease 
development (80-82, 396).  To better understand how specific components of MCS—




measured urinary formate, acetate, 3-hydroxypropylmercapturic acid (3HPMA), and 3-
hydroxy-1-methylpropylmercapturic acid (HPMMA), as well as total urinary nicotine 
metabolites (nicotine, cotinine, and trans-3’-hydroxycotinine (3HC)) by gas 
chromatography/mass spectrometry (GC-MS) or ultra-performance liquid-
chromatography tandem mass spectrometry (UPLC-MS/MS) as biomarkers of MCS-
related aldehyde exposure.  For this, male mice were exposed to MCS (50% of smoke of 
12 KY Reference 3R4F cigarettes, 6h), and urine was collected immediately after this 
single exposure session.  Urinary levels of formate (p=0.01), 3HPMA (p=0.01), HPMMA 
(p<0.001), and total nicotine metabolites (p<0.001) measured within the first 3 hours post-
exposure significantly exceeded levels measured after a 6h exposure to HEPA (Fig. 4.1).  
Levels of formate and acetate after the overnight (3-16h) collection were elevated 
compared with levels 0-3h post-exposure; these elevations are related to generation by 
food, as mice were given free access to food during this collection period (Fig. 4.1). 
2. Systemic Toxicity of Acute Exposure to Inhaled MCS 
Tobacco use is responsible for an estimated 7 million global deaths each year (398), 
with many of these deaths due to CVD (399).  Tobacco smoke contains thousands of 
compounds, including many unidentified compounds, many of which can contribute to 
CVD development even in very small quantities (82, 396).  We therefore tested for changes 
in systemic and hematological biomarkers in mice exposed to MCS (50% of smoke of 12 
KY Reference 3R4F cigarettes).  Acute (6h/day; 4d) exposure had modest effects on organ 
and body weights (or ratios) and CBCs.  MCS exposure caused a lower final body weight 
(-9%; p=0.003), liver/body weight ratio (-17%; p=0.02), and, modestly, heart/body weight 







Fig. 4.1.  Urinary metabolites after acute mainstream cigarette smoke (MCS) 
exposure.  Male mice were exposed (6h) to mainstream cigarette smoke (MCS; 50% of 
smoke of 12 KY Reference 3R4F cigarettes) after which urine was collected at 0–1, 1–2, 
2–3, and 3–16h (overnight) and aldehyde and tobacco alkaloid metabolites quantified. 
Values are mean ± SE (n=12 mice per group).  Dashed lines indicate metabolite measures 
(µg) after HEPA exposure (6h).  Abbr.: 3HPMA, 3-hydroxypropylmercapturic acid; 
HPMMA, 3-hydroxy-1-methylpropylmercapturic acid; Total NIC, total urinary nicotine 






Table 4.1. Systemic parameters of male C57BL/6 mice acutely exposed to either air or mainstream cigarette smoke (MCS; 50% of 
smoke of 12 KY Reference 3R4F cigarettes). 
 Exposure (4 days) 
Variable Air Control MCS 
Final BWT (g) 30 ± 0 27 ± 0* 
Heart/BWT (mg/g) 5.5 ± 0.2 5.0 ± 0.1# 
Lung/BWT (mg/g) 5.9 ± 0.2 5.7 ± 0.3 
Liver/BWT (mg/g) 48.4 ± 2.6 40.4 ± 0.7* 
Kidney/BWT (mg/g) 13.9 ± 0.4 13.3 ± 0.1 
                        Plasma Measurements 
Cholesterol (mg/dL) 102.97 ± 2.56 100.25 ± 3.72 
Triglycerides (mg/dL) 28.75 ± 6.19 25.91 ± 2.11 
Albumin (g/dL) 3.53 ± 0.17 3.96 ± 0.04* 
Total Protein (g/dL) 4.88 ± 0.19 4.94 ± 0.05 
ALT (U/I) 21.55 ± 1.19 22.63 ± 0.65 
AST (U/I) 52.67 ± 5.41 62.93 ± 6.89 
CK (U/I) 251.56 ± 45.78 234.16 ± 31.19 
LDH (U/I) 185.12 ± 5.76 187.65 ± 9.32 
Creatinine (mg/dL) 0.49 ± 0.10 0.35 ± 0.01 
 
Values = mean ± SE (n=4-7 mice per group); Creatinine compared using Rank Sum Test.  Abbr.: ALT, alanine aminotransferase; AST, 
aspartate aminotransferase; BWT, body weight; CK, creatine kinase; LDH, lactate dehydrogenase; MCS, mainstream cigarette smoke; 
*, p<0.05 compared with air control based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with air control based on 




significantly decreased with exposure (-60%; p=0.01), driven by a decrease in lymphocytes 
(-58%; p=0.01), as was mean corpuscular volume (-10%; p=0.002), while mean 
corpuscular hemoglobin concentration was increased (+11%; p<0.001) (Table 4.2).  
Plasma levels of liver (ALT, AST), muscle (CK), and LDH enzymes and creatinine were 
unaffected by exposure, but albumin was significantly increased (+12%; p=0.004) (Table 
4.1). 
3. Acute Exposure to MCS and Circulating Angiogenic Cells  
Acute (4d) exposure to MCS (50% of smoke of 12 KY Reference 3R4F cigarettes) 
caused a significant decrease in levels of Sca-1+ cells (-56%; p=0.03) (Fig. 4.2A) but did 
not change the levels of CACs (Fig. 4.2B). 
4. Urinary Metabolites in JUUL E-Cig-Exposed Mice 
The use of e-cig devices has been increasing dramatically in both adolescents and 
adults over the past several years (83, 181-183, 325).  Although e-cigs are commonly touted 
as a healthier alternative to traditional cigarettes (173-175, 177, 181, 184), the health effects 
of these devices are still largely unknown.  Furthermore, a number of studies have detected 
harmful constituents including aldehydes in the aerosol of these devices, which may 
indicate that e-cigs can contribute to adverse health risks in a fashion similar to traditional 
cigarettes (96, 180, 207, 211).  To better characterize exposure to e-cig aerosol, we 
measured urinary formate, acetate, 3HPMA, and total urinary nicotine metabolites 
(nicotine, cotinine, and 3HC)  by GC-MS and UPLC-MS/MS to evaluate the presence of 
aldehydes in aerosols generated by e-cig devices.  For this, male mice were exposed to 






Table 4.2. Hematological measures of male C57BL/6 mice acutely exposed to either air or mainstream cigarette smoke (MCS; 50% of 
smoke of 12 KY Reference 3R4F cigarettes). 
 
 Exposure (4 days) 
Hematological Measurements Air Control MCS 
White Blood Cell (K/uL) 1.69 ± 0.21 0.68 ± 0.09* 
Neutrophils (K/uL) 0.47 ± 0.09 0.15 ± 0.02 
Lymphocytes (K/uL) 1.17 ± 0.17 0.50 ± 0.07* 
Monocytes (K/uL) 0.05 ± 0.01 0.03 ± 0.01 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 8.31 ±0.14 8.78 ±0.14 
Hemoglobin (g/dL) 11.6 ± 0.5 12.1 ± 0.1 
Hematocrit (%) 39.0 ± 1.8 36.8 ± 0.6 
Mean Corpuscular Volume (fL) 46.8 ± 1.4 41.9 ± 0.6* 
Mean Corpuscular Hemoglobin (pg) 13.9 ± 0.4 13.8 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 29.7 ± 0.1 32.9 ± 0.3* 
Red Cell Distribution Width (%) 17.6 ± 0.2 17.9 ± 0.2 
Platelets (K/uL) 912 ± 105 1049 ± 28 
Mean Platelet Volume (fL) 4..6 ± 0.1 4.5 ± 0 
 
Values = mean ± SE (n=4-5 mice per group); Abbr.: MCS, mainstream cigarette smoke; *, p<0.05 compared with air control based on 







Fig. 4.2.  Effects of acute mainstream cigarette smoke (MCS) exposure on circulating stem cells in male mice.  Hematopoietic 
stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice 
exposed to HEPA-filtered air or MCS (50% of smoke of 12 KY Reference 3R4F Cigarettes, 6h/d) for 4 days. After 4 days of exposure 
to MCS, the level of circulating Sca-1+ cells was significantly decreased in WT mice (A), however, no change in the level of CACs 
(Flk-1+/Sca-1+ cells) was detected relative to air-exposed control mice (B). Values = mean ± SE (n=4-5 mice per group).  *, p<0.05 




6h), and urine was collected immediately after the exposure sessions.  Although acrolein 
has been measured in e-cig aerosol, urinary levels of 3HPMA after the JUUL exposures 
were not significantly different from levels after acute air exposure (6h) (Figs. 4.3, 4.4, & 
4.5).  Likewise, levels of urinary formate and acetate were not significantly different from 
levels in air-exposed mice (Figs. 4.3, 4.4, & 4.5).  Measures of total urinary nicotine 
metabolites, however, were significantly elevated post-JUUL exposure (VA Tobacco: 
p<0.001; Mango and Menthol: p=0.002); mice exposed to either JUUL Mango or JUUL 
Menthol showed similar levels of urinary nicotine (p=0.2), which were significantly higher 
than levels in mice exposed to JUUL VA Tobacco (p=0.02 for both) (Figs. 4.3, 4.4, & 4.5).  
Levels of formate and acetate after the overnight (3-16h) collection were elevated 
compared with levels 0-3h post-exposure for exposure to all three JUUL products; these 
elevations are likely related to generation by food, as mice were given free access to food 
during this collection period (Figs. 4.3, 4.4, & 4.5). 
5. Systemic Toxicity of Acute Exposure to Inhaled JUUL Mango E-cig 
Aerosol  
Because of the known health effects of aldehydes found to be generated in the 
aerosol of e-cigarette (e-cig) devices (96, 180, 207-213) and because of the potential risks 
of flavorings used in these devices (183, 218, 220-223), we tested for changes in systemic 
and hematological biomarkers in female mice exposed to aerosol from a JUUL e-cig device 
with mango flavoring (JUUL Mango).  Acute (6h/day; 4d) exposure had a number of 
significant effects on organ and body weights (or ratios) and CBC.  For example, exposure 
to JUUL Mango caused a greater change in body weight compared with air-exposed control 







Fig. 4.3.  Urinary metabolites after acute electronic cigarette aerosol (e-cig; JUUL VA 
Tobacco) exposure.  Male mice were exposed (6h) to e-cig aerosol (JUUL VA Tobacco) 
after which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and aldehyde and 
tobacco alkaloid metabolites quantified. Values are mean ± SE (n=5 mice per group).  
Dashed lines indicate metabolite measures (µg) after HEPA exposure (6h).  Abbr.: 
3HPMA, 3-hydroxypropylmercapturic acid; Total NIC, total urinary nicotine metabolites 









Fig. 4.4.  Urinary metabolites after acute electronic cigarette aerosol (e-cig; JUUL 
Mango) exposure.  Male mice were exposed (6h) to e-cig aerosol (JUUL VA Mango) after 
which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and aldehyde and 
tobacco alkaloid metabolites quantified. Values are mean ± SE (n=4 mice per group).  
Dashed lines indicate metabolite measures (µg) after HEPA exposure (6h).  Abbr.: 
3HPMA, 3-hydroxypropylmercapturic acid; Total NIC, total urinary nicotine metabolites 








Fig. 4.5. Urinary metabolites after acute electronic cigarette aerosol (e-cig; JUUL 
Menthol) exposure.  Male mice were exposed (6h) to e-cig aerosol (JUUL Menthol) after 
which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and aldehyde and 
tobacco alkaloid metabolites quantified. Values are mean ± SE (n=4 mice per group).  
Dashed lines indicate metabolite measures (µg) after HEPA exposure (6h).  Abbr.: 
3HPMA, 3-hydroxypropylmercapturic acid; Total NIC, total urinary nicotine metabolites 




p=0.06) and a significant increase in kidney/body weight ratio (+7%; p=0.045) (Table 4.3).  
The overall leukocyte count was significantly decreased (-48%; p=0.001), driven by 
decreases in neutrophils (-54%; p=0.004), lymphocytes (-46%; p=0.002), and monocytes 
(-48%; p=0.06) (Table 4.4).  However, changes in erythrocytic measures were only seen in 
hemoglobin (+3%; p=0.02) and hematocrit (+4%; p=0.05) (Table 4.4).  Although plasma 
levels of muscle (CK) and LDH enzyme and creatinine were unchanged in exposed mice, 
exposure caused modestly significant increases in both albumin (+8%; p=0.06) and AST 
(+34%; p=0.06) (Table 4.3).   
6. Acute JUUL Mango E-cig Aerosol Exposure and CACs 
Acute (4d) exposure to JUUL Mango aerosol caused modest decreases in levels of 
both Sca-1+ cells (-67%; p=0.06) and CACs (-75%; p=0.06) (Fig. 4.6A & B). 
7. Systemic Toxicity of Acute Exposure to blu Plus+ E-cig Aerosol 
E-cig aerosol has been linked to negative health effects (174, 190-192), but the 
mechanism of these effects has not been identified.  Thus, we tested for changes in systemic 
and hematological biomarkers in mice exposed to e-cig (blu Plus+) aerosol (4d).  Acutely-
exposed male mice showed a significantly decreased final body weight (-6%; p=0.003) but 
no changes in measured organ/body weight ratios (Table 4.5).  Although plasma levels of 
liver (ALT, AST), muscle (CK), and LDH enzymes and creatinine were unaffected by 
exposure, triglycerides were modestly decreased (-12%; p=0.09) (Table 4.5).  Measures of 
toxicity by CBC showed considerable effects.  For example, e-cig exposure significantly 
decreased leukocyte count (-36%; p<0.001), driven by decreases in all leukocyte 
subpopulations (Table 4.6).  Increases in mean corpuscular hemoglobin (+7%; p<0.001), 






Table 4.3. Systemic parameters of female C57BL/6 mice acutely exposed to either air or electronic cigarette aerosol (e-cig; JUUL 
Mango). 
 
 Exposure (4 days) 
Variable Air Control JUUL Mango 
Change in BWT (g) -2 ± 0 -3 ± 0* 
Heart/BWT (mg/g) 5.0 ± 0.1 5.3 ± 0.1# 
 
Lung/BWT (mg/g) 6.5 ± 0.2 6.6 ± 0.2 
Liver/BWT (mg/g) 42.9 ± 0.7 43.5 ± 1.0 
Kidney/BWT (mg/g) 12.7 ± 0.2 13.7 ± 0.3* 
                        Plasma Measurements 
Cholesterol (mg/dL) 59.40 ± 1.12 56.20 ± 1.77 
HDL (mg/dL) 30.40 ± 0.93 29.20 ± 1.24 
LDL (mg/dL) 21.44 ± 0.42 20.20 ± 1.10 
Triglycerides (mg/dL) 37.80 ± 0.92 34.00 ± 3.61 
Albumin (g/dL) 2.68 ± 0.07 2.90 ± 0.05# 
Total Protein (g/dL) 4.46 ± 0.09 4.66 ± 0.09 
ALT (U/I) 7.20 ± 0.92 7.60 ± 0.60 
AST (U/I) 35.75 ± 2.63 47.80 ± 4.42# 
CK (U/I) 105.25 ± 7.12 175.60 ± 47.54 
LDH (U/I) 120.20 ± 19.34 117.80 ± 6.15 
Creatinine (mg/dL) 0.19 ± 0.01 0.19 ± 0.01 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 
weight; CK, creatine kinase; E-cig, electronic cigarette; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density 






Table 4.4. Hematological measures of female C57BL/6 mice acutely exposed to either air or electronic cigarette aerosol (e-cig; JUUL 
Mango). 
 
 Exposure (4 days) 
Hematological Measurements Air Control JUUL Mango 
White Blood Cell (K/uL) 1.15 ± 0.13 0.60 ± 0.07* 
Neutrophils (K/uL) 0.23 ± 0.03 0.11 ± 0.01* 
Lymphocytes (K/uL) 0.88 ± 0.10 0.48 ± 0.06* 
Monocytes (K/uL) 0.03 ± 0.01 0.02 ± 0# 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 9.07 ± 0.08 9.33 ± 0.14 
Hemoglobin (g/dL) 12.6 ± 0.1 13.0 ± 0.1* 
Hematocrit (%) 46.9 ± 0.5 48.6 ± 0.5# 
Mean Corpuscular Volume (fL) 51.7 ± 0.3 51.5 ± 0.2 
Mean Corpuscular Hemoglobin (pg) 13.8  ± 0.1 13.8 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 26.8 ± 0.1 26.7 ± 0.2 
Red Cell Distribution Width (%) 16.3 ± 0.1 16.2 ± 0.1 
Platelets (K/uL) 723 ± 15 694 ± 24 
Mean Platelet Volume (fL) 4.4 ± 0 4.3 ± 0 
 
Values = mean ± SE (n=10 mice per group); Abbr.: E-cig, electronic cigarette; *, p<0.05 compared with air control; #, 0.05≤p≤0.10 











Fig. 4.6. Effects of acute electronic cigarette (e-cig; JUUL Mango) aerosol exposure on circulating stem cells in female mice.  
Hematopoietic stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in female C57BL/6J (wild 
type, WT) mice exposed to HEPA-filtered air or JUUL Mango e-cigarette (e-cig) aerosol (6h/d) for 4 days. After 4 days of exposure to 
JUUL Mango, the level of both circulating Sca-1+ cells (A) and the level of CACs (Flk-1+/Sca-1+ cells) (B) decreased relative to air-






Table 4.5. Systemic parameters of male C57BL/6 mice acutely exposed to either air or electronic cigarette aerosol (e-cig; blu Plus+). 
 
 Exposure (4 days) 
Variable Air Control blu Plus+ e-cig 
Final BWT (g) 27 ± 0 25 ± 0* 
Heart/BWT (mg/g) 5.1 ± 0.1 5.2 ± 0.1 
Lung/BWT (mg/g) 5.6 ± 0.1 5.8 ± 0.2 
Liver/BWT (mg/g) 45.0 ± 0.8 44.3 ± 0.8 
Kidney/BWT (mg/g) 12.1 ± 0.3 12.3 ± 0.2 
                        Plasma Measurements 
Cholesterol (mg/dL) 83.25 ± 2.53 78.45 ± 2.78 
HDL (mg/dL) 49.57 ± 1.04 44.85 ± 5.50 
LDL (mg/dL) 5.84 ± 0.42 6.09 ± 1.07 
Triglycerides (mg/dL) 44.19 ± 2.09 39.01 ± 1.69# 
Albumin (g/dL) 2.86 ± 0.04 2.93 ± 0.05 
Total Protein (g/dL) 4.04 ± 0.16 3.89 ± 0.16 
ALT (U/I) 23.46 ± 2.46 20.18 ± 2.08 
AST (U/I) 53.03 ± 6.73 40.94 ± 2.89 
CK (U/I) 178.42 ± 18.62 157.50 ± 11.00 
LDH (U/I) 166.19 ± 12.36 155.11 ± 11.36 
Creatinine (mg/dL) 0.23 ± 0.01 0.24 ± 0.01 
 
Values = mean ± SE (n=9-10 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 
weight; CK, creatine kinase; E-cig, electronic cigarette; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density 







Table 4.6. Hematological measures of male C57BL/6 mice acutely exposed to either air or electronic cigarette aerosol (e-cig; blu 
Plus+). 
 Exposure (4 days) 
Hematological Measurements Air Control blu Plus+ e-cig 
White Blood Cell (K/uL) 1.80 ± 0.16 1.15 ± 0.12* 
Neutrophils (K/uL) 0.45 ± 0.07 0.28 ± 0.05* 
Lymphocytes (K/uL) 1.29 ± 0.11 0.85 ± 0.08* 
Monocytes (K/uL) 0.06 ± 0.01 0.03 ± 0* 
Eosinophils (K/uL) 0.01 ± 0 0 ± 0* 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 7.66 ± 0.29 7.98 ± 0.33 
Hemoglobin (g/dL) 10.5 ± 0.5 11.7 ± 0.6# 
Hematocrit (%) 33.6 ± 1.4 35.1 ± 1.6 
Mean Corpuscular Volume (fL) 43.7 ± 0.2 42.3 ± 1.7 
Mean Corpuscular Hemoglobin (pg) 13.7 ± 0.1 14.6 ± 0.4* 
Mean Corpuscular Hemoglobin Concentration (g/dL) 31.3 ± 0.2 33.3 ± 0.4* 
Red Cell Distribution Width (%) 16.9 ± 0.2 17.4 ± 0.4 
Platelets (K/uL) 592 ± 21 4.2 ± 0 
Mean Platelet Volume (fL) 605 ± 30 4.4 ± 0.2 
 
Values = mean ± SE (n=9-10 mice per group); Abbr.: E-cig, electronic cigarette; *, p<0.05 compared with air control; #, 0.05≤p≤0.10 






(+11%; p=0.10) were also seen in e-cig-exposed mice compared with air-exposed control 
mice (Table 4.6).   
8. Acute blu Plus+ E-cig Aerosol Exposure and Circulating Angiogenic Cells 
Male mice acutely exposed to e-cig (blu Plus+) aerosol (4d) showed no changes in 
the levels of CACs or Sca-1+ cells (Fig. 4.7A & B).   
9. Urinary Metabolites in PG:VG-Exposed Mice 
PG and VG are commonly used as humectants in e-cig devices (179).  The ratio of 
these compounds can vary between different e-cig devices, as well as with user 
modification, and variations in these ratios may influence the generation of different 
compounds in the e-cig aerosol (179).  To better characterize exposure to PG:VG in e-cig 
devices and to determine how varying ratios may impact aldehyde production, we 
measured urinary formate, acetate, 3HPMA, HPMMA, and/or total urinary nicotine 
metabolites by GC-MS and UPLC-MS/MS to evaluate the presence of PG:VG-related 
aldehydes in aerosols generated by e-cig devices.  For this, male mice were exposed to 
PG:VG (50%:50% or 30%:70%, 6h), and urine was collected immediately after exposure.  
Urinary levels of formate during the first three hours post-exposure were significantly 
increased in mice exposed to 50%:50% PG:VG compared with control mice (p=0.003) 
(Fig. 4.8), while urinary acetate was increased with exposure to 30%:70% PG:VG 
(p=0.047) (Fig. 4.9).  Similarly, the first three hours post-exposure showed significantly 
increased levels of urinary 3HPMA after exposure to either ratio of PG:VG (p<0.001 for 
50%50% PG:VG; p=0.02 for 30%:70% PG:VG) (Figs. 4.8 & 4.9).  Mice exposed to 
50%:50% PG:VG also showed a small but measurable level of HPMMA, the major urinary 







Fig. 4.7. Effects of acute electronic cigarette (e-cig; blu Plus+) aerosol exposure on circulating stem cells in male mice. 
Hematopoietic stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild 
type, WT) mice exposed to HEPA-filtered air or e-cig aerosol (blu Plus+, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and 









Fig. 4.8. Urinary metabolites after acute propylene glycol:vegetable glycerin (PG:VG; 
50%:50%) exposure.  Male mice were exposed (6h) to PG:VG (50%:50%) after which 
urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and aldehyde metabolites 
quantified. Values are mean ± SE (n=5 mice per group).  Dashed lines indicate metabolite 
measures (µg) after HEPA exposure (6h).  Abbr.: 3HPMA, 3-hydroxypropylmercapturic 



































Fig. 4.9. Urinary metabolites after acute propylene glycol:vegetable glycerin (PG:VG; 
30%:70%) exposure.  Male mice were exposed (6h) to PG:VG (30%:70%) after which 
urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and aldehyde and tobacco 
alkaloid metabolites quantified. Values are mean ± SE (n=4 mice per group).  Dashed lines 
indicate metabolite measures (µg) after HEPA exposure (6h).  Abbr.: 3HPMA, 3-
hydroxypropylmercapturic acid; HPMMA, 3-hydroxy-1-methylpropylmercapturic acid; 
PG:VG, propylene glycol:vegetable glycerin; Total NIC, total urinary nicotine 





than that measured after air exposure (Fig. 4.8).  Levels of formate and acetate after the 
overnight (3-16h) collections were elevated compared with levels 0-3h post-exposure with 
either ratio of PG:VG; these elevations are likely related to generation by food, as mice 
were given free access to food during this collection period (Figs. 4.8 & 4.9). 
10. Systemic Toxicity of Acute Exposure to Inhaled PG:VG 
Because PG and VG, two humectants commonly used in e-cig devices, have been 
shown to generate measurable levels of aldehydes (168, 214-216), we tested for changes 
in systemic and hematological biomarkers in female mice exposed to PG:VG (30%:70%).  
PG:VG-exposed female mice showed a greater change in body weight during the exposure 
period (-2 g vs -1 g; p=0.01) but no changes in measured organ/body weight ratios (Table 
4.7).  Acute exposure had considerable effects on CBC measures.  Exposed mice showed 
a significant decrease in leukocytes (-47%; p=0.003), driven by decreases in both 
neutrophils (-54%; p=0.01) and lymphocytes (-46%; p=0.003) (Table 4.8).  Red blood cell 
levels were increased (+6%; p<0.001) as were measures of hemoglobin (+4%; p=0.002) 
and hematocrit (+6%; p=0.002) in PG:VG-exposed mice, while mean platelet volume (4%; 
p=0.01) and, modestly, mean corpuscular hemoglobin (-2%; p=0.06) were decreased 
(Table 4.8).  Measures of systemic biomarkers showed no changes in muscle (CK) or LDH 
enzymes or creatinine but did show a significant increase in cholesterol (+15%; p=0.03) 
driven by an increase in LDL (+26%; p=0.03) (Table 4.7).  Conversely, ALT was 
significantly decreased in exposed mice (-20%; p=0.02) (Table 4.7).   
11. Acute Exposure to Inhaled PG:VG and Circulating Angiogenic Cells 
Female mice exposed to 30%:70% PG:VG showed no change in the levels of CACs 






Table 4.7. Systemic parameters of female C57BL/6 mice acutely exposed to either air or propylene glycol:vegetable glycerin 
(PG:VG; 30%:70%). 
 Exposure (4 days) 
Variable Air Control 30%:70% PG:VG 
Change in BWT (g) -1 ± 0  -2 ± 0* 
Heart/BWT (mg/g) 5.2 ± 0.2 4.8 ± 0.1 
Lung/BWT (mg/g) 6.4 ± 0.1 6.3 ± 0.2 
Liver/BWT (mg/g) 38.8 ± 1.3 38.0 ± 0.6 
Kidney/BWT (mg/g) 12.7 ± 0.3 11.8 ± 0.2 
                        Plasma Measurements 
Cholesterol (mg/dL) 44.74 ± 1.31 51.45 ± 1.77* 
HDL (mg/dL) 25.78 ± 1.05 30.36 ± 2.00 
LDL (mg/dL) 12.80 ± 0.85 16.14 ± 0.47* 
Triglycerides (mg/dL) 30.81 ± 5.26 26.28 ± 1.54 
Albumin (g/dL) 2.82 ± 0.07 2.98 ± 0.07 
Total Protein (g/dL) 3.78 ± 0.11 3.94 ± 0.05 
ALT (U/I) 20.20 ± 0.56 16.18 ± 0.34* 
AST (U/I) 64.10 ± 4.40 57.11 ± 4.33 
CK (U/I) 164.16 ± 11.04 158.73 ± 24.29 
LDH (U/I) 125.46 ± 8.91 127.20 ± 10.71 
Creatinine (mg/dL) 0.21 ± 0.04 0.17 ± 0.01 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 
weight; CK, creatine kinase; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; PG:VG, 






Table 4.8. Hematological measures of female C57BL/6 mice acutely exposed to either air or propylene glycol:vegetable glycerin 
(PG:VG; 30%:70%). 
 
 Exposure (4 days) 
Hematological Measurements Air Control 30%:70% PG:VG 
White Blood Cell (K/uL) 1.34 ± 0.16 0.70 ± 0.05* 
Neutrophils (K/uL) 0.30 ± 0.06 0.14 ± 0.01* 
Lymphocytes (K/uL) 1.00 ± 0.11 0.54 ± 0.04* 
Monocytes (K/uL) 0.04 ± 0.01 0.02 ± 0.01 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 8.73 ± 0.07 9.29 ± 0.07* 
Hemoglobin (g/dL) 12.1 ± 0.1 12.6 ± 0.1* 
Hematocrit (%) 44.9 ± 0.4 47.6 ± 0.5* 
Mean Corpuscular Volume (fL) 51.5 ± 0.5 51.2 ± 0.2 
Mean Corpuscular Hemoglobin (pg) 13.9 ± 0.2 13.6 ± 0.1# 
Mean Corpuscular Hemoglobin Concentration (g/dL) 27.0 ± 0.3 26.5 ± 0.2 
Red Cell Distribution Width (%) 17.0 ± 0.2 16.8 ± 0.1 
Platelets (K/uL) 656 ± 27 710 ± 36 
Mean Platelet Volume (fL) 4.4 ± 0 4.2 ± 0* 
 
Values = mean ± SE (n=10 mice per group); Abbr.: PG:VG, propylene glycol:vegetable glycerin; *, p<0.05 compared with air control; 









Fig. 4.10. Effects of acute propylene glycol:vegetable glycerin (PG:VG; 30%:70%) exposure on circulating stem cells in female 
mice.  Hematopoietic stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in female C57BL/6J 
(wild type, WT) mice exposed to HEPA-filtered air or PG:VG (30%:70%, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and 






Tobacco smoking is the most significant modifiable risk factor in the development 
of CVD (14).  As previously mentioned, tobacco smoke contains hundreds of thousands of 
compounds (396), and while the number of compounds generated in e-cig aerosols is still 
unknown, early analyses of the aerosol have shown that these devices still generate many 
of the harmful compounds found in MCS (96, 168, 400).  The goal of this study was to 
examine the systemic, hematological, and endothelium-related effects of MCS, e-cig 
aerosol, and humectants used in e-cigs.   
The results of these inhalation exposure studies revealed a number of important and 
novel observations and also confirmed findings previously described in the literature.  
Urinary analysis of male mice exposed to MCS showed that traditional cigarettes contain 
high levels of acrolein (measured via its urinary metabolite, 3HPMA), confirming previous 
data (114, 117, 147), but levels of other measured aldehyde metabolites are low in 
comparison.  This may indicate that acrolein is responsible for the majority of the effects 
noted in response to MCS exposure; the significant role of acrolein in the toxicity of MCS 
has already been shown (145, 149).  Exposure to JUUL VA Tobacco and Mango showed 
similar levels of urinary 3HPMA, suggesting that acrolein may also play a role in the health 
outcomes of these flavorings.  However, exposure to aerosol from a JUUL device with 
either VA Tobacco, Mango, or Menthol flavoring significantly increased levels of total 
urinary nicotine metabolites (nicotine, cotinine, and 3HC).  Nicotine, an important 
constituent in MCS, stimulates the sympathetic nervous system and has been shown to 
increase heart rate, blood pressure, platelet aggregation, myocardial contractility, and 
atherosclerotic development (401).  JUUL devices use nicotine salts to deliver nicotine to 




with one JUUL pod capable of providing a dose of nicotine similar to that of an entire pack 
of traditional cigarettes (402).  Thus, it may be that the effects of JUUL devices are related 
to high levels of nicotine, although additional studies are needed to better understand the 
relationship between the levels of nicotine found in JUUL devices and our cardiovascular 
outcomes of interest. 
Interestingly, although the levels of total urinary nicotine metabolites were 
increased in response to exposure to all of the flavored JUUL products compared with air-
exposed control mice and MCS-exposed mice, levels were significantly higher after 
exposure to the mango and menthol flavorings than after exposure to VA Tobacco.  This 
may suggest that the Mango and Menthol flavorings differ from VA Tobacco in some way 
that allows for greater nicotine exposure.  Although there has not been much study of the 
JUUL Mango flavoring, menthol has long been used to provide a cooling or mint flavor in 
traditional cigarettes.  Many studies have shown that the use of mentholated cigarettes 
allows for greater exposure to harmful constituents of MCS compared with the use of non-
mentholated cigarettes (403, 404), whether through the attenuation of the respiratory 
irritation typically induced by MCS (405) or through decreased nicotine metabolism (406).  
The menthol flavoring used in JUUL devices may be inducing a similar effect and thus 
allowing for greater nicotine exposure.  These differences in measures of urinary 
metabolites between flavors emphasizes the need to study individual e-liquid flavors to 
determine how they may induce different, specific health effects.  Additionally, nationally 
representative survey data collected from approximately 14,000 middle and high school 
aged individuals showed that mint and mango were the most commonly used flavorings in 




particular.   
Analysis of the urinary metabolites in mice exposed to 30%:70% PG:VG or 
50%:50% PG:VG showed significant increases in 3HPMA compared with baseline 
measures but varied in levels of formate and acetate.  Thus, as with individual flavors, these 
data indicate the need to determine how varying ratios of PG:VG used in different e-cig 
devices may have varying health effects. 
Acute exposure to MCS induced leukocyte suppression, driven by a decrease in 
lymphocytes.  This is contrary to what is seen in epidemiological studies, where smokers 
show increased levels of leukocytes driven by increases in neutrophils, lymphocytes, and 
monocytes (345, 351-355).  These changes are likely linked to the systemic inflammatory 
response activated by MCS exposure and the subsequent increase in the release of cells 
from the bone marrow (408, 409).  The difference in outcomes may be due to the duration 
of our exposure; many epidemiological studies of smoking examine individuals who are 
chronic smokers and who may already have a significantly altered inflammatory response, 
while our mice are naïve animals never exposed to MCS or other air pollutants and whose 
response may be more similar to that seen in non-smokers.   
In fact, analysis of more than 7,000 never-smoking adults from the third National 
Health and Nutrition Examination Survey found that participants with low but detectable 
cotinine levels—that is, individuals with secondhand smoke exposure—actually had 
decreased leukocyte levels compared with individuals without detectable cotinine levels 
(410).  The authors of the study do not propose a hypothesis for why their leukocyte data 
are contrary to that seen in other epidemiological studies, but it does suggest that there are 




to be explored, perhaps in relation to levels of circulating Sca-1+ cells, the hematological 
stem cell population from which leukocytes are derived.  Acute MCS exposure in the 
current study did not change levels of CACs but did significantly decrease levels of Sca-
1+ cells, and although the production of leukocytes occurs within the bone marrow, the 
decreased levels of Sca-1+ cells in the circulation may reflect decreased levels of these stem 
cells within the bone marrow as well, thus limiting leukocyte production.  Additional 
studies of these stem cells in the bone marrow after MCS exposure could help clarify these 
outcomes. 
Additional studies of the hematological response to MCS largely show that 
smoking increases several erythrocytic measures, including hemoglobin and platelets (345, 
355, 411-413); levels of red blood cells are also often found to be increased (345, 414), 
although this is not always observed (355).  Changes in erythrocytic measures, such as 
increased levels of hemoglobin, that are commonly seen in smokers are believed to be a 
compensatory mechanism to account for lower blood oxygen levels.  Smoking introduces 
other gases such as carbon monoxide into the bloodstream where they can displace oxygen 
and lead to the activation of compensatory pathways that upregulate the production of 
hematological factors.  Changes in mean corpuscular volume, mean corpuscular 
hemoglobin, and mean corpuscular hemoglobin concentration are also indices based on the 
composition of the hemoglobin found in red blood cells, and as hemoglobin changes in 
response to MCS exposure, so do these indices.  The current MCS study confirms these 
findings; data reveal that the exposed mice have altered erythrocytic measures, showing 
significant changes in hemoglobin, hematocrit, mean corpuscular hemoglobin, and mean 




platelet size.  The presence of these changes but not changes within leukocytes which are 
also commonly noted in smokers may indicate that changes in the hematological 
parameters occur earlier than those in leukocyte levels, although additional studies 
including chronic exposures to MCS are needed to confirm this hypothesis.   
Electronic tobacco products such as e-cigs have not been in use for a period long 
enough to thoroughly determine the chronic outcomes of use, but acute studies using e-cig 
aerosol or various e-cig flavoring chemicals have shown that they have the potential to 
contribute to the development of CVD in a fashion similar to traditional cigarettes, 
including the development of endothelium dysfunction (190, 241), platelet activation and 
aggregation (370-372), and increases in markers of inflammation (415, 416).  The results 
of our acute blu Plus+ e-cig exposure study largely agree with these early reports of e-cig 
toxicity.  Leukocyte count was significantly decreased with exposure, driven by decreases 
in neutrophils, lymphocytes, and monocytes, and a handful of erythrocytic measures, 
including hemoglobin, were increased in response to exposure.  Measures of endothelium 
function, however, did not indicate that blu Plus+ e-cig aerosol was contributing to 
dysfunction, as there was no change in the level of CACs in response to exposure.  As there 
were also no change in CACs after MCS exposure, these outcomes may indicate that the 
endothelium dysfunction noted in response to exposure to these tobacco products takes 
longer than four days to develop.  Nonetheless, the fact that MCS- and e-cig aerosol-
exposures both show a number of similar outcomes that could contribute to the 
development of CVD may indicate that these outcomes are being driven by shared 
constituents, a premise that may be particularly important to the FDA as they seek to 




Because risk for and prevalence of CVD have been shown to differ between men 
and women (417-422), we also examined the effects of tobacco product exposures on 
female mice.  Like their MCS- and blu Plus+-exposed male counterparts, female mice 
acutely (4d) exposed to JUUL Mango showed a significant decrease in overall leukocyte 
count in addition to changes in erythrocytic measures, as did female mice acutely (4d) 
exposed to 30%:70% PG:VG.  However, female mice exposed to JUUL Mango also 
showed modest decreases in levels of both Sca-1+ cells and CACs; although MCS exposure 
decreased the level of Sca-1+ cells in male mice, there was no change in CACs, and neither 
male mice exposed to blu Plus+ e-cig aerosol or female mice exposed to 30%:70% PG:VG 
showed changes in either cell type.  Measures of systemic biomarkers showed that while 
female mice exposed to JUUL Mango only had minimal effects (modestly increased 
albumin and AST), female mice exposed to 30%:70% PG:VG had significantly increased 
cholesterol, driven by an increase in LDL.  The risk of coronary heart disease has been 
correlated with levels of LDL (423), and a high level of cholesterol is a known risk factor 
for ischemic and coronary heart diseases (424).  Although males are more likely than 
females to use traditional cigarettes (182, 325, 425, 426), and early reports of e-cig use 
suggest that males are also more likely than females to use these devices (182, 325, 427-
429), there is preliminary data indicating that female smokers may have a greater 
prevalence of tobacco-related negative health outcomes than male smokers (426, 430).  The 
change in Sca-1+ cells and CACs noted in female mice exposed to JUUL Mango may 
indicate a sex-dependent susceptibility to some component of this particular flavor, as these 
changes are not seen after exposure to 30%:70% PG:VG, the ratio of humectants 
commonly used in JUUL devices, in female mice.  These data may also indicate that the 
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development of endothelium dysfunction is one of the earliest changes noted in response 
to exposure to JUUL Mango aerosol.  Conversely, the change in cholesterol noted in 
30%:70% PG:VG-exposed female mice may indicate that the e-cig humectants are first 
affecting systemic biomarkers rather than inducing changes in the endothelium.  Additional 
studies are needed to determine whether these effects are seen in male mice exposed to 
30%:70% PG:VG and JUUL Mango, to examine potential sex-dependent differences 
related to other e-cig flavors, and to better understand the vascular, hematological, and 
systemic effects of other e-cig flavors in general.  Likewise, chronic exposure to both MCS 
and e-cig aerosols could reveal further sex-dependence in biomarkers of cardiovascular 
health 
In summary, the studies presented in this chapter have demonstrated the impacts of 
traditional and emerging tobacco products on systemic and vascular health.  In particular, 
these studies showed that exposure to e-cig aerosol (blu Plus+ and JUUL) produced levels 
of urinary aldehyde and tobacco alkaloid metabolites at levels similar to those found after 
MCS exposure, indicating that ENDS generate harmful and potentially harmful 
constituents much like MCS.  Furthermore, data from systemic and hematological 
measures indicate that, like exposure to MCS, exposure to e-cig aerosol can significantly 
decrease levels of leukocytes, which could put users at a higher risk for infection.  The 
decrease in CACs seen in female mice exposed to JUUL Mango but not 30%:70% PG:VG 
may indicate the potential for endothelium injury related to this specific flavor, but a 
comparable study in male mice exposed to JUUL Mango is needed to determine whether 
this specific outcome is sex-dependent.  Likewise, the increase in cholesterol and LDL seen 




systemic effects known to contribute to the development of CVD in response to humectant 
exposure, but, again, a comparable study in male mice is needed to determine whether these 
outcomes are sex-dependent.  As the use of emerging tobacco products continues to 
increase—particularly among youths—and as diseases such as EVALI continue to impact 
e-cig users, these studies provide novel insight into the health impacts of e-cigs and related 
components.  Furthermore, these studies show similarities in exposure to aerosol from e-
cigs and smoke from traditional cigarettes, whose roles in morbidity and mortality are well-
known, and emphasize the need to study the health effects of e-cigs in both males and 




SYSTEMIC, HEMATOLOGICAL, AND ENDOTHELIUM-RELATED EFFECTS OF 
FORMALDEHYDE AND ACETALDEHYDE IN MICE 
A. Introduction 
The saturated aldehydes formaldehyde (FR) and acetaldehyde (AA) are the smallest 
of the aldehydes.  Both of these compounds can be found in a variety of food and drinks 
(99, 105, 106), and each is produced endogenously in small amounts (93, 97, 98, 105, 106).  
However, anthropogenic sources account for the majority of human exposure.  FR is used 
in many consumer products, including carpets, manufactured wood products, paints, and 
preservatives (102), and both FR and AA are formed as products of combustion from 
industry, vehicle exhaust, and fires (101-103, 105, 106).  Exposure to mainstream cigarette 
(MCS) or secondhand smoke can significantly increase the level of exposure to FR and 
AA.  The World Health Organization estimates that smoking 20 cigarettes a day can 
increase exposure to FR up to 300% (99, 114, 117).  Most AA exposure comes from food 
and drinks, so any inhalation can significantly increase exposure, with studies estimating 
that MCS can more than double AA exposure (107, 109, 117, 118).  The Institute of 
Medicine ranks FR and AA as two of the most significant toxins in MCS, particularly in 
relation to cardiovascular disease (CVD) (96).  The negative cardiovascular effects of FR 




hematotoxicity, decreasing both red (93, 120, 122) and white (93, 120-122) blood  cell and 
platelet counts (93, 120, 122) as well as levels of myeloid progenitor cells (120, 122).  FR 
has also been linked to decreases in blood pressure, both via inhalation in rats (123) and 
ingestion in humans (128); in vitro studies show a concentration-dependent vascular 
relaxation in response to FR that supports these findings (124-127).  Occupational 
exposures show also an association between increased exposure to FR and an increased 
incidence of heart disease (129-131).  The cardiovascular effects of AA have largely been 
studied in relation to aldehyde dehydrogenase (ALDH2), the enzyme responsible for AA 
metabolism, and specifically the ALDH2 mutation that prevents AA metabolism, thus 
allowing blood levels of AA to increase (132).  Increased blood levels of AA have been 
linked to a number of CVDs (132, 134-138) and changes in hematological factors (139-
142).  
Despite the significant exposure to FR and AA from MCS—as well as from 
electronic cigarette (e-cig) aerosol, as these devices have been shown to generate a variety 
of aldehydes (96, 180, 207-213)—and despite the high percent of the world’s population 
affected by mutated ALDH2 and who are thus more susceptible to AA exposure (133), few 
studies have addressed the effect of these compounds on endothelium function.  Thus, the 
goal of these studies was to measure concentration- and duration-dependent as well as sex-
dependent changes in biomarkers of vascular injury, specifically circulating angiogenic 
cells (CACs), and systemic and hematological biomarkers in mice exposed to FR and AA. 
B. Experimental Procedures 
1. Exposures 
Animals were exposed to constituents via full-body inhalation as described in 
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Chapter II, Sections B.2.  Upon completion of the exposure, mice were euthanized and 
tissues collected as described in Chapter II, Section B.5.  
2. Urine Collection
Urine samples were collected post-exposure as described in Chapter II, Section B.3. 
3. Urine Metabolite Quantification
Collected urine was used to quantify levels of volatile organic compounds (VOC), 
saturated aldehyde, and tobacco alkaloid metabolites using analytical methods as described 
in Chapter II, Section B.4. 
4. Complete Blood Cell Count (CBC)
A sample of whole blood was collected after the final day of exposure for a 
complete blood cell count (CBC) as described in Chapter II, Section B.6. 
5. Plasma Biomarkers Quantification
Plasma was prepared from each sample for an analysis of a number of biomarkers 
as described in Chapter II, Section B.7. 
6. Circulating Angiogenic Cell (CAC) Quantification
Flow cytometry was used to analyze the number of CACs in each sample as 
described in Chapter II, Section B.8. 
7. Statistical Analyses
Statistical analyses were performed as described in Chapter II, Section B.10. 
C. Results 
1. Urinary Formaldehyde Metabolite in MCS-, PG:VG-, and Formaldehyde-
Exposed Mice 




products or by exposure to exhaust and other combustion products (100-104), the use of 
tobacco products results in a much greater level of exposure to FR (93, 95, 99).  
Furthermore, although formate, the primary urinary metabolite of FR, has not been 
validated as a urinary biomarker of tobacco exposure (431, 432), studies have shown that 
it can be used in conjunction with other biomarkers as an indicator of tobacco product use 
or exposure (168, 293, 433).  To better understand how FR-alone exposure related to MCS 
exposure from a known number of cigarettes and to e-cig exposure from known ratios of 
PG:VG, we measured urinary formate by UPLC-MS/MS to confirm that the concentration 
of FR used in our FR-alone exposure was comparable to exposures from real-world 
sources.  For this, male mice were exposed to FR (5 ppm, 6h), MCS (50% of smoke of 12 
KY Reference 3R4F cigarettes, 6h), or PG:VG (50%:50% or 30%:70%, 6h), and urine was 
collected immediately after the exposure sessions. 
Urinary formate levels in the first three hours post-exposure were not significantly 
different between mice exposed to FR (5 ppm) or to 30%:70% PG:VG compared with 
baseline, but mice exposed to MCS or 50%:50% PG:VG showed significantly increased 
levels (p=0.009 and p=0.003, respectively) (Fig. 5.1).  Additionally, levels of formate in 
MCS-exposed mice were significantly higher than levels in FR-exposed mice (Fig. 5.1).  
Formate levels in FR-exposed mice were not significantly different from those in PG:VG-
exposed mice, likely indicating that the concentration of FR generated for the FR-alone 
exposure (5 ppm) is similar to the levels generated in PG:VG, regardless of the ratio (Fig. 
5.1).  Levels of formate after the overnight (3-16h) collections were elevated compared 
with levels 0-3h post-exposure with all exposures; these elevations are likely related to 







Fig. 5.1.  Urinary formate levels in formaldehyde- or tobacco product-exposed male 
mice.  Male mice were exposed (6h) to formaldehyde (5 ppm), mainstream cigarette smoke 
(MCS; 50% smoke of 12 cigarettes), or propylene glycol:vegetable glycerin (PG:VG; 
50%:50% or 30%:70%, 6h) after which urine was collected at 0–1, 1–2, 2–3, and 3–16h 
(overnight) and formate quantified. Values are mean ± SE (n=4-12 mice per group).  *, 




(Fig. 5.1).  Additionally, mice exposed to FR had lower levels of formate after the overnight 
exposure compared with baseline (Fig. 5.1). 
2. Systemic Toxicity of Two-Week Exposure to Inhaled Formaldehyde 
Because of the potential for MCS to significantly increase levels of FR exposure 
(99, 114, 117), we tested for changes in systemic and hematological biomarkers in mice 
exposed to FR (5 ppm).  Body weight and organ/body weight ratios showed significant 
changes between the air- and FR-exposed groups; exposure to 5 ppm FR caused decreases 
in final body weight (-8%; p=0.02) and the liver/body weight ratio (-5%; p=0.08) and an 
increase in the lung/body weight ratio (+12%, p=0.002) (Table 5.1).  Two weeks of 
exposure had modest to considerable effects on CBC and plasma biomarkers.  Exposed 
mice had a decreased level of leukocytes (-46%; p=0.004), driven by decreases in all 
leukocyte subpopulations, but an increased level of red blood cells (+9%; p=0.01) (Table 
5.2).  Likewise, hemoglobin levels (+7%; p=0.02) were increased, while mean corpuscular 
hemoglobin concentration (-2%; p=0.08), platelet count (-17%; p=0.01), and mean platelet 
volume (-12%; p=0.002) were all decreased (Table 5.2).  A low volume of plasma limited 
additional measurements of systemic toxicity, but exposed mice showed a significant 
decrease in cholesterol compared with air-exposed control mice (-32%; p=0.03) (Table 
5.1).  
3. Two-Week Exposure to Formaldehyde and Circulating Angiogenic Cells 
Decreased levels of CACs have been associated with increased CVD risk, and it is 
thought that CAC levels serve as a predictor of overall cardiovascular health and future 
cardiovascular events (66). Altered CAC levels are noted in individuals exposed to 






Table 5.1. Systemic parameters of male C57BL/6 mice acutely exposed to either air or formaldehyde (FR; 1, 2, or 5 ppm). 
 
Exposure 
  4 days 2 weeks 
Variable Air Control FR (1 ppm) FR (2 ppm) FR (5 ppm) FR (5 ppm) 
Final BWT (g) 28 ± 0 29 ± 0 29 ± 1 27 ± 1 26 ± 0* 
Heart/BWT (mg/g) 5.0 ± 0.1 5.0 ± 0.3 4.9 ± 0.1 5.1 ± 0.2 4.8 ± 0.1 
Lung/BWT (mg/g) 5.6 ± 0.1 5.1 ± 0.2 5.2 ± 0.1 5.5 ± 0.2 6.2 ± 0.1* 
Liver/BWT (mg/g) 42.1 ± 0.6 42.9 ± 1.0 42.3 ± 0.8 40.5 ± 1.2 40.2 ± 1.0 
Kidney/BWT (mg/g) 12.9 ± 0.2 12.6 ± 0.2 12.2 ± 0.2* 11.2 ± 0.8* 13.1 ± 0.3 
Plasma Measurements 
Cholesterol (mg/dL) 96.03 ± 3.67 117.89 ± 2.64* 103.83 ± 3.13 94.23 ± 2.32 65.45 ± 5.29* 
HDL (mg/dL) 66.31 ± 4.33 N/A N/A 67.88 ± 2.90 N/A 
Triglycerides (mg/dL) 47.84 ± 2.20 44.57 ± 2.22 33.75 ± 3.86* 43.64 ± 2.01 50.48 ± 2.15 
Albumin (g/dL) 3.37 ± 0.06 3.71 ± 0.05* 3.66 ± 0.05* 3.21 ± 0.06 N/A 
Total Protein (g/dL) 4.74 ± 0.08 4.50 ± 0.07# 4.67 ± 0.05 5.18 ± 0.13* N/A 
ALT (U/I) 24.40 ± 1.65 19.99 ± 0.71 24.84 ± 1.82 38.44 ± 7.75# N/A 
AST (U/I) 77.33 ± 7.55 40.63 ± 2.72* 60.61 ± 3.96 104.26 ± 14.34* N/A 
CK (U/I) 277.82 ± 26.67 169.65 ± 12.31* 267.89 ± 34.08 314.13 ± 68.39 N/A 
LDH (U/I) 230.89 ± 21.17 156.74 ± 7.25* 263.01 ± 24.92 188.06 ± 23.20 N/A 
Creatinine (mg/dL) 0.31 ± 0.01 0.30 ± 0.01 0.38 ± 0.01* 0.37 ± 0.01* N/A 
 
Values = mean ± SE (n=6-11 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 
weight; CK, creatine kinase; FR, formaldehyde; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; *, p<0.05 compared with 







Table 5.2. Hematological measures of male C57BL/6 mice acutely exposed to either air or formaldehyde (FR; 1, 2, or 5 ppm). 
 
  4 days 2 weeks 
Hematological Measurements Air Control FR (1 ppm) FR (2 ppm) FR (5 ppm) FR (5 ppm) 
White Blood Cell (K/uL) 2.35 ± 0.18 2.11 ± 0.23 2.06 ± 0.10 2.94 ± 0.49 1.27 ± 0.15* 
Neutrophils (K/uL) 0.66 ± 0.11 0.27 ± 0.03* 0.46 ± 0.04 0.79 ± 0.16 0.31 ± 0.05# 
Lymphocytes (K/uL) 1.60 ± 0.12 1.71 ± 0.19 1.44 ± 0.11 2.07 ± 0.40 0.92 ± 0.11* 
Monocytes (K/uL) 0.07 ± 0.01 0.08 ± 0.02 0.06 ± 0.01 0.06 ± 0.01 0.04 ± 0.01* 
Eosinophils (K/uL) 0.01 ± 0 0.06 ± 0.01* 0.01 ± 0 0.01 ± 0.01 0 ± 0# 
Basophils (K/uL) 0.01 ± 0 0 ± 0 0 ± 0 0.01 ± 0 0 ± 0* 
Red Blood Cell (M/uL) 9.54 ± 0.16 9.49 ± 0.13 9.13 ± 0.26 8.45 ± 0.17* 10.39 ± 0.11* 
Hemoglobin (g/dL) 13.6 ± 0.2 13.6 ± 0.1 12.3 ± 0.3* 12.3 ± 0.2# 14.6 ± 0.1* 
Hematocrit (%) 41.3 ± 0.7 45.1 ± 0.5* 39.0 ± 1.1# 35.0 ± 0.7* 43.9 ± 0.5 
Mean Corpuscular Volume (fL) 43.3 ± 0.3 47.5 ± 0.3* 42.7 ± 0.2 41.5 ± 0.3* 42.2 ± 0.4 
Mean Corpuscular Hemoglobin 
(pg) 
14.2 ± 0.1 14.3 ± 0.1 13.6 ± 0.2* 14.6 ± 0.1# 14.0 ± 0.1# 
Mean Corpuscular Hemoglobin 
Concentration (g/dL) 
32.9 ± 0.3 30.1 ± 0.2* 31.7 ± 0.3 35.3 ± 0.4* 33.2 ± 0.3 
Red Cell Distribution Width (%) 18.4 ± 0.2 N/A 17.6 ± 0.2* 17.6 ± 0.4 17.9 ± 0.3 
Platelets (K/uL) 735 ± 24 800 ± 16 810 ± 34 715 ± 30 612 ± 55* 
Mean Platelet Volume (fL) 4.8 ± 0.1 6.0 ± 0* 4.7 ± 0.1 4.5 ± 0 4.3 ± 0.1* 
 
Values = mean ± SE (n=6-11 mice per group); Abbr.: FR, formaldehyde; *, p<0.05 compared with air control; #, 0.05≤p≤0.10 compared 






response to tobacco smoke, there was a significant decrease in the level of CACs (Flk-
1+/Sca-1+ cells) after two weeks of FR exposure (5 ppm; -56%, p=0.003) (Fig. 5.2B).  
Levels of Sca-1+ cells, the larger hematopoietic stem cell population from which CACs are 
derived, were also significantly decreased compared with air-exposed control mice (-50%; 
p=0.01) (Fig. 5.2A).   
4. Systemic Toxicity of Acute Exposure to Inhaled Formaldehyde 
Because two weeks of exposure to FR (5 ppm) had specific systemic toxicity that 
included changes in body weight, CBC (leukocytes, red blood cells, hemoglobin), plasma 
factors (cholesterol), and CACs (decreased), we performed acute FR exposures to better 
understand the temporal relationships between these factors.  Thus, we tested whether acute 
FR exposures would induce rapid toxicity that was otherwise compensated for in a longer 
setting.  Acute exposure of male mice (1, 2, or 5 ppm; 4 days) had limited effects on organ 
and body weights (or ratios) or in leukocytes, but caused significant changes in 
erythrocytes and related measures (Tables 5.1 & 5.2).  Exposure to a higher concentration 
of FR (5 ppm) caused no change in overall body weight but induced a significant decrease 
in kidney/body weight ratio (-13%; p=0.001) (Table 5.1).  Although the overall leukocyte 
count and counts of subpopulations were unchanged, FR-exposed mice showed decreased 
red blood cell count (-11%; p=0.003), hemoglobin (-9%; p=0.10), hematocrit (-15%; 
p<0.001), and mean corpuscular volume (-4%; p=0.003) but increased mean corpuscular 
hemoglobin (+3%; p=0.06) and mean corpuscular hemoglobin concentration (+7%; 
p=0.002) (Table 5.2).  Acute exposure to FR (5 ppm) did not affect plasma levels of CK 
(striated muscle) or LDH (non-specific cell toxicity) enzymes, but did increase levels of 








Fig. 5.2.  Effects of two-week formaldehyde (FR; 5 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem 
cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice 
exposed to HEPA-filtered air or formaldehyde (5 ppm, 6h/d) for two weeks. After two weeks of exposure to FR, the levels of both 
circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells) (B) were significantly decreased in WT mice.  Values = mean ± SE (n= 9-





p=0.03), and, modestly, ALT (liver) (+58%; p=0.07) compared with the air-exposed 
control group (Table 5.1). 
Unsurprisingly, acute (4d) exposure to FR at lower concentrations (1 and 2 ppm) 
showed similar but diminished effects overall on markers of systemic and hematological 
toxicity than 5 ppm exposure.  Exposure to FR (2 ppm) showed a similar decrease in 
kidney/body weight ratio (-6%; p=0.04) but no changes in leukocytes (Tables 5.1 & 5.2).  
Measures of hemoglobin and hematocrit were likewise decreased (-9%; p=0.02 and -6%; 
p=0.08, respectively), but red cell distribution width was also increased (-4%; p=0.02), 
while mean corpuscular hemoglobin was decreased rather than increased as was seen at a 
higher FR concentration (5 ppm) (-5%; p<0.001) (Table 5.2).  Creatinine was again 
increased (+23%; p<0.001), and changes in triglycerides (-29%; p=0.003) and albumin 
(+9%; p=0.002) were also induced at this level of exposure (2 ppm) (Table 5.1).  At the 
lowest-tested concentration of FR (1 ppm), acute (4d) exposure caused no changes in organ 
or body weights (or ratios) (Table 5.1).  Plasma levels of triglycerides, ALT, and creatinine 
remained unchanged, however, levels of plasma cholesterol and albumin were increased 
(+23%; p=0.004 and +10%; p=0.01, respectively), while levels of plasma total protein (-
5%; p=0.08), AST (-47%; p=0.001), CK (-39%; p=0.04), and LDH (-32%; p=0.01) were 
decreased (Table 5.1).  Although there was no change in overall leukocyte count, 
neutrophil count was decreased (-60%; p=0.04) and eosinophils increased (+438%; 
p<0.001) (Table 5.2).  Contrary to changes seen at higher FR concentrations (2 and/or 5 
ppm), both hematocrit (+9%; p=0.01) and mean corpuscular volume (+10%; p<0.001) 
were increased and mean corpuscular hemoglobin concentration decreased (-8%; p<0.001) 




low level (1 ppm) FR exposure (+24%; p=0.002) (Table 5.2).   
In female mice, acute exposure to FR (2 or 5 ppm; 4 days) had limited to modest 
effects on organ and body weights (or ratios), CBC, or plasma biomarkers (Tables 5.3 & 
5.4).  For example, female mice acutely exposed to 2 ppm FR had no change in overall 
body weight or organ/body weight ratios (Table 5.3) and only increases in eosinophils 
(+231%; p=0.01) and basophils (+141%; p=0.09) (Table 5.4).  Plasma levels in liver (ALT, 
AST) and CK (muscle) enzymes and creatinine were unchanged, but LDH and, modestly, 
albumin were increased (+37%; p=0.03 and +6%; p=0.09, respectively) (Table 5.3).  
Surprisingly, 4 days of FR (5 ppm) exposure in female mice has a similarly minimal effect 
on markers of systemic toxicity.  Cholesterol (-32%; p=0.02), triglycerides (-14%; p=0.05), 
albumin (-14%; p=0.01), and total protein (-9%; p=0.03) were all decreased, as were 
monocyte levels (-37%; p=0.04) and mean platelet volume (-9%; p=0.004) (Table 5.3).   
5. Acute Exposure to Formaldehyde and Circulating Angiogenic Cells 
Acute (4d) exposure to 5 ppm FR increased the levels of CACs in male mice 
(+62%; p=0.002), but there was no change in the level of Sca-1+ cells (Fig. 5.3A & B).  
Acute (4d) exposure to 2 ppm FR did not change the level of Sca-1+ cells or CACs (Fig. 
5.4A & B).  Likewise, female mice had no change in the levels of CACs or Sca-1+ cells 
with acute FR (2 or 5 ppm) exposure (Figs. 5.5A & B and 5.6A & B). 
6. Urinary Acetaldehyde Metabolite in MCS-, PG:VG-, and Acetaldehyde-
Exposed Mice 
Although exposure to AA occurs largely through the ingestion of various food 
products, particularly via alcohol consumption (105-107), the use of tobacco products can 






Table 5.3. Systemic parameters of female C57BL/6 mice acutely exposed to either air or formaldehyde (FR; 2 or 5 ppm). 
 
Exposure 
Variable Air Control FR (2 ppm) FR (5 ppm) 
Final BWT (g) 26 ± 1 25 ± 1 26 ± 1 
Heart/BWT (mg/g) 4.8 ± 0.1 5.0 ± 0.1 N/A 
Lung/BWT (mg/g) 7.0 ± 0.3 6.6 ± 0.2 N/A 
Liver/BWT (mg/g) 43.5 ± 1.0 41.9 ± 1.7 N/A 
Kidney/BWT (mg/g) 11.5 ± 0.2 11.8 ± 0.2 N/A 
Plasma Measurements 
Cholesterol (mg/dL) 69.58 ± 5.64 78.89 ± 3.13 48.09 ± 4.01* 
HDL (mg/dL) 62.82 ± 2.73 55.89 ± 3.15 N/A  
Triglycerides (mg/dL) 31.17 ± 2.04 35.76 ± 3.51 26.83 ± 1.82# 
Albumin (g/dL) 3.03 ± 0.08 3.21 ± 0.06# 2.60 ± 0.06* 
Total Protein (g/dL) 4.93 ± 0.23 5.17 ± 0.10 4.47 ± 0.20* 
ALT (U/I) 20.32 ± 1.31 21.24 ± 1.43 16.77 ± 1.29 
AST (U/I) 77.51 ± 5.80 94.87 ± 13.23 77.62 ± 15.65 
CK (U/I) 240.68 ± 33.97 318.58 ± 46.05 229.07 ± 50.25 
LDH (U/I) 158.19 ± 13.62 217.01 ± 28.28* 139.31 ± 15.86 
Creatinine (mg/dL) 0.29 ± 0.02 0.32 ± 0.01 0.25 ± 0.01 
 
Values = mean ± SE (n=6-10 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 
weight; CK, creatine kinase; FR, formaldehyde; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; *, p<0.05 compared with 







Table 5.4. Hematological measures of female C57BL/6 mice acutely exposed to either air or formaldehyde (FR; 2 or 5 ppm). 
 
 Exposure 
Hematological Measurements Air Control FR (2 ppm) FR (5 ppm) 
White Blood Cell (K/uL) 2.20 ± 0.26 2.24 ± 0.24 2.13 ± 0.34 
Neutrophils (K/uL) 0.55 ± 0.07 0.57 ± 0.07 0.75 ± 0.20 
Lymphocytes (K/uL) 1.57 ± 0.21 1.54 ± 0.18 1.34 ± 0.19 
Monocytes (K/uL) 0.08 ± 0.01 0.09 ± 0.01 0.05 ± 0.01* 
Eosinophils (K/uL) 0.01 ± 0.01 0.03 ± 0.01* 0 ± 0 
Basophils (K/uL) 0 ± 0 0.01 ± 0.01# 0 ± 0 
Red Blood Cell (M/uL) 8.46 ± 0.23 8.68 ± 0.27 8.93 ± 0.20 
Hemoglobin (g/dL) 12.2 ± 0.4 13.0 ± 0.3 12.1 ± 0.2 
Hematocrit (%) 35.9 ± 1.0 37.6 ± 1.1 37.5 ± 0.7 
Mean Corpuscular Volume (fL) 42.5 ± 0.3 43.3 ± 0.4 42.0 ± 0.4 
Mean Corpuscular Hemoglobin 
(pg) 
14.5 ± 0.3 15.0 ± 0.2 13.6 ± 0.2 
Mean Corpuscular Hemoglobin 
Concentration (g/dL) 
34.0 ± 14.0 34.5 ± 0.3 32.3 ± 0.2 
Red Cell Distribution Width (%) 17.5 ± 0.2 17.5 ± 0.2 17.6 ± 0.2 
Platelets (K/uL) 803 ± 45 737 ± 31 684 ± 49 
Mean Platelet Volume (fL) 4.9 ± 0.1 4.9 ± 0.1 4.4 ± 0.1* 
 
Values = mean ± SE (n=6-10 mice per group); Abbr.: FR, formaldehyde; *, p<0.05 compared with air control; #, 0.05≤p≤0.10 compared 











Fig. 5.3.  Effects of acute formaldehyde (FR; 5 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or formaldehyde (5 ppm, 6h/d) for 4 days.  After four days of exposure to FR, the levels of circulating Sca-1+ cells 
were unchanged (A), however, the level of CACs (Flk-1+/Sca-1+ cells) was significantly increased in WT mice (B).  Values = mean ± 









Fig. 5.4.  Effects of acute formaldehyde (FR; 2 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or formaldehyde (2 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; 










Fig. 5.5.  Effects of acute formaldehyde (FR; 2 ppm) exposure on circulating stem cells in female mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in female C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or formaldehyde (2 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; 










Fig. 5.6.  Effects of acute formaldehyde (FR; 5 ppm) exposure on circulating stem cells in female mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in female C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or formaldehyde (5 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; 





primary urinary metabolite of AA, has not been validated as a urinary biomarker of tobacco 
exposure (431, 432), but it has been shown to increase with tobacco-product use (168, 293, 
434).  To better understand how exposure to AA-alone related to MCS exposure from a 
known number of cigarettes and to e-cig exposure from known ratios of PG:VG, we 
measured urinary acetate by UPLC-MS/MS to confirm that the concentration of AA used 
in our AA-alone exposure was comparable to exposures from real-world sources.  For this, 
male mice were exposed to AA (5 ppm, 6h), MCS (50% of smoke of 12 KY Reference 
3R4F cigarettes 6h), or PG:VG (50%:50% or 30%:70%, 6h), and urine was collected 
immediately after the exposure sessions.  Measures of urinary acetate in AA-, MCS-, and 
50%:50% PG:VG-exposed mice were not significantly different from baseline during the 
first three hours post-exposed, but mice exposed to 30%:70% PG:VG showed increased 
levels (p=0.047) (Fig. 5.7).  As the levels of acetate in AA-exposed mice were not 
significantly different from MCS-exposed mice, this likely indicates that the concentration 
of AA generated for the AA-alone exposure (5 ppm) is similar to the level generated in 
MCS (Fig. 5.7).  Levels of acetate after the overnight (3-16h) collections were elevated 
compared with levels 0-3h post-exposure with all exposures; these elevations are likely 
related to generation by food, as mice were given free access to food during this collection 
period (Fig. 5.7).  Additionally, levels of acetate during the overnight collection were 
significantly higher in 30%:70% PG:VG-exposed mice compared with baseline (Fig. 5.7).   
7. Systemic Toxicity of Two-Week Exposure to Inhaled Acetaldehyde 
Because of the potential for MCS to significantly increase levels of AA exposure 
(107, 118), we tested for changes in systemic and hematological biomarkers in mice 







Fig. 5.7.  Urinary acetate levels in acetaldehyde- or tobacco product-exposed male 
mice.  Male mice were exposed (6h) to acetaldehyde (5 ppm), mainstream cigarette smoke 
(MCS; 50% smoke of 12 cigarettes), or propylene glycol:vegetable glycerin (PG:VG; 
50%:50% or 30%:70%, 6h) after which urine was collected at 0–1, 1–2, 2–3, and 3–16h 
(overnight) and acetate quantified. Values are mean ± SE (n=4-12 mice per group).  *, 





and body weights (or ratios), CBC, or plasma markers (Tables 5.5 & 5.6).  For example, 
exposure to 5 ppm AA caused a modest decrease in final body weight (-4%; p=0.09) but a 
slight increase in the heart/body weight ratio (+8%; p=0.02) (Table 5.5), and although low 
plasma volumes limited many other measures of systemic toxicity, AA-exposed mice 
showed a modest decrease in cholesterol (-16%; p=0.05) compared with their air-exposed 
control counterparts (Table 5.6). 
8. Two-Week Exposure to Acetaldehyde and Circulating Angiogenic Cells 
Despite the minimal systemic effects noted in AA-exposed male mice (5 ppm; 2 
weeks), AA induced a modest increase in the level of Sca-1+ cells (+58%; p=0.06), 
although CACs were not significantly changed (Fig. 5.8A & B). 
9. Systemic Toxicity of Acute Exposure to Inhaled Acetaldehyde 
Although two weeks of exposure to AA (5 ppm) has minimal systemic toxicity 
(decreased body weight, decreased cholesterol, increased neutrophils), we performed acute 
(4d) AA exposures to test whether acute CR exposure would induce rapid toxicity that was 
otherwise compensated for in a longer setting.  Male mice acutely exposed to AA (5 ppm) 
showed an increased body weight (+11%; p=0.01), a modestly increased heart/body weight 
ratio (+9%; p=0.06), and a modestly decreased lung/body weight ratio (-6%; p=0.06) 
(Table 5.5).  Plasma levels of cholesterol, HDL, LDL, and albumin were unchanged with 
acute exposure, while levels of total protein were modestly decreased (-4%; p=0.07) (Table 
5.5).  Acute (4d) exposure to AA (5 ppm) induced a number of hematological changes, 
decreasing red blood count, hemoglobin, and hematocrit levels (-14%, p=0.01; -16%, 
p=0.05; and -12%, p=0.03, respectively), while increasing mean platelet volume (+6; 






Table 5.5. Systemic parameters of male C57BL/6 mice acutely exposed to either air or acetaldehyde (AA; 5 ppm). 
 
Exposure 
  AA (5 ppm) 
Variable Air Control 4 days 2 weeks 
Final BWT (g) 28 ± 0 31 ± 1* 27 ± 1# 
Heart/BWT (mg/g) 4.8 ± 0 5.3 ± 0.2# 5.2 ± 0.2* 
Lung/BWT (mg/g) 5.5 ± 0 5.2 ± 0.1# 5.7 ± 0.2 
Liver/BWT (mg/g) 40.0 ± 1 38.4 ± 1.3 41.9 ± 1.1 
Kidney/BWT (mg/g) 12.9 ± 1 13.2 ± 0.5 12.7 ± 0.3 
Plasma Measurements 
Cholesterol (mg/dL) 65.05 ± 3.46 72.37 ± 4.30 54.84 ± 3.35* 
HDL (mg/dL) 41.68 ± 4.60 48.86 ± 4.24 35.24 ± 1.06 
LDL (mg/dL) 5.49 ± 0.91 5.71 ± 1.07 N/A 
Triglycerides (mg/dL) 49.76 ± 1.71 N/A 52.19 ± 2.07 
Albumin (g/dL) 2.94 ± 0.05 2.87 ± 0.04 2.91 ± 0.06 
Total Protein (g/dL) 4.98 ± 0.08 4.76 ± 0.06# 4.85 ± 0.12 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: AA, acetaldehyde; BWT, body weight; HDL, high-density lipoprotein; LDL, 













 AA (5 ppm) 
Hematological Measurements Air Control 4 days 2 weeks 
White Blood Cell (K/uL) 1.10 ± 0.15 1.24 ± 0.19 1.29 ± 0.18 
Neutrophils (K/uL) 0.32 ± 0.05 0.45 ± 0.19 0.61 ± 0.12* 
Lymphocytes (K/uL) 0.74 ± 0.11 0.73 ± 0.10 0.66 ± 0.06 
Monocytes (K/uL) 0.04 ± 0 0.05 ± 0.01 0.03 ± 0.01 
Eosinophils (K/uL) 0 ± 0 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 8.76 ± 0.12 7.52 ± 0.53* 8.89 ± 0.12 
Hemoglobin (g/dL) 12.5 ± 0.3 10.5 ± 0.8* 13.2 ± 0.1 
Hematocrit (%) 35.6 ± 0.4 31.5 ± 2.2* 35.9 ± 0.4 
Mean Corpuscular Volume (fL) 40.7 ± 0.3 41.8 ± 0.2 40.4 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 14.2 ± 0.2 13.9 ± 0.2 14.8 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 35.0 ± 0.8 33.1 ± 0.4 36.6 ± 0.3 
Red Cell Distribution Width (%) 18.3 ± 0.3 18.3 ± 0.4 19.0 ± 0.5 
Platelets (K/uL) 731 ± 35 782 ± 81 716 ± 45 
Mean Platelet Volume (fL) 4.4 ± 0.1 4.7 ± 0.1* 4.3 ± 0.1 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: AA, acetaldehyde; *, p<0.05 compared with air control; #, 0.05≤p≤0.10 compared 










Fig. 5.8. Effects of two-week acetaldehyde (AA; 5 ppm) exposure on circulating stem cells in male mice.  Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) male mice 
exposed to HEPA-filtered air or acetaldehyde (5 ppm, 6h/d) for two weeks. After two weeks of exposure to AA, the levels of circulating 
Sca-1+ cells were significantly increased in WT mice (A), however, no change in the level of CACs (Flk-1+/Sca-1+ cells) was detected 




observed in female mice exposed for 4 days to 5 ppm AA (Table 5.7); low plasma volumes 
prevented additional measures of systemic toxicity. 
10. Acute Exposure to Acetaldehyde and Circulating Angiogenic Cells 
Neither male nor female mice acutely exposed to AA (5 ppm; 4d) showed changes 
in the levels of CACs or Sca-1+ cells (Figs. 5.9A & B, 5.10A & B). 
D. Discussion 
Exposures to FR and AA have been shown to have negative cardiovascular effects, 
and they are known to be significant toxins in MCS (96).  Although exposure to these 
saturated aldehydes is fairly ubiquitous, exposure to MCS or secondhand smoke can 
significantly increase the level of exposure (117).  Likewise, new electronic tobacco 
products including e-cigs, which have become increasingly popular among adolescents 
(182, 183), have been shown to produce high levels of FR and AA (96, 180), potentially 
subjecting a new segment of the population to acute, high-level exposures of these 
compounds.  There are still gaps in our understanding of how saturated aldehydes such as 
FR and AA contribute to the endothelium dysfunction and subsequent CVD linked to MCS 
and e- cig aerosol exposures.  The goal of the current studies was to measure biomarkers 
of systemic and vascular injury in mice exposed to FR or AA.  Furthermore, these studies 
explored the dependence of concentration, duration, and sex on these outcomes. 
Measures of formate, the urinary metabolite of FR, showed that FR generation may 
differ significantly between tobacco products.  Levels of formate in MCS-exposed mice 
were significantly higher than levels after exposure to 5 ppm FR.  Levels of formate 
differed even between different compositions of PG:VG, with 50%:50% PG:VG, the 






Table 5.7. Systemic changes in female C57BL/6 mice acutely exposed to either air or acetaldehyde (AA; 5 ppm). 
 
 Exposure 
Variable Air Control AA (5 ppm) 
Final BWT (g) 21 ± 0 23 ± 1 
Heart/BWT (mg/g) 5.0 ± 0.2 5.0 ± 0.2 
Lung/BWT (mg/g) 7.0 ± 0.2 6.8 ± 0.2 
Liver/BWT (mg/g) 44.8 ± 0.9 46.1 ± 1.8 
Kidney/BWT (mg/g) 12.6 ± 0.4 13.0 ± 0.3 
             Hematological Measurements   
White Blood Cell (K/uL) 1.60 ± 0.34 1.15 ± 0.17 
Neutrophils (K/uL) 0.45 ± 0.14 0.28 ± 0.03 
Lymphocytes (K/uL) 1.10 ± 0.19 0.82 ± 0.14 
Monocytes (K/uL) 0.04 ± 0.01 0.04 ± 0.01 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 9.23 ± 0.05 9.32 ± 0.11 
Hemoglobin (g/dL) 11.9 ± 0.1 11.7 ± 0.2 
Hematocrit (%) 38.5 ± 0.3 38.1 ± 0.5 
Mean Corpuscular Volume (fL) 41.7 ± 0.3 40.9 ± 0.7 
Mean Corpuscular Hemoglobin (pg) 13.0 ± 0.1 12.5 ± 0.3 
Mean Corpuscular Hemoglobin Concentration (g/dL) 31.0 ± 0.3 30.6 ± 0.4 
Red Cell Distribution Width (%) 17.7 ± 0.2 17.6 ± 0.1 
Platelets (K/uL) 695 ± 36 680 ± 22 
Mean Platelet Volume (fL) 4.4 ± 0.1 4.4 ± 0.1 
 











Fig. 5.9.  Effects of acute acetaldehyde (AA; 5 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or acetaldehyde (5 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; B) 










Fig. 5.10.  Effects of acute acetaldehyde (AA; 5 ppm) exposure on circulating stem cells in female mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in female C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or acetaldehyde (5 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; B) 





PG:VG, the composition used in JUUL devices, although this was not a significant 
difference.  As formate measured in MCS-exposed mice was not significantly different 
than measured in PG:VG-exposed mice, the current data would suggest that e-cigs do not 
generate more FR than traditional cigarettes.  Additionally, the data suggest that, as there 
was no significant increase in formate with an increased level of VG in the tested PG:VG 
ratios, VG is not the primary producer of FR in e-cigs.  Previous data, however, have shown 
that the generation of FR does in fact differ between MCS and e-cigs.  Ogunwale et al. (96) 
report significantly higher levels of FR generation in MCS than in aerosol from a number 
of different blu cartridges, although levels of FR similar to levels in MCS were measured 
in a handful of different e-cig liquids outside of the blu brand.  As our study only exposed 
mice to 50% of smoke from 12 KY 3R4F cigarettes, it may be that the amount of FR 
generated was not sufficient to show a significant increase over levels from PG:VG 
exposure despite showing a significant increase compared with baseline.  Additional 
studies exposing mice to 100% of the smoke from the same number of cigarettes may show 
results similar to those found in the literature.  Furthermore, measures of aldehyde 
generation in PG- and VG-alone showed higher levels of FR per puff with VG-alone 
compared with PG-alone (168).  These differences may indicate that PG and VG together 
are capable of generating FR at different concentrations than generated by the individual 
humectants.   
Measures of urinary acetate, the urinary metabolite of AA, also differed between 
MCS and PG:VG exposures, with levels measured in MCS-exposed mice similar to levels 
in 50%:50% PG:VG-exposed mice but lower than those in 30%:70% PG:VG-exposed 




of AA in MCS and e-cigs (96), but the similar levels measured in 50%:50% and 30%:70% 
PG:VG-exposed mice is comparable to the similar levels of acetate measured after PG- and 
VG-alone exposures (168).  Exposure to 5 ppm AA produced urinary acetate levels similar 
to those measured in the 50%:50% PG:VG-exposed mice, likely indicating that the level 
of AA generated by the equivalent blu Plus+ e-cig devices is around 5 ppm.   
Studies have shown that additional factors such as the voltage of the e-cig device 
can influence aldehyde generation (96, 208).  Additionally, flavored e-cig liquids have been 
shown to produce high levels of both FR and AA (213, 435), and as the use of ENDS has 
grown increasingly customizable (436), accurate measurements of aldehyde generation—
as well as generation of other harmful constituents—have become more difficult.  This 
makes research on the generation of aldehydes by individual components of e-cigs even 
more imperative, as a baseline understanding of potential product harm must be established 
in order to understand how the more complex web of factors contributes to e-cig-related 
health effects.  As research into e-cigs and their health effects is still a fairly new field, it 
is not unexpected that studies may produce varying results, especially as different products, 
flavors, and humectants may be used for testing.  This emphasizes the complexity of e-cigs 
as well as the need for more research.  Nonetheless, our studies show that the 
concentrations used for our aldehyde-alone exposures produce urinary metabolites at 
similar levels as produced in MCS- and PG:VG-exposed mice, justifying the use of these 
concentrations as relevant real-world exposure levels. 
Overall, exposures to FR seemed to produce little to moderate systemic effects.  
Although some significant changes were seen in response to acute exposure to FR at 1, 2, 




measurements typically still within the normal physiological range for specific biomarkers.  
However, two weeks of exposure to FR (5 ppm) produced significant changes in 
hematological measures; two-week-exposed male mice showed significant decreases in 
leukocytes and in platelets, changes which have been previously reported (120, 121).  
Interestingly, after two weeks, we saw an increase in red blood cell count rather than a 
decrease as reported in the literature (120), but a significant decrease in red blood cells was 
seen after four days of exposure at the same level (5 ppm).  These results could indicate 
that FR causes a decrease in red blood cells early on but that homeostatic mechanisms were 
able to compensate after a longer exposure duration.  A similar increase was noted in rats 
exposed to high-level FR (437), although the authors note that the increased levels were 
not outside the expected range for that strain of rat and were therefore uncertain of its 
clinical relevance.  Likewise, our values remain within the normal range for this strain of 
mice, so while the values may not indicate physiological significance, this pattern may 
point towards changes in red blood cell production that could contribute to cardiovascular 
injury or disease development.  Hemoglobin showed a similar pattern of change between 
four days and two weeks of exposure at 5 ppm FR.   
Biomarkers of vascular injury showed no change after four days of FR (2 ppm), but 
CACs (Flk-1+/Sca-1+ cells) were significantly increased after four days of FR at a higher 
concentration (5 ppm), and there was also a trend towards increased levels of Sca-1+ cells.  
After two weeks of exposure (5 ppm), however, both cell types were decreased, which may 
indicate that there was significant injury early on which necessitated increased levels of 
CACs for repair but that these increased levels could not be maintained to repair consistent 




proper endothelium function (62, 63), and decreased levels of these cells can allow for the 
development of endothelium dysfunction (66, 70).  Exposure to other aldehydes such as 
acrolein (71, 74, 151) as well as MCS itself  (72, 318) have also been shown to decrease 
the levels and function of CACs and contribute to endothelium dysfunction, although the 
shorter time frame in which these effects are produced likely indicates that acrolein is more 
toxic for these cells than FR.  Wheat et al. (74) have shown that acrolein decreases levels 
of CACs in the blood through the inhibition of vascular endothelial growth factor-induced 
mobilization of these cells from the bone marrow; future studies of FR exposed should 
examine levels of CACs in the bone marrow to determine whether this aldehyde’s effect 
on CACs is the result of this mechanism.  Nonetheless, the decrease in CACs noted after 
two weeks of exposure may indicate that FR is capable of inducing endothelium 
dysfunction, which has been previously suggested (438).  However, ex vivo studies in blood 
vessels did not observe evidence of endothelium dysfunction even in response to high 
levels of FR (127).  This discrepancy could indicate that the effect of FR on endothelium 
function varies between intact animals and ex vivo vessels, but more studies are needed to 
better understand this relationship.   
Exposure to AA (5 ppm, 4 days and 2 weeks) showed minimal systemic and 
hematological effects.  Unlike FR, AA-exposed mice showed no significant changes in 
overall leukocyte counts, and although mice exposed to AA for four days showed decreases 
in red blood cell count, hemoglobin, and hematocrit, these changes were not seen after two 
weeks of exposure.  Two weeks of exposure did cause a significant increase in Sca-1+ cells, 
but CACs remained unchanged.  One study has found a link between AA and the potential 
development of endothelium dysfunction (439), but this hypothesis is still largely 
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unexplored.  Although our findings do not suggest that AA is linked to the development of 
endothelium dysfunction, studies with a larger number of mice and for longer durations 
would allow for a more definitive clarification of the relationship between AA and 
endothelium dysfunction. 
We also sought to determine whether saturated aldehyde-induced effects on 
systemic and hematological biomarkers and CACs are sex-dependent.  Like their male 
counterparts, female WT mice exposed to FR (2 or 5 ppm; 4d) or AA (5 ppm; 4d) showed 
minimal cardiovascular effects.  The few significant changes noted in response to FR 
exposure (2 or 5 ppm) are not likely to be physiologically significant, and no changes were 
noted in AA-exposed mice.  Likewise, neither FR nor AA exposure in female mice induced 
changes in CACs.  The difference in outcomes between male and female mice exposed to 
FR or AA at the same concentration and for similar durations may indicate that the 
aldehyde-induced cardiovascular changes are sex-dependent, particularly the FR-induced 
effects in CACs, although more robust studies are needed to truly make this determination.  
Although a small number of studies have reported sex differences in response to other 
aldehydes (269, 440), sex-related differences in acetaldehyde exposures have mainly been 
explored in relation to AA ingestion rather than inhalation  (441-444), and of the historical 
studies examining long-term effects of formaldehyde exposure (445-449), only Maronpot 
et al. (445) report significant differences between males and females.  Our studies therefore 
represent novel observations regarding the potential sex-dependence of full-body saturated 
aldehyde inhalation exposure on cardiovascular effects in mice, especially in regard to 
differences in biomarkers of vascular injury in response to FR exposure.  




of research into the saturated aldehydes FR and AA as potential contributors of systemic 
and vascular injury in response to inhalation exposure.  Levels of these constituents were 
measured at levels comparable to those generated in response to exposure from MCS and 
varying compositions of PG:VG, indicating their real-world relevance in determining the 
health effects of e-cig use.  Two weeks of exposure to FR (5 ppm) in particular induced 
significant systemic changes that confirm the results of previous studies and implicate FR 
as a promoter of CVD.  This exposure also induced changes in CACs that suggest FR may 
play a role in the development of endothelium dysfunction in vivo.  Furthermore, the CAC 
effects induced by FR seem to be sex-dependent, although additional studies are needed to 
confirm this finding.  As smoking conventional cigarettes remains a global health threat 
and as the number of e-cig users continues to increase, these studies provide novel insight 
into the role of saturated aldehydes in the development of CVD and suggest differences 
between male and females that could play an important role in the therapeutic treatment of 




SYSTEMIC, HEMATOLOGICAL, AND ENDOTHELIUM-RELATED EFFECTS OF 
ACROLEIN AND CROTONALDEHYDE IN MICE 
A. Introduction 
The unsaturated aldehydes acrolein and crotonaldehyde (CR) are classified as eye, 
nose, skin, and respiratory irritants, with inhalation of even low levels capable of producing 
extreme respiratory distress (94, 155).  Exposure to both acrolein and CR can occur 
naturally through foods and drinks (94), and each is produced endogenously in small 
amounts (94, 155-157).  Most exposure to these compounds, however, occurs via 
anthropogenic sources, including vehicular exhaust, industrial emissions, and smoke from 
fires (94, 155-157), with a large portion of exposure related to tobacco smoke (90, 114, 
117, 147, 156, 159).  Acrolein in particular plays a significant role in mainstream cigarette 
smoke (MCS) and its related health effects; Stabbert et al. (149) have shown that the 
majority of the cytotoxicity related to the gas vapor constituents of MCS is due to acrolein, 
and Haussmann (145) reports that almost 90% of the non-cancer health risk (cardiovascular 
and pulmonary disease) associated with smoking is likely due to acrolein.  
Much epidemiological and experimental evidence exists linking acrolein with 
increased cardiovascular disease (CVD) risk.  Both acute and chronic inhalation exposures
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to acrolein have been shown to suppress levels of circulating angiogenic cells (CACs) (74, 
151), enhance thrombotic markers (450), and initiate endothelium dysfunction in 
susceptible mice (150), while ingestion promotes atherosclerosis in mice (153).  Moreover, 
urinary levels of 3-hydroxypropylmercapturic acid (3HPMA), the primary urinary 
metabolite of acrolein, are associated with increased CVD risk, decreased levels of CACs, 
and increased platelet-leukocyte aggregation in humans (71).  By comparison, inhalation 
exposure to 1,3-butadiene, a parent source of CR, accelerates arteriosclerotic lesion 
development in cockerels (167), and is linked with an increased risk of atherosclerosis in 
African-American factory workers (166).  Likewise, African-American men who worked 
in a 1,3-butadiene production plant for at least 6 months had increases in standardized 
mortality ratio for arteriosclerotic heart disease (165).  Furthermore, although CR has been 
shown to induce oxidative stress in cells (163, 164) and to cause cardiomyocyte 
dysfunction (164), CR inhalation studies with measures of cardiovascular injury have not 
been performed.  Thus, the goal of these studies was to address these gaps in knowledge 
regarding the potential cardiovascular toxicity of CR. 
B. Experimental Procedures 
1. Exposures
Animals were exposed to constituents via full-body inhalation as described in 
Chapter II, Sections B.2.  Upon completion of the exposure, mice were euthanized and 
tissues collected as described in Chapter II, Section B.5.  
2. Urine Collection
Urine samples were collected post-exposure as described in Chapter II, Section B.3. 
3. Urine Metabolite Quantification
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Collected urine was used to quantify levels of volatile organic compound (VOC) 
and tobacco alkaloid metabolites using analytical methods as described in Chapter II, 
Section B.4. 
4. Complete Blood Cell Count (CBC)
A sample of whole blood was collected after the final day of exposure for a 
complete blood cell count (CBC) as described in Chapter II, Section B.6. 
5. Plasma Biomarkers Quantification
Plasma was prepared from each sample for an analysis of a number of biomarkers 
as described in Chapter II, Section B.7. 
6. Circulating Angiogenic Cell (CAC) Quantification
Flow cytometry was used to analyze the number of CACs in each sample as 
described in Chapter II, Section B.8. 
7. Leukocyte Subpopulation Quantification
Flow cytometry was used to analyze the leukocyte subpopulations in each sample 
as described in Chapter II, Section B.9. 
8. Statistical Analyses
Statistical analyses were performed as described in Chapter II, Section B.10. 
C. Results 
1. Urinary Acrolein Metabolite in MCS-, PG:VG-, and Acrolein-Exposed
Mice 
The urinary metabolite of acrolein, 3HPMA, has been positively associated with 
increased CVD risk in smokers (71) and has been shown to be a useful biomarker of 




biomarker of e-cig exposure has not been studied.  To better understand how acrolein-alone 
exposure related to e-cig exposure from known ratios of PG:VG, we measured urinary 
3HPMA by UPLC-MS/MS as a biomarker of acrolein exposure.  For this, male mice were 
exposed to acrolein (1 ppm, 6h), MCS (50% of smoke of 12 KY Reference 3R4F cigarettes, 
6h), or PG:VG (50%:50% or 30%:70%, 6h), and urine was collected immediately after the 
exposure sessions.  Acrolein alone exposure (p=0.02) as well as exposure to MCS 
(p=0.005) and both 50%:50% (p<0.001) and 30%:70% PG:VG (p=0.02) caused a 
significant increase in levels of 3HPMA in the first three hours post exposure compared 
with baseline (Fig. 6.1).  Levels of 3HPMA in acrolein-exposed mice were similar to levels 
in MCS-exposed and 30%:70% PG:VG-exposed mice, but mice exposed to 50%:50% 
PG:VG showed significantly higher levels compared to acrolein-alone mice (p=0.01) (Fig. 
6.1).  Comparison of 3HPMA levels in PG:VG-exposed mice showed that mice exposed 
to 50%:50% PG:VG also had a significantly higher level of 3HPMA compared with mice 
exposed to 30%:70% PG:VG (p=0.02) (Fig. 6.1).   
2. Systemic Toxicity of Acute Exposure to Inhaled Acrolein 
The unsaturated aldehyde acrolein is found in high levels in MCS (90, 114, 117, 
147) and is suggested to be one of the most significant factors in MCS-induced 
cardiovascular toxicity (145, 149).  Environmental exposure to acrolein has been linked to 
an increased CVD risk score, in part through decreased levels of select CAC populations 
(71), and direct inhalation exposure in mice has also caused the suppression of CACs (74, 
151) as well as the related development of endothelium dysfunction (150).  Chronic 
inhalation exposure (1 ppm) showed significant decreases in white blood cells count driven 








Fig. 6.1.  Urinary 3HPMA levels in acrolein- or tobacco product-exposed male mice.  
Male mice were exposed (6h) to mainstream cigarette smoke (MCS; 50% smoke of 12 KY 
Reference 3R4F cigarettes) or propylene glycol:vegetable glycerin (PG:VG; 50%:50% or 
30%:70%, 6h) after which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and 
3-hydroxypropylmercapturic acid (3HPMA) quantified. Values are mean ± SE (n=4-12 





noted in humans and in chronically-exposed mice, we performed an acute acrolein 
exposure to better understand the temporal relationship between these factors.  Male mice 
exposed to acrolein (1 ppm) for 4 days (6h/d) had a greater change in overall body weight 
compared with air-exposed control mice (-3 g versus -1 g; p=0.004), and the liver/body 
weight ratio was significantly decreased (-10%; p=0.007) (Table 6.1).  Exposure had 
considerable effects on CBC.  Exposed mice showed a significant decrease in leukocytes 
(-50%; p=0.02), driven by decreases in neutrophils (-57%; p=0.02), lymphocytes (-46%; 
p=0.06), and monocytes (-59%; p=0.03) (Table 6.2).  Acrolein exposure also induced 
changes in erythrocytic parameters; red blood cell levels (+6%; p=0.05) and hemoglobin 
(+5%; p=0.06) were modestly increased, while hematocrit was significantly increased 
(+6%; p=0.04) (Table 6.2).  Measures of systemic biomarkers showed no changes in liver 
(ALT, AST), muscle (CK) or LDH enzymes or creatinine but did show a modestly 
significant decrease in triglycerides (-22%; p=0.06) (Table 6.1). 
3. Acute Exposure to Acrolein and Circulating Angiogenic Cells 
Male mice acutely exposed to acrolein (1 ppm; 4d) showed no changes in the levels 
of CACs or Sca-1+ cells (Fig. 6.2A & B).   
4. Urinary Crotonaldehyde Metabolite in MCS-, PG:VG-, and 
Crotonaldehyde-Exposed Mice 
The primary urinary metabolite of CR, 3-hydroxy-1-methylpropylmercapturic acid 
(HPMMA), is associated with combusted tobacco, and the number of cigarettes per day is 
a significant predictor of increased urinary HPMMA (159).  To better understand how CR-
alone exposure relates to MCS exposure from a known number of cigarettes and to e-cig 






Table 6.1. Systemic parameters of male C57BL/6 mice acutely exposed to either air or acrolein (1 ppm). 
 
 Exposure (4 days) 
Variable Air Control Acrolein (1 ppm) 
Change in BWT (g) -1 ± 0 -3 ± 0* 
Heart/BWT (mg/g) 4.8 ± 0.1 5.0 ± 0.1 
Lung/BWT (mg/g) 5.7 ± 0.1 5.6 ± 0.1 
Liver/BWT (mg/g) 46.0 ± 1.1 41.3 ± 0.08* 
Kidney/BWT (mg/g) 12.8 ± 0.2 12.6 ± 0.2 
                        Plasma Measurements 
Cholesterol (mg/dL) 74.89 ± 3.35 70.67 ± 2.6 
Triglycerides (mg/dL) 55.33 ± 4.31 43.36 ± 3.36# 
Albumin (g/dL) 2.92 ± 0.13 2.90 ± 0.23 
Total Protein (g/dL) 3.94 ± 0.06 4.47 ± 0.18 
AST (U/I) 65.64 ± 6.70 60.94 ± 5.56 
CK (U/I) 144.14 ± 41.37 105.87 ± 21.03 
LDH (U/I) 178.37 ± 20.37 164.29 ± 21.52 
Creatinine (mg/dL) 0.22 ± 0.01 0.23 ± 0.02 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: AST, aspartate aminotransferase; BWT, body weight; CK, creatine kinase; LDH, 








Table 6.2. Hematological measurements of male C57BL/6 mice acutely exposed to either air or acrolein (1 ppm). 
 
 Exposure (4 days) 
Hematological Measurements Air Control Acrolein (1 ppm) 
White Blood Cell (K/uL) 1.92 ± 0.34 0.96 ± 0.13* 
Neutrophils (K/uL) 0.63 ± 0.13 0.27 ± 0.04* 
8 
8 
Lymphocytes (K/uL) 1.24 ± 0.23 0.68 ± 0.09# 
Monocytes (K/uL) 0.04 ± 0.01 0.02 ± 0.01* 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 8.83 ± 0.15 9.38 ± 0.16# 
Hemoglobin (g/dL) 12.2 ± 0.3 12.9 ± 0.2# 
Hematocrit (%) 44.0 ± 0.9 46.7 ± 0.7* 
Mean Corpuscular Volume (fL) 49.8 ± 0.4 49.8 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 13.8 ± 0.1 13.8 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 27.8 ± 0.2 27.6 ± 0.1 
Red Cell Distribution Width (%) 17.5 ± 0.2 17.1 ± 0.2 
Platelets (K/uL) 575 ± 27 585 ± 14 
Mean Platelet Volume (fL) 4.3 ± 0.1 4.2 ± 0.1 
 











Fig. 6.2.  Effects of acute acrolein (1 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells (Sca-1+) and 
circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed to HEPA-
filtered air or acrolein (1 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; B) were unchanged 




as a biomarker of CR exposure (168).  For this, male mice were exposed to CR (1 ppm, 
6h), MCS (50% of smoke of 12 KY Reference 3R4F cigarettes, 6h) or 50%:50% PG:VG 
(6h), and urine was collected immediately after each exposure session.  Urinary HPMMA 
levels were significantly increased in mice exposed to CR (p<0.001) or MCS (p<0.001) 
compared with baseline in the first three hours post exposure, while levels in 50%:50% 
PG:VG-exposed mice remained near baseline (Fig. 6.3).  Mice exposed to CR-alone also 
showed significantly higher levels of urinary HPMMA than mice exposed to MCS 
(p=0.003) or 50%:50% PG:VG (p=0.007) (Fig. 6.3).  Unlike humans, laboratory-housed, 
naïve mice have modest HPMMA levels in urine, indicating minimal CR exposure via 
exogenous sources including ambient air or intermediary metabolism (Fig. 6.3).  After 11 
weeks of exposure to 1 ppm CR exposure, the level of urinary HPMMA in the first three 
hours post-exposure was approximately 5-times that measured following acute MCS 
exposure (Fig. 6.3), indicating that MCS exposure was equivalent to 0.2 ppm of continuous 
CR exposure.   
5. Systemic Toxicity of Chronic Exposure to Inhaled Crotonaldehyde 
Because chronic exposure to acrolein (12 weeks, 1 ppm) induced significant 
systemic toxicity in mice (151), we tested whether chronic CR (1 ppm) exposure would 
elicit similar outcomes.  Body weight and organ/body weight ratios and CBCs were not 
different between the air- and CR- exposed groups (Tables 6.3 & 6.4).  Chronic CR also 
did not affect plasma levels of ALT and AST (liver), CK (striated muscle), or LDH (non-
specific cell toxicity) enzymes or creatinine, but did increase levels of plasma total 
cholesterol (+11%; p=0.04), HDL (+16%; p=0.01), triglycerides (+25%; p=0.01), albumin 







Fig. 6.3.  Urinary HPMMA levels in crotonaldehyde- or tobacco product-exposed 
male mice.  Male mice were exposed (6h) to crotonaldehyde (CR; 1 ppm, 11th week of 
chronic exposure), mainstream cigarette smoke (MCS; 50% smoke of 12 KY Reference 
3R4F cigarettes), or propylene glycol:vegetable glycerin (PG:VG; 50%:50% or 30%:70%, 
6h) after which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and 3-hydroxy-
1-methylpropylmercapturic acid (HPMMA) quantified. Values are mean ± SE (n=5-12 











Variable Air Control CR (1 ppm) 
Change in BWT (g) +5 ± 0 +4 ± 0 
Heart/BWT (mg/g) 4.5 ± 0.1 4.6 ± 0.1 
Lung/BWT (mg/g) 5.4 ± 0.2 5.4 ± 0.2 
Liver/BWT (mg/g) 44.3 ± 1.6 41.8 ± 1.7 
Kidney/BWT (mg/g) 12.3 ± 0.3 13.1 ± 0.5 
Pancreas/BWT (mg/g) 3.9 ± 0.2 4.6 ± 0.4 
Spleen/BWT (mg/g) 3.1 ± 0.2 3.0 ± 0.2 
Epididymal Fat Pad/BWT (mg/g) 8.8 ± 0.5 9.0 ± 0.8 
                  Plasma Measurements 
Cholesterol (mg/dL) 58.83 ± 3.82 69.51 ± 2.10* 
HDL (mg/dL) 41.93 ± 4.04 53.05 ± 0.94* 
LDL (mg/dL) 4.94 ± 1.01 3.51 ± 0.33 
Triglycerides (mg/dL) 37.12 ± 2.85 56.56 ± 7.31* 
Albumin (g/dL) 2.81 ± 0.06 2.89 ± 0.07* 
Total Protein (g/dL) 4.52 ± 0.08 4.67 ± 0.08# 
ALT (U/I) 19.37 ± 3.76 15.95 ± 1.46 
AST (U/I) 49.43 ± 13.16 46.74 ± 4.56 
CK (U/I) 260.92 ± 39.83 149.57 ± 44.55 
LDH (U/I) 83.03 ± 8.30 83.65 ± 4.80 
Creatinine (mg/dL) 0.25 ± 0.02 0.25 ± 0.01 
 
Values = mean ± SE (n=9-10 mice per group). Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWT, body 














Table 6.4. Hematological measures of male C57BL/6J mice chronically exposed to either air or crotonaldehyde (CR; 1 ppm). 
 
 Exposure 
Hematological Measurements Air Control CR (1 ppm) 
White Blood Cell (K/µL) 1.96 ± 0.19 2.12 ± 0.18 
Neutrophils (K/µL) 0.50 ± 0.08 0.60 ± 0.07 
Lymphocytes (K/µL) 1.41 ± 0.12 1.47 ± 0.14 
Monocytes (K/µL) 0.05 ± 0.01 0.04 ± 0.01 
Eosinophils (K/µL) 0 ± 0 0 ± 0 
Basophils (K/µL) 0 ± 0 0 ± 0 
Red Blood Cell (M/µL) 8.30 ± 0.15 8.32 ± 0.14 
Hemoglobin (g/dL) 12.1 ± 0.1 12.0 ± 0.1 
Hematocrit (%) 35.1 ± 0.7 34.8 ± 0.5 
Mean Corpuscular Volume (fL) 42.3 ± 0.2 41.8 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 14.6 ± 0.2 14.4 ± 0.3 
Mean Corpuscular Hemoglobin Concentration (g/dL) 34.6 ± 0.5 34.5 ± 0.5 
Red Cell Distribution Width (%) 18.0 ± 0.3 18.0 ± 0.2 
Platelets (K/µL) 728 ± 30 694 ± 31 
Mean Platelet Volume (fL) 4.2 ± 0.0 4.3 ± 0.1 
                           Blood Immune Cells 
NK1.1+-Cells (count/µL) 8.22 ± 1.57 7.00 ± 1.11 
CD19+ B-Cells (count/µL) 266.72 ± 31.36 291.24 ± 51.23 
CD4+ T-Cells (count/µL) 31.43 ± 2.91 33.79 ± 3.10 
CD8+ T-Cells (count/µL) 0.85 ± 0.17 1.04 ± 0.18 
CD11b+ Monocytes (count/µL) 25.01 ± 1.95 27.06 ± 2.65 
Ly6Chigh Cells (count/µL) 1.2 ± 0.2 1.9 ± 0.4 
Ly6Clow Cells (count/µL) 23.8 ± 1.9 25.2 ± 2.5 
Gr1+ Granulocytes (count/µL) 69.87 ± 5.21 82.52 ± 7.51 
 




control group (Table 6.3). 
6. Chronic Exposure to Crotonaldehyde and Hematology 
Chronic exposures to acrolein (12 weeks, 0.5 and 1 ppm) suppress a number of 
leukocyte subpopulations (151).  Thus, in an attempt to understand any selective 
hematological effects of CR, we used hematological measures to quantify changes in 
circulating leukocytes and selective immune subpopulations of mice chronically exposed 
to CR.  CR-exposed mice had no changes in major leukocyte classes, and there were no 
significant changes in levels of NK1.1+-cells, CD19+ B-cells, CD4+ or CD8+ T-cells, Gr1+ 
granulocytes, CD11b+ monocytes, or Ly6Chigh or Ly6Clow monocyte sub-populations 
(Table 6.4). 
7. Chronic Exposure to Crotonaldehyde and Circulating Angiogenic Cells  
Decreased levels of CACs have been associated with increased CVD risk, and it is 
thought that CAC levels serve as a predictor of overall cardiovascular health and future 
cardiovascular events (66).  Altered CAC levels are noted in individuals exposed to 
secondhand smoke (72) and during smoking cessation (318).  Previously, we have shown 
that both (74) acute and chronic (151) exposures of mice to 1 ppm acrolein suppressed 
CACs by 50%. Despite the changes seen with acrolein, there was no significant change in 
the level of Sca-1+ or CACs (Flk-1+/Sca-1+ cells) after chronic CR exposure (Fig. 6.4A & 
B). 
8. Systemic Toxicity of Acute Exposure to Inhaled Crotonaldehyde 
Although chronic exposure to CR (1 ppm) had specific yet limited systemic 
toxicity, we performed acute CR exposures to better understand the temporal relationships 








Fig. 6.4.  Effects of chronic crotonaldehyde (CR; 1 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or CR (1 ppm, 6h/d) for 12 weeks.  Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; B) were 




toxicity that was otherwise compensated for in the chronic setting.  Acute exposure of male 
mice to CR (1 or 3 ppm; 4 days) had limited to modest effects on organ and body weights 
(or ratios), CBC, and plasma biomarkers.  Male mice acutely exposed to 1 ppm CR had no 
change in overall body weight, yet had an increased level of neutrophils (+60%; p=0.06), 
a decreased mean corpuscular volume (-6%; p<0.001), and an increased red blood cell 
distribution width (+6%; p=0.02) (Table 6.5).  Plasma levels of ALT, ASK, CK, and LDH 
enzymes, albumin, and creatinine were unchanged with acute CR exposure in WT male 
mice, however, levels of plasma cholesterol, LDL, triglycerides and total protein were 
decreased (-14%, p=0.002; -6%, p=0.02; -13%, p=0.02; -24%, p=0.002, respectively) 
(Table 6.6).  Surprisingly, 4 days of CR (3 ppm) exposure in male mice had less of an effect 
overall on markers of systemic toxicity.  For example, there were no changes in levels of 
ALT, AST, CK, and LDH enzymes, albumin, or creatinine or any changes in hematological 
biomarkers, with only modest effects on levels of cholesterol (+7%; p=0.09) and total 
protein (+5%; p=0.07) (Tables 6.6).  Similarly, no changes in body weight, organ/body 
weight ratios, CBC, or plasma biomarkers were observed in female mice exposed for 4 
days to 1 ppm CR (Table 6.7), indicating that male WT mice may be more sensitive to CR 
than their female counterparts. 
9. Acute Exposure to Crotonaldehyde and Circulating Angiogenic Cells 
Acute (4d) exposure to 1 ppm CR increased the level of Sca-1+ cells (Fig. 6.5A); 
Sca-1+ cells make up the hematopoietic stem cell pool from which CACs are derived.  
However, there was no change in the levels of CACs (Fig. 6.5B).  Acute (4d) exposure to 
3 ppm CR did not change the levels of Sca-1+ cells or CACs (Fig. 6.6A & B).  Likewise, 






Table 6.5. Systemic measures in male C57BL/6J mice acutely exposed to either air or crotonaldehyde (CR; 1 or 3 ppm). 
 
 Exposure Duration (4 days) 
Variable Air Control CR (1 ppm) CR (3 ppm) 
Change in BWT (g) -1 ± 0 -1 ± 0 -1 ± 0 
Heart/BWT (mg/g) 4.9 ± 0.1 5.2 ± 0.1 4.9 ± 0.1 
Lung/BWT (mg/g) 5.6 ± 0.1 6.0 ± 0.1 5.4 ± 0.1 
Liver/BWT (mg/g) 44.6 ± 0.6 43.7 ± 1.5 43.6 ± 0.9 
Kidney/BWT (mg/g) 12.5 ± 0.1 12.7 ± 0.3 12.4 ± 0.2 
                      Hematological Measurements 
White Blood Cell (K/µL) 1.57 ± 0.13 1.96 ± 0.16 1.55 ± 0.14 
Neutrophils (K/µL) 0.39 ± 0.06 0.62 ± 0.10# 0.29 ± 0.03 
Lymphocytes (K/µL) 1.13 ± 0.09 1.28 ± 0.10 1.22 ± 0.11 
Monocytes (K/µL) 0.04 ± 0 0.06 ± 0.01 0.04 ± 0 
Eosinophils (K/µL) 0.01 ± 0 0 ± 0 0 ± 0 
Basophils (K/µL) 0 ± 0 0 ± 0 0 ± 0 
Red Blood Cell (M/µL) 8.62 ± 0.10 8.71 ± 0.10 8.83 ± 0.11 
Hemoglobin (g/dL) 11.7 ± 0.2 11.7 ± 0.2 11.9 ± 0.1 
Hematocrit (%) 39.2 ± 0.8 37.5 ± 0.7 42.1 ± 0.5 
Mean Corpuscular Volume (fL) 45.9 ± 0.5 43.1 ± 0.5* 47.7 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 13.6 ± 0.2 13.5 ± 0.3 13.5 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 29.6 ± 0.6 31.4 ± 1.1 28.3 ± 0.1 
Red Cell Distribution Width (%) 16.9 ± 0.1 17.9 ± 0.3* 17.2 ± 0.3 
Platelets (K/µL) 616 ± 16 670 ± 25 584 ± 15 
Mean Platelet Volume (fL) 4.3 ± 0 4.2 ± 0.1 4.3 ± 0 
 
Values = mean ± SE (n=9-15 mice per group); Abbr.: BWT, body weight; CR, crotonaldehyde; *, p<0.05 compared with air control 






Table 6.6. Plasma biomarkers in male C57BL/6J mice acutely exposed to either air or crotonaldehyde (CR; 1 or 3 ppm). 
 
 Exposure Duration (4 days) 
Plasma Measurements Air Control CR (1 ppm) CR (3 ppm) 
Cholesterol (mg/dL) 69.97 ± 1.83 60.16 ±1.84* 74.72 ± 1.89# 
HDL (mg/dL) 50.96 ± 1.21 44.57 ± 2.31* 53.10 ± 1.43 
LDL (mg/dL) 4.49 ± 0.37 4.32 ± 0.62 5.52 ± 0.19 
Triglycerides (mg/dL) 43.76 ± 1.39 33.36 ± 2.39* 41.31 ± 2.22 
Albumin (g/dL) 2.81 ± 0.04 2.65 ± 0.05 2.85 ± 0.05 
Total Protein (g/dL) 4.76 ± 0.07 4.45 ± 0.06* 5.01 ± 0.08# 
ALT (U/I) 23.34 ± 1.25 23.74 ± 2.92 19.37 ± 0.63 
AST (U/I) 61.99 ± 4.97 56.39 ± 6.12 52.86 ± 4.05 
CK (U/I) 188.84 ± 21.28 127.15 ± 13.94 262.70 ± 33.38 
LDH (U/I) 135.90 ± 7.72 132.28 ± 11.21 141.10 ± 10.36 
Creatinine (mg/dL) 0.28 ± 0.01 0.24 ± 0.01# 0.31 ± 0.01 
 
Values = mean ± SE (n=5-10 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine 
kinase; CR, crotonaldehyde; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; *, p<0.05 
compared with air control based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with air control based on Bonferroni’s 






Table 6.7. Systemic measures in female C57BL/6J mice acutely exposed to either air or crotonaldehyde (CR; 1 ppm). 
 
 Exposure 
Variable Air Control CR (1 ppm) 
Change in BWT (g) -1 ± 0 -1 ± 0 
Heart/BWT (mg/g) 5.2 ± 0.1 5.0 ± 0.1 
Lung/BWT (mg/g) 6.6 ± 0.1 6.3 ± 0.2 
Liver/BWT (mg/g) 45.4 ± 1.8 44.4 ± 1.4 
Kidney/BWT (mg/g) 13.3 ± 0.4 13.1 ± 0.2 
Hematological Measurements (n=9-10 mice per group) 
White Blood Cell (K/µL) 1.30 ± 0.14 1.15 ± 0.16 
Neutrophils (K/µL) 0.30 ± 0.05 0.26 ± 0.05 
Lymphocytes (K/µL) 0.96 ± 0.10 0.86 ± 0.12 
Monocytes (K/µL) 0.03 ± 0 0.03 ± 0.01 
Eosinophils (K/µL) 0 ± 0 0 ± 0 
Basophils (K/µL) 0 ± 0 0 ± 0 
Red Blood Cell count (M/µL) 8.99 ± 0.10 9.05 ± 0.13 
Hemoglobin (g/dL) 13.0 ± 0.2 13.3 ± 0.1 
Hematocrit (%) 44.4 ± 0.5 44.9 ± 0.7 
Mean Corpuscular Volume (fL) 49.4 ± 0.4 49.6 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 14.4 ± 0.2 14.7 ± 0.3 
Mean Corpuscular Hemoglobin Concentration 
(g/dL) 
29.2 ± 0.5 29.7 ± 0.5 
Re  Cell Distribution Width (%) 16.5 ± 0.2 16.6 ± 0.2 
Platelets (K/µL) 499 ± 16 503 ± 10 
Mean Platelet Volume (fL) 4.3 ± 0 4.2 ± 0.1 
Plasma Measurements (n=7-8 mice per group) 
Cholesterol (mg/dL) 57.40 ± 4.68 54.87 ± 2.66 
HDL (mg/dL) 34.37 ± 1.67 35.34 ± 2.55 






Albumin (g/dL) 2.91 ± 0.03 2.92 ± 0.06 
Total Protein (g/dL) 4.54 ± 0.09 4.56 ± 0.09 
 









Fig. 6.5.  Effects of acute crotonaldehyde (CR; 1 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or CR (1 ppm, 6h/d) for 4 days.  After 4 days of exposure to CR, the level of circulating Sca-1+ cells was 
significantly increased in WT mice (A), however, no change in the level of CACs (Flk-1+/Sca-1+ cells) was detected relative to air-
exposed control mice (B).  Values = mean ± SE (n=10 mice per group); *, p<0.05 compared with air control based on Bonferroni’s or 









Fig. 6.6. Effects of acute crotonaldehyde (CR; 3 ppm) exposure on circulating stem cells in male mice. Hematopoietic stem cells 
(Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male C57BL/6J (wild type, WT) mice exposed 
to HEPA-filtered air or CR (1 ppm, 6h/d) for 4 days.  Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; B) were 





 (1 ppm) exposure (Fig. 6.7A & B). 
D. Discussion 
MCS is a known source of the unsaturated aldehydes acrolein (18-98 µg/cigarette) 
and CR (10-43 µg/cigarette) (147, 451), and levels of the major urinary metabolites of 
acrolein (3HPMA) and CR (HPMMA) are significantly increased in smokers versus non-
smokers (147, 159).  The results of our urinary metabolite studies showed significant 
increases in both 3HPMA and HPMMA compared with baseline measures.  Exposure to 
MCS and 30%:70% PG:VG produced similar levels of 3HPMA, while 50%:50% PG:VG 
produced a peak level higher than even that measured after acrolein-alone exposure (151).  
Conklin et al. (168) showed that levels of acrolein detected in PG-alone aerosol were below 
the detectable limit, while VG-alone produced levels of acrolein comparable to those 
measured in flavored e-liquids.  Our results, however, indicate that PG is likely driving the 
production of acrolein, again suggesting that perhaps PG and VG in combination are 
capable of producing levels of aldehydes that vary compared with PG or VG alone.  
Regardless, it seems clear that the proportion of PG:VG used in an e-cig device can create 
significant variation in the aldehydes produced.  Conversely, while levels of HPMMA were 
not below the limit of detection in 50%:50% PG:VG-exposed mice, they were very low 
and not significantly different from baseline.  Previous studies have reported little if any 
generation of CR in e-cigs (96, 168), so HPMMA should not be used as a biomarker of e-
cig use.  HPMMA is, however, increased after exposure to MCS, meaning HPMMA would 
be a more selective biomarker for MCS exposure.  Chronic exposure to CR-alone showed 
a rapid increase in urinary HPMMA, with the level after 11 weeks of exposure exceeding 









Fig. 6.7.  Effects of acute crotonaldehyde (CR; 1 ppm) exposure on circulating stem cells in female mice.  Hematopoietic stem 
cells (Sca-1+) and circulating angiogenic cells (CAC) were measured by flow cytometry gating in female C57BL/6J (wild type, WT) 
mice exposed to HEPA-filtered air or CR (1 ppm, 6h/d) for 4 days. Levels of circulating Sca-1+ cells (A) and CACs (Flk-1+/Sca-1+ cells; 




previous findings that levels of CR in MCS are not as high as levels of acrolein but that 
there is a significant level of CR in cigarettes that may contribute to the cardiovascular 
effects of smoking. 
A number of epidemiological and experimental studies have linked acrolein 
exposure with increased CVD risk.  Previous studies in our group have shown that acrolein 
contributes to the development of CVD through CAC suppression (74, 151), platelet 
activation (450), and endothelium dysfunction (150).  However, acute (4d; 1 ppm) 
exposure to acrolein produced no systemic toxicity as measured by CBC or measured in 
plasma biomarkers (74), and even chronic exposure (12 weeks; 1 ppm) only showed 
significant changes in leukocytes (151).  The current acute (4d) study shows significant 
decreases in leukocytes, but only minimal changes in plasma biomarkers, and while we did 
not see a significant decrease in levels of CACs as was previously seen after acrolein 
exposure (74, 151), there was a trend towards decreased levels that likely did not reach 
significance due to our small sample size (n=4 air; n=3 acrolein).  Although the change in 
leukocytes seen in the current acute study (1 ppm) vary from the results of the previous 
study (74), they support the findings of the chronic study (151), indicating that the variation 
between the acute studies may simply be due to the use of a different set of mice.  However, 
the significant decrease (74) and trending decrease in CACs in the acute studies likely 
indicate that acrolein primarily induces injury in the endothelium before inducing more 
systemic changes, although these changes may still occur at a time point earlier than 12 
weeks.   
Despite the physical and chemical similarities and the shared exposure sources 




toxicity of inhaled CR is not well studied.  To our knowledge, these studies are the first to 
evaluate the systemic and vascular effects of acute and chronic CR inhalation exposure.  
Although CR is known to trigger inflammation (91), the current data do not show changes 
in circulating leukocytes or specific immune cell differentials in either acute (1 or 3 ppm) 
or chronic exposures, an outcome differing from that after acute (4d, 1 ppm) and chronic 
acrolein exposure (12 weeks; 1 ppm) (74, 151).  Of course, CR exposure could lead to the 
suppression of immune function (452, 453) independent of leukocyte numbers as described 
for alveolar macrophages following acrolein exposure (454).  However, these other studies 
of CR or acrolein are hard to compare with the current studies due to the high-level CR 
doses given by intratracheal installation that led to mortality (452) or to the use of in vitro 
methods (453, 454).  From the inhalation studies presented here, it can be inferred that the 
immune system overall appears a less sensitive target of CR exposure than of acrolein. 
In other systemic measures, chronic CR exposure results in dyslipidemic changes 
through increases in both cholesterol and triglycerides. High levels of cholesterol and 
triglycerides are known risk factors of ischemic (455) and coronary heart disease (456).  
Triglycerides release pre-formed mediators of oxidative stress that influence endothelial 
cell function by stimulating intracellular production of reactive oxygen species (457), 
inducing endothelium dysfunction (458, 459), and promoting atherosclerotic plaques 
(460).  Although levels of both cholesterol and triglycerides increased in this chronic study, 
neither biomarker increased after acute (4d; 1 ppm) exposure.  In fact, both cholesterol and 
triglycerides significantly decrease in the CR-exposed group compared with air-exposed 
control mice, indicating that chronic increases in lipids are not the primary change initiated 
by CR exposure.  
170 
Over the past decade, studies in our group have shown that exposures of mice and 
humans to air pollutants (particulate matter (PM2.5), acrolein) lead to the suppression of 
CACs (71, 73, 74), yet no changes in CACs were observed in these studies. It can therefore 
be inferred that 1 ppm CR is not as potent of a stimulus of CAC suppression as is either 
PM2.5 or acrolein (1 ppm). 
These studies also examined the effect of sex on the measured CR-induced 
outcomes.  Female mice acutely exposed to CR (4d; 1 ppm) showed no significant changes 
in any systemic or vascular biomarkers, indicating that the effects of CR exposure are likely 
sex-dependent.  Epidemiological studies seem to support this outcome; analysis of male 
versus female smokers in the National Health and Nutrition Examination Study 
(NHANES) 2005-2006 and 2011-2012 cohorts showed significant differences in urinary 
HPMMA (159).  As previous studies in acrolein-exposed mice also show that the effects 
of acrolein are sex-dependent (269), it may be that there are sex differences in the 
pharmacodynamics and pharmacokinetics in the metabolism of the unsaturated aldehydes.  
Additional studies of acrolein and CR exposure in both male and female mice should work 
to identify the mechanism of this female-dependent protection with the idea that this 
clarification could be used in the development of effective interventions and treatments for 
unsaturated aldehyde exposure. 
In summary, the studies presented in this chapter overall confirm the results of 
previous work examining the effects of acrolein exposure and have demonstrated the 
systemic and hematological effects of both acute and chronic CR exposure.  In particular, 
chronic CR exposure was shown to increase levels of plasma biomarkers indicative of 




Comparisons of the outcomes between acrolein and CR seem to demonstrate that acrolein 
is more toxic than CR, at least at the concentrations and durations tested.  However, the 
presence of high levels of CR in MCS and other sources, as well as the lack of previous 
research, demonstrate the need for a better understanding of how CR exposure contributes 
to the cardiovascular pathology of real-world combustion-related exposures.  Furthermore, 
the sex-dependence shown in relation to acute CR exposure supports the idea of sex-
dependence in the cardiovascular effects of unsaturated aldehyde exposures, an area that 
requires additional study.  As exposures to acrolein and CR remain a daily occurrence for 
most of the global population, these studies confirm previous research and provide novel 
insight into the role of unsaturated aldehydes in the development of CVD, specifically 





ROLES OF EXTRACELLULAR SUPEROXIDE DISMUTASE AND TRANSIENT 
RECEPTOR POTENTIAL ANKYRIN 1 IN THE CARDIOVASCULAR EFFECTS OF 
TOBACCO PRODUCTS AND CONSTITUENT ALDEHYDES 
A. Introduction 
One of the mechanisms proposed by Brook et al. (16) to explain how air pollutants 
may contribute to the development of cardiovascular disease (CVD) is the development of 
systemic oxidative stress and inflammation within the vasculature.  In this hypothesis, 
oxidative stress results from overproduction of reactive oxygen species (ROS), which are 
highly reactive, oxygen-containing molecules (16, 40-43).  ROS have been shown to play 
a beneficial role when maintained at normal levels (42-44), but excess production can lead 
to the development of oxidative stress (40-42, 44, 47), which has been linked to incidence 
of CVD (42, 48-52).  Mechanistically, the ROS-related development of CVD is at least in 
part mediated by changes in the bioavailability of nitric oxide (NO) and the development 
of endothelium dysfunction (40-42).  The enzyme superoxide dismutase (SOD) indirectly 
plays an important role in regulating levels of NO in the blood; SOD catalyzes the 
dismutation of superoxide, but when the enzyme is inactivated, the free superoxide 




The subsequent imbalance of vasoactive factors in the vasculature can result in 
endothelium dysfunction (40, 41), which is one of the earliest vascular changes in a number 
of CVDs (54-58).  Although ROS have been identified as therapeutic targets for the 
treatment of CVD (59-61), more research is needed to better understand the relationship 
between these vascular changes and disease development. 
One of the many channels activated by ROS is the transient receptor potential 
ankyrin 1 (TRPA1) channel (263-266, 461, 462).  The TRPA1 channel has also been shown 
to be activated by a number of other stimuli, including physical factors (260, 262) and air 
pollutants including diesel exhaust, mainstream cigarette smoke (MCS), and aldehydes 
(127, 260, 262, 266, 268-270).  TRPA1 is primarily recognized as a pain (262, 272, 279) 
or irritant (262, 264, 279, 286) receptor, but a number of other studies have demonstrated 
the role of TRPA1 in vasodilation (127, 260, 265, 266, 270, 272).  Additionally, Conklin 
et al. (269) demonstrated that the TRPA1 channel plays an important role in the 
cardiopulmonary toxicity and lethality induced by high-level exposure to the aldehyde 
acrolein, and several other studies have also shown that the negative cardiovascular effects 
of inhaled acrolein are TRPA1-dependent (261, 289, 290).  However, the role of TRPA1 
in the cardiovascular toxicity of other aldehydes, including crotonaldehyde (CR), is not 
well explored.  Thus, the goal of these studies was to examine the roles of SOD, specifically 
extracellular SOD (ecSOD), and the TRPA1 channel in the mechanism through which 
constituents of personal air pollutant exposures mediate cardiovascular toxicity.   
B. Experimental Procedures 
1. Exposures 
Animals were exposed to compounds or constituents via full-body inhalation as 
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described in Chapter II, Sections B.2.  Upon completion of the exposure, mice were 
euthanized and tissues collected as described in Chapter II, Section B.5. 
2. Urine Collection
Urine samples were collected post-exposure as described in Chapter II, Section B.3. 
3. Urine Metabolite Quantification
Collected urine was used to quantify levels of volatile organic compound (VOC) 
and tobacco alkaloid metabolites using analytical methods as described in Chapter II, 
Section B.4. 
4. Complete Blood Cell Count (CBC)
A sample of whole blood was collected from each mouse after the final day of 
exposure for a complete blood cell count (CBC) as described in Chapter II, Section B.6. 
3. Plasma Biomarkers Quantification
Plasma was prepared from each sample for an analysis of a number of biomarkers 
as described in Chapter II, Section B.7. 
4. Circulating Angiogenic Cell (CAC) Quantification
Flow cytometry was used to analyze the number of circulating angiogenic cells 
(CACs) in each sample as described in Chapter II, Section B.8. 
5. Statistical Analyses
Statistical analyses were performed as described in Chapter II, Section B.10. 
C. Results 




Because TRPA1 activation and neurogenic inflammation are induced by MCS, we 
performed acute exposures to MCS (4 days; 50% of smoke of 12 KY Reference 3R4F 
cigarettes) using TRPA1-null male mice.  Similar to the effects seen in MCS-exposed WT 
mice, TRPA-1 null mice showed a decreased final body weight (-11%; p<0.001), but no 
changes in organ/body weight ratios (Table 7.1).  Also similar to the WT mice, overall 
leukocyte count was significantly decreased with MCS exposure (-51%; p<0.001), 
although this decrease was driven by decreases in both lymphocytes and monocytes (-34%; 
p=0.004 and -40%; p=0.02, respectively) (Table 7.2).  MCS exposure otherwise had 
limited effects on CBC measures, inducing only a slight but significant increase in red cell 
distribution width (+2%; p=0.03) and a modest decrease in platelet count (-16%; p=0.06) 
(Table 7.2).  Measures of liver (ALT, AST), muscle (CK), and LDH enzymes were 
unaffected by exposure, but exposed TRPA1-null mice showed a modest decrease in LDL 
(-23%; p=0.05) and a modest increase in albumin (+9%; p=0.07) (Table 7.1). 
2. Acute Exposure to Crotonaldehyde and the Role of TRPA1 
Because TRPA1 activation and neurogenic inflammation are induced by MCS and 
acrolein (261), we performed acute exposures to CR (4 days; 1 ppm) using TRPA1-null 
male mice.  In contrast to the effects observed in CR-exposed male WT mice, TRPA1-null 
mice had no systemic changes in CBC (Table 7.3) yet did have a decreased kidney/body 
weight ratio (-9%; p<0.001) relative to air-exposed control mice (Table 7.3).  Plasma levels 
of ALT, AST, CK, and LDH enzymes, albumin, and creatinine were unchanged between 
the air- and CR-exposed TRPA1-null mice (Table 7.4).  Cholesterol was decreased by CR 
exposure in the TRPA1-null mice (-17%; p=0.003; a change also observed in WT mice), a 






Table 7.1. Systemic parameters of male TRPA1-null mice acutely exposed to either air or mainstream cigarette smoke (MCS; 50% of 
smoke of 12 KY Reference 3R4F cigarettes). 
 
 Exposure (4 days) 
Variable Air Control MCS 
Final BWT (g) 33 ± 0† 29 ± 1*† 
Heart/BWT (mg/g) 5.5 ± 0.1 5.6 ± 0.1† 
Lung/BWT (mg/g) 6.1 ± 0.2 6.0 ± 0.1 
Liver/BWT (mg/g) 46.6 ± 2.2 47.7 ± 2.2† 
Kidney/BWT (mg/g) 14.2 ± 0.6 13.4 ± 0.4 
                         Plasma Measurements 
 Cholesterol (mg/dL) 81.83 ± 4.48 78.00 ± 3.57 
HDL (mg/dL) 45.83 ± 2.26 48.29 ± 3.41 
LDL (mg/dL) 26.47 ± 2.21 20.34 ± 0.78# 
Triglycerides (mg/dL) 47.67 ± 1.82† 46.86 ± 1.65† 
Albumin (g/dL) 2.57 ± 0.03† 2.79 ± 0.06#† 
Total Protein (g/dL) 5.07 ± 0.11 5.01 ± 0.07 
ALT (U/I) 12.67 ± 2.16† 12.00 ± 1.48† 
AST (U/I) 44.17 ± 3.49 48.43 ± 10.95 
CK (U/I) 112.67 ± 11.78† 144.73 ± 52.39 
LDH (U/I) 142.67 ± 9.64† 134.14 ± 10.29† 
 
Values = mean ± SE (n=6-7 mice per group); HDL & LDL compared using Rank Sum Test.  Abbr.: ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; BWT, body weight; CK, creatine kinase; HDL, high-density lipoprotein; LDH, lactate 






*, p<0.05 compared with air control based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with air control based on 







Table 7.2. Hematological measures of male TRPA1-null mice acutely exposed to either air or mainstream cigarette smoke (MCS; 
50% of smoke of 12 KY Reference 3R4F cigarettes). 
 
 Exposure (4 days) 
Hematological Measurements Air Control MCS 
White Blood Cell (K/uL) 3.87 ± 0.41† 1.91 ± 0.17*† 
Neutrophils (K/uL) 1.65 ± 0.34 0.46 ± 0.04 
Lymphocytes (K/uL) 2.13 ± 0.20† 1.40 ± 0.15*† 
Monocytes (K/uL) 0.09 ± 0.01† 0.05 ± 0.01*¶ 
Eosinophils (K/uL) 0 ± 0 0 ± 0 
Basophils (K/uL) 0 ± 0 0 ± 0 
Red Blood Cell (M/uL) 8.91 ± 0.24† 8.88 ± 0.19 
Hemoglobin (g/dL) 13.1 ± 0.3† 13.3 ± 0.2† 
Hematocrit (%) 44.0 ± 1.0† 44.9 ± 1.0† 
Mean Corpuscular Volume (fL) 49.5 ± 0.8† 50.6 ± 0.3† 
Mean Corpuscular Hemoglobin (pg) 14.7 ± 0.3† 15.0 ± 0.1† 
Mean Corpuscular Hemoglobin Concentration (g/dL) 29.7 ± 0.4 29.7 ± 0.2† 
Red Cell Distribution Width (%) 18.5 ± 0.6¶ 17.4 ± 0.3* 
Platelets (K/uL) 880 ± 108 648 ± 36#† 
Mean Platelet Volume (fL) 4.5 ± 0 4.3 ± 0.1 
 
Values = mean ± SE (n=6-7 mice per group); Abbr.: MCS, mainstream cigarette smoke; TRPA1, transient receptor potential ankyrin 
1; *, p<0.05 compared with air control based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with air control based on 
Bonferroni’s or Dunn’s post-test; †, p<0.05 for WT vs TRPA1-null based on Dunn’s post-test; ¶, 0.05≤p≤0.10 for WT vs TRPA1-null 






Table 7.3. Systemic measures in male TRPA1-null mice acutely exposed to either air or crotonaldehyde (CR; 1 ppm). 
 
 Exposure Duration (4 days) 
Variable Air Control CR (1 ppm) 
Change in BWT (g) -1 ± 1 -1 ± 0 
Heart/BWT (mg/g) 5.3 ± 0.2 5.0 ± 0.2 
Lung/BWT (mg/g) 5.7 ± 0.2 5.4 ± 0.2 
Liver/BWT (mg/g) 47.8 ± 2.0† 47.8 ± 1.0† 
Kidney/BWT (mg/g) 14.2 ± 0.4† 12.9 ± 0.2* 
                      Hematological Measurements 
White Blood Cell (K/µL) 1.70 ± 0.24 1.57 ± 0.27 
Neutrophils (K/µL) 0.59 ± 0.12 0.47 ± 0.09 
Lymphocytes (K/µL) 1.06 ± 0.12 1.06 ± 0.18 
Monocytes (K/µL) 0.05 ± 0.01 0.08 ± 0.04 
Eosinophils (K/µL) 0 ± 0 0 ± 0 
Basophils (K/µL) 0 ± 0 0 ± 0 
Red Blood Cell (M/µL) 8.40 ± 0.13 8.72 ± 0.10 
Hemoglobin (g/dL) 11.6 ± 0.2 12.1 ± 0.1 
Hematocrit (%) 37.8 ± 0.7 39.5 ± 0.4 
Mean Corpuscular Volume (fL) 45.0 ± 0.3 45.3 ± 0.3† 
Mean Corpuscular Hemoglobin (pg) 13.9 ± 0.1 13.8 ± 0.1 
Mean Corpuscular Hemoglobin Concentration (g/dL) 30.8 ± 0.2 30.6 ± 0.3 
Red Cell Distribution Width (%) 18.3 ± 0.4† 17.7 ± 0.3 
Platelets (K/µL) 869 ± 51† 862 ± 56† 
Mean Platelet Volume (fL) 4.5 ± 0.1† 4.6 ± 0.1† 
 
Values = mean ± SE (n=9-15 mice per group); Abbr.: BWT, body weight; CR, crotonaldehyde; TRPA1, transient receptor potential 













Table 7.4. Plasma biomarkers in male TRPA1-null mice acutely exposed to either air or crotonaldehyde (CR; 1 ppm). 
 
 Exposures (4 days) 
Plasma Measurements Air Control CR (1 ppm) 
Cholesterol (mg/dL) 81.39 ± 3.13† 67.27 ± 3.48* 
HDL (mg/dL) 49.95 ± 2.89 47.34 ± 2.80 
LDL (mg/dL) 8.73 ± 0.96† 4.49 ± 0.52* 
Triglycerides (mg/dL) 40.77 ± 3.60 27.39 ± 1.66 
Albumin (g/dL) 2.75 ± 0.10 2.77 ± 0.07 
Total Protein (g/dL) 5.11 ± 0.17† 4.83 ± 0.11† 
ALT (U/I) 28.91 ± 1.43 33.71 ± 5.31 
AST (U/I) 70.62 ± 4.13 69.88 ± 8.82 
CK (U/I) 222.70 ± 27.59 233.81 ± 31.69 
LDH (U/I) 138.03 ± 7.35 160.28 ± 12.70 
Creatinine (mg/dL) 0.25 ± 0.01 0.24 ± 0.01 
 
 
Values = mean ± SE (n=5-6 mice per group); Abbr.: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine 
kinase; CR, crotonaldehyde; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; TRPA1, 
transient receptor potential ankyrin 1; *, p<0.05 compared with air control based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 





observed in WT mice (Table 7.4).  As with the WT mice, TRPA1-null mice acutely 
exposed to 1 ppm CR had no change in the levels of circulating Sca-1+ cells or Flk-1+/Sca-
1+ cells (Fig. 7.1A & B). 
3. Urinary Metabolites in MCS-Exposed WT and ecSOD-Tg Mice 
The antioxidant enzyme superoxide dismutase (SOD) catalyzes the dismutation of 
superoxide molecules to prevent their binding with nitric oxide and the subsequent 
formation of peroxynitrite (40-42, 53).  Peroxynitrite can disrupt the proper production of 
nitric oxide, which contributes to the development of endothelium dysfunction (40, 41).  
This dysfunction is one of the early vascular changes noted in a number of CVDs (54-57), 
but increased levels of SOD, particularly extracellular SOD (ecSOD), have been shown to 
be protective in cardiac tissues (463).  To better understand the role of ecSOD in the 
cardiovascular-related effects of MCS, we measured urinary metabolites by UPLC-MS/MS 
and GC-MS/MS in mice exposed to a known number of cigarettes.  For this, male mice 
overexpressing ecSOD (ecSOD-Tg; Tg) and their wild type littermates (WT) were exposed 
to MCS (50% of smoke of 12 or 6 KY Reference 3R4F cigarettes, 6h/day, 4d), and urine 
was immediately collected after the exposure sessions.  Urinary levels of 3-
hydroxypropylmercapturic acid (3HPMA) were not significantly different between WT 
and Tg mice at baseline (Fig. 7.2A).  Likewise, levels of 3HPMA after the first three hours 
post-MCS exposure were not significantly different from baseline, nor were levels different 
between background (WT or Tg) or between number of cigarettes (12 or 6) (Fig. 7.2A). 
Conversely, urinary HPMMA levels were significantly increased in both WT (p=0.02) and 
Tg (p=0.003) mice exposed to 12 cigarettes and WT (p=0.02) and Tg (p=0.006) mice 









Fig. 7.1.  Effects of acute crotonaldehyde (CR; 1 ppm) exposure on circulating stem cells in male TRPA1-null mice. 
Hematopoietic stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in male TRPA1-null 
male mice exposed to HEPA-filtered air or CR (1 ppm, 6h/d) for 4 days. After 4 days of exposure to CR, TRPA1-null mice had no 
change in the level of Sca-1+ cells (A) but had a modest increase in the level of CACs (Flk-1+/Sca-1+ cells (B) compared with air-








Fig. 7.2.  Urinary 3HPMA & HPMMA levels after acute mainstream cigarette smoke (MCS) exposure.  Male WT and ecSOD-Tg 
mice were exposed (6h) to mainstream cigarette smoke (MCS; MCS I: 50% of smoke of 12 KY Reference 3R4F cigarettes; MCS II: 
50% of smoke of 6 KY Reference 3R4F cigarettes) after which urine was collected at 0–1, 1–2, 2–3, and 3–16h (overnight) and 3-
hydroxypropylmercapturic acid (3HPMA; A) and 3-hydroxy-1-methylpropylmercapturic acid (HPMMA; B) quantified. Values are 






particulate air; 3HPMA, 3-hydroxypropylmercapturic acid; HPMMA, 3-hydroxy-1-methylpropylmercapturic acid; MCS, mainstream 




significant differences in HPMMA between WT and Tg mice exposed to the same number 
of cigarettes (Fig. 7.2B).  Levels of total urinary nicotine metabolites were below the limit 
of detection in HEPA-exposed mice, and mice exposed to either 6 or 12 cigarettes showed 
significant increases in the first three hours post-exposure regardless of background (WT: 
p=0.02 for both; Tg: p<0.001 for both) (Fig. 7.3).  Levels were not different, however, 
between mice of the same background exposed to the same number of cigarettes (Fig. 7.3). 
4. Acute Exposure to MCS and the Role of ecSOD 
Because of the protective cardiopulmonary effects seen with overexpression of the 
antioxidant enzyme ecSOD (463-465), we tested for the potential benefit of this 
overexpression in biomarkers of systemic and hematological injury in mice exposed to 
MCS (50% of smoke of 6 or 12 3R4F KY reference cigarettes).  Tg mice acutely (4d) 
exposed to 6 cigarettes showed a greater final body weight compared with their 6 cigarette-
exposed WT littermates (+6%; p=0.07) (Table 7.5), while no change was seen between 
WT and Tg mice exposed to 12 cigarettes (Table 7.6).  The lung/body weight ratio, 
however, was significantly lower in Tg mice exposed to 12 cigarettes compared with 12 
cigarette-exposed WT mice (-20%; p=0.02) (Table 7.6); only the liver/body weight ratio 
was different between WT and Tg mice exposed to 6 cigarettes, with Tg mice showing a 
modestly lower ratio (-7%; p=0.07) (Table 7.5). Acute exposure showed minimal 
differences in both CBC and plasma biomarkers between WT and Tg mice exposed to the 
same number of cigarettes but considerable differences in mice of the same background 
exposed to a different number of cigarettes.  For example, in mice exposed to 6 cigarettes, 
lymphocyte counts were lower in Tg mice (-23%; p=0.08) (Table 7.5), but no differences 







Fig. 7.3.  Total urinary nicotine metabolite levels after acute mainstream cigarette 
smoke (MCS) exposure.  Male WT and ecSOD-Tg mice were exposed (6h) to mainstream 
cigarette smoke (MCS; MCS I: 50% of 12 KY Reference 3R4F cigarettes; MCS II: 50% 
of smoke of 6 KY Reference 3R4F cigarettes) after which urine was collected at 0–1, 1–2, 
2–3, and 3–16h (overnight) and total urinary nicotine metabolites (nicotine, cotinine, and 
trans-3’-hydroxycotinine) quantified. Values are mean ± SE (n=3-5 mice per group).  
Abbr.: ecSOD-Tg; extracellular superoxide dismutase transgenic; HEPA, high-efficiency 
particulate air; MCS, mainstream cigarette smoke; WT, wild type.  *, p<0.05 compared 







Table 7.5. Systemic changes in male WT or ecSOD-Tg mice acutely exposed to either air or mainstream cigarette smoke (MCS; 50% 
of smoke of 6 KY Reference 3R4F cigarettes). 
 
 MCS (6 cigs, 4d) 
Variable WT ecSOD-Tg 
Final BWT (g) 30 ± 1 32 ± 1# 
Heart/BWT (mg/g) 5.4 ± 0.3 4.7 ± 0.1 
Lung/BWT (mg/g) 5.3 ± 0.3 5.1 ± 0.1 
Liver/BWT (mg/g) 42.7 ± 1.1 39.7 ± 0.6# 
                      Hematological Measurements 
White Blood Cell (K/µL) 3.83 ± 0.63† 3.55 ± 0.51¶ 
Neutrophils (K/µL) 1.27 ± 0.53 1.55 ± 0.49¶ 
Lymphocytes (K/µL) 2.48 ± 0.34† 1.91 ± 0.19#¶ 
Monocytes (K/µL) 0.07 ± 0.01 0.08 ± 0.02¶ 
Eosinophils (K/µL) 0.01 ± 0 0.01 ± 0.01 
Basophils (K/µL) 0 ± 0 0 ± 0 
Red Blood Cell (M/µL) 8.35 ±  0.35 8.54 ± 0.16¶ 
Hemoglobin (g/dL) 12.3 ± 0.9 12.6 ± 0.5¶ 
Hematocrit (%) 36.3 ± 1.4 37.3 ± 0.8¶ 
Mean Corpuscular Volume (fL) 43.5 ± 0.2 43.7 ± 0.2 
Mean Corpuscular Hemoglobin (pg) 14.7 ± 0.6 14.8 ± 0.4 
Mean Corpuscular Hemoglobin Concentration (g/dL) 33.8 ± 1.5 33.9 ± 0.7 
Red Cell Distribution Width (%) 18.2 ± 0.2 18.0 ± 0.2 
Platelets (K/µL) 776 ± 57 788 ± 24 
Mean Platelet Volume (fL) 4.7 ± 0 4.7 ± 0 
 






extracellular superoxide dismutase transgenic; MCS, mainstream cigarette smoke; WT, wild type; *, p<0.05 compared with WT based 
on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with WT based on Bonferroni’s or Dunn’s post-test; †, 0.05≤p≤0.10 for 









Table 7.6. Systemic changes in male WT or ecSOD-Tg mice acutely exposed to either air or mainstream cigarette smoke (MCS; 50% 
of smoke of 12 KY Reference 3R4F cigarettes). 
 
 MCS (12 cigs, 4d) 
Variable WT ecSOD-Tg 
Final BWT (g) 31 ± 0 32 ± 1 
Heart/BWT (mg/g) 4.8 ± 0.2 4.1 ± 0.5 
Lung/BWT (mg/g) 6.1 ± 0.3 4.8 ± 0.5* 
Liver/BWT (mg/g) 39.9 ± 1.4 40.9 ± 1.1 
                      Hematological Measurements 
White Blood Cell (K/µL) 1.38 ± 0.24 1.25 ± 0.21 
Neutrophils (K/µL) 0.43 ± 0.12 0.40 ± 0.05 
Lymphocytes (K/µL) 0.90 ± 0.11 0.81 ± 0.19 
Monocytes (K/µL) 0.04 ± 0.01 0.04 ± 0.01 
Eosinophils (K/µL) 0 ± 0 0 ± 0 
Basophils (K/µL) 0 ± 0 0 ± 0 
Red Blood Cell (M/µL) 7.66 ± 0.39 7.26 ± 0.37 
Hemoglobin (g/dL) 10.8 ± 0.3 10.3 ± 0.7 
Hematocrit (%) 33.5 ± 1.7 31.6 ± 1.8 
Mean Corpuscular Volume (fL) 43.7 ± 0.1 43.5 ± 0.3 
Mean Corpuscular Hemoglobin (pg) 14.1 ± 0.4 14.1 ± 0.3 
Mean Corpuscular Hemoglobin Concentration (g/dL) 32.3 ± 0.9 32.2 ± 0.7 
Red Cell Distribution Width (%) 18.6 ± 0.4 18.0 ± 0.3 
Platelets (K/µL) 823 ± 66 826 ± 45 
Mean Platelet Volume (fL) 4.6 ± 0.1 4.6 ± 0.1 
 






extracellular superoxide dismutase transgenic; MCS, mainstream cigarette smoke; WT, wild type; *, p<0.05 compared with ecSOD-
WT based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with WT based on Bonferroni’s or Dunn’s post-test; †, p<0.05 





showed higher levels of leukocytes after exposure to 6 cigarettes compared with levels 
after exposure to 12 cigarettes (+178%; p=0.002 and +185%; p=0.001, respectively) 
(Tables 7.5 & 7.6).  Likewise, lymphocytes were higher in both WT (+174%; p<0.001) and 
Tg (+137%; p=0.001) mice after exposure to 6 cigarettes than after exposure to 12 
cigarettes, while neutrophils (+289%; p=0.04) and monocytes (+90%; p=0.07) were only 
higher in Tg mice (Tables 7.5 & 7.6).  MCS seemed to induce a greater response mice in 
erythrocytic measures of Tg mice, with differences noted in red blood cell count (+18%; 
p=0.01) and measures of hemoglobin (+23%; p=0.01) and hematocrit (+18%; p=0.01) 
between Tg mice exposed to 12 or 6 cigarettes (Tables 7.5 & 7.6).  Acute exposure to MCS 
(6 or 12 cigarettes) did not affect plasma levels of CK (striated muscle), ALT or AST 
(liver), or LDH (non-specific cell toxicity) enzymes in either WT or Tg mice (Tables 7.7 
& 7.8), but a number of differences were once again noted between mice of the same 
background exposed to a different number of cigarettes.  Cholesterol was modestly higher 
in both WT (+16%; p=0.07) and Tg (+13%; p=0.08) mice exposed to 6 cigarettes compared 
with mice exposed to 12 cigarettes (Tables 7.7 & 7.8); both albumin (WT: +17%, p=0.02; 
Tg: +10%, p=0.09) and total protein (WT: +16%, p=0.01; Tg: +15%, p=0.01) showed this 
same pattern, while LDL was higher in only Tg mice exposed to 6 cigarettes compared 
with Tg mice exposed to 12 cigarettes (+16%; p=0.08) (Tables 7.7 & 7.8).  No differences 
were seen in levels of Sca-1+ cells or CACs regardless of background or exposure (Fig. 
7.5A & B).   
D. Discussion 
Studies have shown MCS to be both a source of ROS (466-470) and a promoter of 






Table 7.7. Plasma biomarkers in male WT or ecSOD-Tg mice acutely exposed to either air or mainstream cigarette smoke (50% of 
smoke of MCS; 6 KY Reference 3R4F cigarettes). 
 
 MCS (6 cigs, 4d) 
Plasma Measurements ecSOD-WT ecSOD-Tg 
Cholesterol (mg/dL) 85.70 ± 5.02† 85.55 ± 3.96¶ 
HDL (mg/dL) 35.81 ± 2.68 37.56 ± 2.79 
LDL (mg/dL) 32.62 ± 1.98 32.81 ± 1.87¶ 
Triglycerides (mg/dL) 49.70 ± 5.88 51.68 ± 2.63 
Albumin (g/dL) 3.17 ± 0.17† 2.98 ± 0.08¶ 
Total Protein (g/dL) 5.26 ± 0.23† 5.11 ± 0.08¶ 
ALT (U/I) 27.58 ± 4.61† 27.02 ± 2.95¶ 
AST (U/I) 63.36 ± 14.19 67.20 ± 4.75 
CK (U/I) 260.89 ± 111.04 333.57 ± 25.98 
LDH (U/I) 218.80 ± 44.05 260.40 ± 30.58 
Creatinine (mg/dL) 0.25 ± 0 0.28 ± 0 
 
Values = mean ± SE (n=4-6 mice per group); Abbr.: ecSOD, extracellular superoxide dismutase; ecSOD-Tg, extracellular superoxide 
dismutase transgenic; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCS, mainstream cigarette smoke; WT, wild 
type; *, p<0.05 compared with WT based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with WT based on Bonferroni’s 
or Dunn’s post-test; †, p<0.05 for 12 vs 6 cigarettes in WT mice based on Dunn’s post-test; ¶, 0.05≤p≤0.10 for 12 vs 6 cigarettes in 







Table 7.8. Plasma biomarkers in male ecSOD-WT or ecSOD-Tg mice acutely exposed to either air or mainstream cigarette smoke 
(MCS; 50% of smoke of 12 KY Reference 3R4F cigarettes). 
 MCS (12 cigs, 4d) 
Plasma Measurements ecSOD-WT ecSOD-Tg 
Cholesterol (mg/dL) 73.91 ± 3.20 75.42 ± 4.09 
HDL (mg/dL) 33.10 ± 1.32 33.15 ± 1.84 
LDL (mg/dL) 28.93 ± 1.29 28.33 ± 1.83 
Triglycerides (mg/dL) 41.86 ± 8.75 38.89 ± 3.44 
Albumin (g/dL) 2.72 ± 0.10 2.71 ± 0.11 
Total Protein (g/dL) 4.54 ± 0.16 4.43 ± 0.18  
ALT (U/I) 17.03 ± 1.19 19.95 ± 0.69 
AST (U/I) 49.35 ± 4.89 55.83 ± 4.82 
CK (U/I) 201.59 ± 29.92 252.97 ± 39.54 
LDH (U/I) 178.21 ± 16.26 202.75 ± 19.31 
Creatinine (mg/dL) 0.27 ± 0.02 0.28 ± 0.03 
 
Values = mean ± SE (n=4-6 mice per group); Abbr.: ecSOD, extracellular superoxide dismutase; ecSOD-Tg, extracellular superoxide 
dismutase transgenic; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MCS, mainstream cigarette smoke; WT, wild 
type; *, p<0.05 compared with WT based on Bonferroni’s or Dunn’s post-test; #, 0.05≤p≤0.10 compared with WT based on 
Bonferroni’s or Dunn’s post-test; †, p<0.05 for 12 vs 6 cigarettes in WT mice based on Dunn’s post-test; ¶, 0.05≤p≤0.10 for 12 vs 6 









Fig. 7.4.  Effects of acute mainstream cigarette smoke (MCS; 6 or 12 cigarettes) exposure on circulating stem cells in male WT 
and ecSOD-Tg mice. Hematopoietic stem cells (Sca-1+) and circulating angiogenic cells (CACs) were measured by flow cytometry in 
male WT and ecSOD-Tg male mice exposed to HEPA-filtered air or MCS (6 or 12 cigs; 6h/d) for 4 days. After 4 days of exposure to 
MCS, there were no changes in the level of Sca-1+ cells (A) or CACs (B) regardless of background or the number of cigarettes.  Values 




mechanism through which MCS contributes to the development of CVD (467, 471-474).  
The SOD enzyme serves to dismutate the superoxide radical and thus works to attenuate 
the development of oxidative stress in the vasculature.  Studies of both under- and 
overexpression of ecSOD have demonstrated the role of this enzyme in the development 
of vascular changes and injury that could contribute to CVD and other smoking-related 
diseases (299, 475-478).  The TRPA1 channel is a non-selective, cation channel and a 
promiscuous receptor concentrated in sensory fibers that mediates pain 
reception/transmission as well as irritant-related pulmonary reflexes including cough and 
bronchoconstriction in response to unsaturated aldehydes generated in MCS (261).  TRPA1 
can also be activated by ROS (263-266, 461, 462), which may also contribute to the 
channel’s role in the development of CVD.  The goal of the current studies was to explore 
the roles of ecSOD and the TRPA1 channel through the use of transgenic (ecSOD-Tg mice 
and TRPA1-null) mice in response to MCS and CR exposures. 
Male ecSOD-Tg mice and their WT littermates were exposed to MCS generated 
from 6 or 12 KY Reference 3R4F cigarettes.  Based on the overall data, there was no 
discernable indication that ecSOD-Tg mice were better protected from MCS-generated 
aldehydes than their similarly-exposed WT counterparts through increased levels of 
pulmonary ecSOD.  Urinary measures of acrolein and crotonaldehyde metabolites showed 
no significant differences between WT and Tg mice exposed to either 6 or 12 cigarettes.  
There were also no significant differences in measures of urinary nicotine between WT and 
Tg mice, and despite one set of mice being exposed to smoke from twice as many 





Measures of systemic injury assessed through CBC and measures of plasma 
biomarkers showed minimal differences between similarly-exposed WT and Tg mice, but 
there were a number of significant differences in both WT and Tg mice between the two 
exposures to a different number of cigarettes.  Mice exposed to 6 cigarettes had higher 
leukocyte counts, with WT mice having a higher level of lymphocytes and Tg mice having 
higher levels of neutrophils, lymphocytes, and monocytes compared with mice exposed to 
12 cigarettes.  Likewise, both WT and Tg mice exposed to 6 cigarettes had higher levels of 
cholesterol, albumin, total protein, and ALT compared with mice exposed to 12 cigarettes.  
Measures of CACs also show that levels of these cells were not significantly different 
between WT and Tg mice exposed to the same number of cigarettes.  
These data demonstrate increased systemic and hematological changes with a 
greater concentration of MCS exposure despite similar levels of urinary nicotine but do not 
seem to indicate that pulmonary overexpression of ecSOD is protective against injury 
related to MCS-exposure.  Despite studies linking ROS with cigarettes and the 
development of CVD, it may be that ROS other than superoxide are responsible for this 
development.  However, studies examining SOD in the role of smoking-related pulmonary 
disease have found that the overexpression of SOD can attenuate pulmonary inflammation 
and impaired lung function as well as the development of emphysema (477, 478), 
implicating superoxide in the development of pulmonary diseases related to the use of 
cigarettes.  Other data demonstrate the role of ecSOD in the PM2.5-related impact on levels 
of CACs (299), and while PM is a known component of cigarette smoke (81), it may be 
that other constituents of MCS have a counteractive effect that, while potentially not 




the adverse effects noted in response to MCS exposure are induced by systemic ROS, and 
thus the overexpression of ecSOD specifically in the lungs would not have an effect.  It has 
been shown via measures of protein-acrolein adducts in the plasma and bone marrow that 
inhaled acrolein, a major constituent of MCS, is able to move into the bloodstream and 
exert its effects on CACs directly rather than indirectly by solely causing effects via the 
lungs (74).  Although there is some endogenous production of acrolein and thus some 
naturally-occurring protein-acrolein adducts, the significantly increased levels of these 
adducts in acrolein-exposed mice indicates delivery of acrolein from the lungs to systemic 
sites where it can induce adverse effects (74).  Based on these data, it may be systemic 
ROS is more important to cardiovascular-related outcomes than those found in the lungs; 
use of mice overexpressing ecSOD outside of the lungs or ecSOD knock-out mice may 
provide additional data regarding the role of ROS in the MCS-induced cardiovascular 
effects.  Additionally, the use of ecSOD-Tg mice in chronic exposures and in exposures to 
specific constituents such as aldehydes could help clarify the role of superoxide in CVD 
and other diseases related to tobacco-product use and could help also identify which 
constituent(s) is responsible for specific outcomes. 
The role of TRPA1 in the cardiovascular response to MCS and a constituent 
unsaturated aldehyde was also explored.  Male TRPA1-null mice acutely exposed to MCS 
(4d; 12 cigarettes) showed minimal systemic changes compared with air-exposed control 
mice, the most significant being a decrease in leukocytes driven by decreases in 
lymphocytes and monocytes.  However, this leukopenia was also noted in WT mice 
exposed to MCS under the same conditions, which would indicate that this effect is not 




TRPA1-null mice after MCS exposure would seem to indicate that the TRPA1 receptor is 
not serving a significant role in regard to these measures.  Additionally, although MCS-
exposed WT mice showed a significant decrease in Sca-1+ cells, neither Sca-1+ cells nor 
CACs were measured in MCS-exposed TRPA1-null mice, so the impact of this receptor 
on these cells cannot be determined from the current study. 
The lack of significant differences between WT and TRPA1-null mice exposed to 
MCS suggest that the outcomes measured in the current study are not mediated by TRPA1.  
However, other studies have clearly demonstrated the role of TRPA1 in MCS-induced 
diseases (261, 288, 479, 480), which may indicate that non-cardiovascular effects (e.g., 
pulmonary effects) are the most sensitive outcomes of MCS-exposure.  The differing data 
may also indicate that our acute (4d) exposure was not long enough to induce significant 
cardiovascular effects detectable in the measured outcomes or that 50% of the smoke from 
12 KY Reference 3R4F cigarettes was not sufficient to produce a significant 
cardiovascular-related effect.   
To test whether the effects of CR, an unsaturated aldehyde found in high levels in 
MCS (156, 159), were also mediated by TRPA1, we exposed male TRPA1-null mice to 
CR (4d; 1 ppm).  In contrast to the effects observed in CR-exposed male WT mice, TRPA1-
null mice had no systemic changes in CBC, and plasma levels of the majority of the 
measured biomarkers were unchanged between the control and CR-exposed TRPA1-null 
mice.  Cholesterol was decreased by CR exposure in the TRPA1-null mice (a change also 
observed in WT mice), although this change was due to decreased levels of LDL rather 
than by HDL as observed in WT mice.  Furthermore, although it was only modestly 
significant, TRPA1-null male mice acutely exposed to CR showed an increase in CACs, 
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whereas WT mice showed no change.  Although some of the changes seen in WT and 
TRPA1-null mice in response to CR exposure are similar, the data overall—including data 
from other outcomes measured in CR-exposed WT and TRPA1-null mice (481, 482)—
seem to indicate that the vascular responses observed in male WT mice following CR 
exposure were mediated by TRPA1 activation, although chronic studies using TRPA1-null 
mice would serve to confirm this finding. 
In summary, the studies presented in this chapter examined the roles of SOD and 
TRPA1 in the mechanism through which MCS and CR, an unsaturated aldehyde 
constituent, contribute to the development of CVD.  Although previous studies have shown 
a role of superoxide and SOD in the development of smoking-related pulmonary diseases 
and in the mechanism through which PM2.5 decreases levels of CACs, the current study did 
not demonstrate a protective effect due to overexpression of pulmonary ecSOD in the 
systemic, hematological, and endothelium-related changes related to MCS.  Chronic 
studies could help clarify whether protection conveyed by ecSOD occurs with longer 
exposure to MCS, while studies exposing ecSOD mice to 100% of the smoke generated 
from 6 or 12 cigarettes would help determine whether the lack of significant data was a 
result of levels of exposure too low to induce systemic or vascular changes.  Additionally, 
exposure to specific constituent aldehydes could help identify whether individual 
components cause cardiovascular injury that may be masked by MCS as a complete 
mixture.  Although the current study did not seem to suggest that the hematological, 
systemic, and CAC-related effects of MCS are produced through TRPA1, the current study 
of TRPA1-null mice exposed to CR does support the hypothesis that the cardiovascular 




TRPA1-null mice exposed to MCS and to CR would further strengthen these findings.   
Because of the commonality of exposure to MCS and unsaturated aldehydes from 
everyday sources and because of the risk of high-level aldehyde exposures related to 
accidents, chemical attacks, or occupational exposures, a better understanding of the 
mechanisms through which these compounds lead to CVD is necessary.  These studies 
present data on the role of SOD in MCS-induced systemic injury and present novel research 
implicating TRPA1 in the mechanism of CR-induced toxicity, strengthening the hypothesis 




SUMMARY & CONCLUSIONS 
A. Major Findings 
1. Louisville Healthy Heart Study
Circulating angiogenic cells (CACs) have been shown to be associated with 
endothelium health (62-66) as well as with well-known cardiovascular disease (CVD) risk 
factors (66, 70, 305-308).  CACs have also been associated with smoking, both with 
mainstream cigarette smoke (MCS) (315-319) and with individual MCS constituents, 
particularly acrolein (71, 74, 151).  Although the health effects of e-cigarettes (e-cigs) are 
still largely unknown, these shared constituents may contribute to adverse cardiovascular 
effects similar to those seen with the use of traditional cigarettes.  Thus, the Louisville 
Healthy Heart Study was designed to examine the effect of tobacco product use (never 
smoker, former smoker, cigarette only use, and e-cig or dual use) on hematological 
measures, measures of urinary VOC and tobacco alkaloid metabolites, and levels of CACs. 
E-cig or dual users were significantly younger than other product use categories, an 
outcome similar to other studies that have found that e-cig use is most common among 
youth and young adults, but had significantly higher levels of leukocytes.  Few studies have 




leukocytes previously seen in smokers (345, 351-355) seem to indicate that there may be a 
similar mechanism inducing this increase.  As this increase in smokers is typically 
attributed to inflammation (345, 354, 356-358), additional measures of inflammatory 
markers in the LHHS cohort could help clarify this relationship.  Analysis of urinary VOC 
metabolites showed significantly higher levels in users of tobacco products compared with 
nonsmokers.  Although there were several metabolites that were significantly higher in 
cigarette only smokers compared with e-cig or dual users—supporting other studies 
showing that the production of VOCs in e-cigs may be less than that of traditional 
cigarettes—the levels measured in e-cig or dual users were still significantly higher than 
levels in both never and former smokers, indicating that the use of e-cigs alone or in 
combination with traditional cigarette retains the potential to induce cardiovascular effects 
through increased levels of VOCs.  Analysis of CACs between the tobacco product use 
categories showed that only e-cig or dual users had levels of CACs that were significantly 
different than never smokers.  CAC-3 (CD31+/CD34+/AC133+/CD45dim), an early 
endothelial progenitor cell population was significantly increased in e-cig or dual users, 
potentially indicative of increase endothelium repair initiated by a low but persistent level 
of injury induced by e-cig use.  CAC-12 (CD45+), however, was significantly decreased 
with e-cig or dual use; more research is needed to clarify the role of the CD45 antigen in 
CACs.   
Additional studies in a larger cohort and/or in a cohort with a greater number of e-
cig only users are needed to strengthen these findings.  However, the similarity of outcomes 
seen between e-cig and dual users and users of traditional cigarettes alone seem to suggest 




subsequently contribute to the development of CVD.  As e-cig alone and dual use becomes 
more prevalent among individuals of all age groups, it is imperative to gain a better 
understand of both the acute and chronic cardiovascular effects induced by these emerging 
tobacco devices. 
2. Constituent Aldehyde Exposures and Systemic and Hematological 
Responses 
Tobacco smoking is the most significant modifiable risk factor in the development 
of CVD (1, 14, 75-77).  Exposure to mainstream cigarette smoke (MCS) and individual 
aldehyde constituents including acrolein, crotonaldehyde (CR), formaldehyde (FR), and 
acetaldehyde (AA) have been linked to negative cardiovascular health outcomes (1, 91-
94).  The cardiovascular effects of emerging tobacco products including e-cigs are still 
largely unknown, although studies have detected aldehydes in e-cig aerosols (96, 180, 207-
213); the presence of these aldehydes may indicate the potential for negative cardiovascular 
effects similar to those seen with MCS.  These studies focused on the systemic and 
hematological changes induced by inhalation exposure to MCS, e-cig aerosol, e-cig 
humectants, or constituent aldehydes (FR, AA, acrolein, and CR).   
Many of our studies of mixtures, humectants, and individual aldehydes showed 
decreases in leukocytes after acute (4d or 2 weeks) exposure.  Specifically, acute (4d) 
exposures to MCS, JUUL Mango and blu Plus+ aerosols, 30%:70% PG:VG, and acrolein 
and two weeks of exposure to formaldehyde (5 ppm) caused significant decreases in 
leukocytes, while the remaining studies showed no significant changes between the air-
exposed control and the pollutant-exposed mice.  Epidemiological studies of tobacco 




levels of leukocytes (345, 351-355), red blood cells (345, 414), and hemoglobin and 
platelets (345, 355, 411-413).  This contradiction may be related to the use of naïve mice, 
which may serve as a better model of health effects in new smokers rather than chronic 
smokers, or to our short exposure durations, which would not necessarily be comparable 
to effects seen in chronic smokers.  Nonetheless, the significance of the changes seen in 
leukocytes reveal the potential of these mixtures and constituents to promote adverse 
hematological changes that could contribute to downstream disease development. 
Systemically, mice exposed to CR (1 ppm) for 12 weeks showed significant 
increases in cholesterol and triglycerides; high levels of both of these biomarkers are 
known risk factors of ischemic (455) and coronary heart disease (456), and their increase 
in response to chronic CR (1 ppm) exposure may indicate that CR plays a role in these 
CVDs when MCS is a contributing factor.  However, levels of these biomarkers did not 
increase with acute (4d; 1 ppm) exposure, indicating that increases in lipids are not the 
primary change initiated by CR exposure. 
Our studies of individual constituent aldehydes revealed that the concentration of 
the saturated aldehyde FR needed to induce significant systemic and hematological 
changes was much higher than the concentration required to see significant changes after 
exposure to unsaturated aldehydes (5 ppm versus 1 ppm).  The carbon-carbon double bond 
in unsaturated aldehydes gives them a higher reactivity than saturated aldehydes, which 
may account for this difference.  Acrolein has been shown to be a more potent irritant than 
FR (483), and odor detection and/or irritation of CR can occur at <1 ppm in approximately 
1 minute (155).  Chronic exposures to a low level (1 ppm) of FR or AA would allow for 




versus unsaturated aldehyde exposures. 
3. Aldehyde Exposures and Circulating Angiogenic Cells 
CACs are a population of stem cells that serve to repair endothelium dysfunction 
(62, 63) and that play an important role in overall endothelial function and health (63-66).  
Levels and function of CACs have been found to be inversely correlated with risk factors 
for atherosclerosis (70) as well as an individual’s Framingham Risk Score (66).  Inhalation 
exposure to acrolein has been shown to decrease levels of CACs in both humans (71) and 
mice (74, 151), but the effect of mixtures and other constituent aldehydes on CACs are still 
relatively unexplored.  These studies focused on examining changes in CACs in response 
to inhalation exposures in mice as a marker of potential endothelium dysfunction.  Data 
from these studies revealed that only female mice acutely (4d) exposed to JUUL Mango 
aerosol and male mice exposed to FR (2 weeks; 5 ppm) showed significant decreases in 
CACs.  Measures of urinary metabolites in JUUL Mango-exposed male mice (6h) showed 
high levels of 3HPMA, the primary urinary metabolite of acrolein; as acrolein has been 
shown to decrease blood levels of CACs, it is likely that the decreased levels of CACs 
noted in JUUL Mango-exposed females is due to acrolein exposure.  Additional studies in 
male mice exposed to JUUL Mango as well as examination of levels of Sca-1+ cells, the 
stem cell population from which CACs are derived, and levels of CACs in the bone marrow 
would help further clarify the mechanism through which JUUL Mango is inducing the 
significant decrease in CACs. 
Although acute (4d) exposure to 5 ppm FR increased levels of CACs, two weeks 
of exposure to the same concentration of FR significantly decreased CACs.  The increase 




endothelium, with the subsequent decrease a sign that this compensatory effect cannot be 
sustained.  Urinary measures of formate in male mice exposed to FR alone (5 ppm, 6h) 
showed similar levels as male mice exposed to MCS (50% smoke of 12 KY 3R4F 
cigarettes, 6h).  Taken with the outcomes from our two-week FR exposure in mice, these 
data may indicate that FR is contributing at least in part to the endothelium dysfunction 
noted in chronic smokers (85).  However, in vitro studies exposing the aorta and the 
superior mesenteric artery to FR did not induce endothelial dysfunction (127), so the 
clinical relevance of these changes in CACs remains unclear.  Likewise, although acrolein 
has been linked to endothelium dysfunction in mice (150), neither acute (4d) nor chronic 
(12 weeks) exposure to CR induced significant endothelium dysfunction (481, 482), nor 
were significant changes in CACs noted in either male (1 or 3 ppm, 4d; 1 ppm, 12 weeks) 
or female (1 ppm, 4d) mice with acute exposure.  This difference may indicate that acrolein 
is more toxic to the endothelium than CR, at least at the levels tested.  Taken together, it 
appears that, at the concentrations and durations of exposure used in the current studies, 
CACs are likely not the earliest biomarker of harm affected in response to FR, AA, or CR 
exposure.  While changes in the levels of these cells may play an important role in vascular 
and cardiovascular health, these data suggest that they should not be used as the only 
indicator of cardiovascular changes induced by aldehyde exposure.  It would seem more 
appropriate that the level of CACs taken in conjunction with changes in systemic and 
hematological biomarkers as well as with measures of vascular function could denote 
exposure-related vascular changes that could indicate the potential for the development of 
CVD.  Nonetheless, more studies in both male and female mice are needed to better 




of endothelium dysfunction and to gain a better understanding of how these aldehydes 
contribute to MCS- and e-cig aerosol-induced CVD.   
4. Aldehyde Exposures and Sex Differences 
The data from our mixtures and individual aldehyde studies are largely consistent 
with data from a previous study showing that female mice exposed to a high level (250 
ppm) of acrolein had reduced morbidity and mortality compared with similarly-exposed 
male mice (269).  Our studies seem to demonstrate that females are protected against FR-
induced systemic and hematological changes as well as changes in CACs.  However, as 
most of the changes induced by FR in males occurred after two weeks, a two-week 
exposure in females at the same concentration (5 ppm) would better clarify this 
dependence.  Additionally, chronic studies in both males and females would provide an 
even greater understanding of this relationship.  Likewise, a chronic exposure of female 
mice to CR (1 ppm, 12 weeks) would allow for a greater understanding of the sex-
dependence noted between male and female mice after acute (4d) exposure to CR (1 ppm).  
Although male mice acutely exposed to CR showed minimal but significant systemic and 
hematological changes as well as a significant increase in Sca-1+ cells (1 ppm), females 
showed no significant changes in any of the measured biomarkers.  These differences seem 
to support the hypothesis that females are somewhat protected against toxicity and injury 
induced by unsaturated aldehydes. 
Several epidemiological studies seem to show outcomes consistent with this 
hypothesis as well, particularly showing that females are less sensitive to tobacco-induced 
atherosclerotic damage than males (484); this difference is likely due to the protective 




a significant role in the sex-dependent role of these aldehydes.  Female mice have been 
shown to have a higher sensitivity to pain-inducing stimuli than males, driven largely by 
levels of prolactin (485).  Prolactin has been shown to regulate expression of the TRPA1 
receptor, which serves as a pain and irritant receptor in sensory neurons (486), and Conklin 
et al. (269) have proposed that perhaps females have a greater expression of TRPA1 that 
promotes a quicker response to irritants such as unsaturated aldehydes.  In fact, females 
exposed to high-level acrolein (250 ppm) showed a quicker “respiratory braking” response 
and decrease their breathing rate quicker than male mice under the same exposure 
conditions (269).  This variance in the change in breathing rate is not seen in male and 
female TRPA1-null mice, further suggesting that the female protection is related to TRPA1 
(277).  Additional studies are needed to determine the exact mechanism of this sex-
dependent protection in response to exposure to unsaturated aldehydes as well as to 
mixtures such as MCS and e-cig aerosol. 
5. Mainstream Cigarette Smoke and Superoxide Dismutase 
The superoxide dismutase (SOD) enzyme indirectly plays a role in maintaining 
proper endothelium function by catalyzing the dismutation of superoxide.  If left as a free 
molecule in the blood, superoxide can bind with nitric oxide (NO) and decrease the 
bioavailability of NO (40, 41, 49, 50, 53); the resulting decrease of this vasodilator can 
allow for the development of endothelium dysfunction (40, 41), which has been linked to 
a number of CVDs (54-58).  SOD has also been linked to the development of cigarette 
smoke-induced pulmonary diseases (477, 478), and the administration of SOD to serve as 
an antioxidant defense against the loss of NO—and the subsequent development of 




The results of our studies in mice overexpressing pulmonary extracellular SOD 
(ecSOD-Tg) after exposure to MCS (50% of smoke of 6 or 12 KY Reference 3R4F 
cigarettes), however, do not seem to support this proposed medical intervention.  Although 
there were differences between WT and ecSOD-Tg mice exposed to cigarettes compared 
with baseline, there were no significant differences between WT and ecSOD-Tg mice 
exposed to the same number of cigarettes.  Measures of urinary metabolites did not show 
significant differences in the excretion of unsaturated aldehyde metabolites or total urinary 
nicotine metabolites between the two strains of mice, and measures of systemic and 
hematological biomarkers showed few if any significant differences between WT and 
ecSOD-Tg mice at the same level of exposure.  Likewise, CAC levels were not 
significantly different between the two strains after exposure to either 6 or 12 cigarettes.  
Chronic studies would help elucidate whether any protective effect of SOD exists but takes 
longer than four days to become apparent in the measured outcomes.  Additionally, 
exposures of ecSOD-Tg mice to individual constituent aldehydes could help explore the 
role of SOD in the mechanism of specific aldehydes. 
6. Aldehydes and the Transient Receptor Potential Ankyrin 1 Channel 
The transient receptor potential ankyrin 1 (TRPA1) channel is activated by a variety 
of air pollutants, including MCS and aldehydes (127, 260, 262, 266, 268-270).  Although 
TRPA1 is primarily recognized as a pain receptor (262, 272, 279), it also play an important 
role in the irritant response induced by inhaled toxins (262, 264, 279, 286), including 
respiratory braking (slowing rate and depth of breathing), which serves to reduce inhalation 
and thus exposure to the toxin (261, 489).  This function is supported by the delayed onset 




null mice exposed to a high level of acrolein compared with similarly-exposed WT mice 
(269).  The limited changes induced by CR in TRPA1-null mice compared with CR-
exposed WT mice seem to indicate that the systemic and hematological changes noted in 
male WT mice following CR exposure were mediated by TRPA1.  Chronic studies using 
TRPA1-null mice would serve to strengthen this finding, while a chronic study exposing 
TRPA1-null mice to acrolein under the same conditions (1 ppm; 12 weeks) would further 
confirm the hypothesis that unsaturated aldehydes induce CVD effects through the TRPA1 
channel.  Additionally, exposures of TRPA1-null mice to FR and AA would allow for the 
determination as to whether saturated aldehydes induce CVD effects through the same 
pathway.  Studies have shown that the pain responses induced by FR and AA are mediated 
through TRPA1 (490, 491) as is the FR-induced—but not the AA-induced—relaxation of 
the superior mesenteric artery (127, 492), but the mechanism through which these 
aldehydes induce cardiovascular effects has not been determined.   
B. Strengths 
There are several strengths of the human study presented in this dissertation.  First, 
although the Louisville Healthy Heart cohort was not as large as national epidemiological 
cohorts, we were still able to examine tobacco product use, urinary VOC metabolites, and 
CACs in a population of up to 143 individuals.  Many previous investigations of CVD and 
CACs (66, 70, 307, 309, 493) as well as several studies that have looked at CACs in relation 
to smoking (315, 316, 318) have utilized cohorts of less than 100 people, while only a few 
studies (311, 494, 495), including the predecessor to our study (71) have examined these 
relationships in larger cohorts.  Additionally, two-thirds of our participants report a 




worldwide, it becomes increasingly important to perform research in susceptible 
individuals to provide accurate data that can be used to inform the development of better 
cardiovascular health care practices.  Our study is also one of the first to look at the 
relationship between CACs and the use of ENDS devices, especially in fifteen antigenically 
distinct CAC populations.  Looking at the association between these populations, product 
use, and CVD allowed us to examine changes in specific cell types and subpopulations that 
may be linked to specific risk factors, as had previously been shown (73). 
There are also a number of strengths in our murine exposure studies.  The results 
of our urinary metabolite studies demonstrate that the levels of exposure used in our 
individual constituent aldehyde studies are comparable to real-world exposures, which 
validates our outcomes as cardiovascular and systemic effects that could be seen in humans 
in response to aldehyde exposures.  Our studies of CR are the first to show the systemic, 
hematological, and endothelium-related effects of CR exposure in vivo and to further show 
that these effects are both sex- and TRPA1-dependent, the latter of which may present a 
therapeutic target for treatment of aldehyde exposures.  Our studies of FR and AA are also 
some of the first to look at cardiovascular effects in response to acute exposures and again 
to suggest sex-dependent differences in outcomes. 
C. Limitations 
Despite the many strengths of our studies, there are also a number of limitations.  
Despite the size of the Louisville Healthy Heart cohort compared with other cohorts 
examining CACs, the study is still relatively small, and it would therefore be unwise to 
extrapolate the findings to the population at large, although the outcomes do present 




number of e-cig only users and dual users was small.  Other cohorts report similar 
limitations in recruiting e-cig-only users (395), and large epidemiological studies have 
reported that e-cig users are likely to be dual users (496, 497), making recruitment of e-cig 
only users more difficult.  However, if dual use is the most common form of e-cig use, 
having a dual use group in future cohort studies would allow for analysis of outcomes in a 
group most relevant to real-world e-cig use.  Of the e-cig alone and dual users in our study, 
all reported use of 1st and 2nd generation e-cigs (cigalikes and vape pens, respectively), and 
thus our findings cannot be generalized to users of 3rd (box mod) and 4th (vape pod) 
generation e-cig devices or to more recent products such as puff pods and puff bars.  The 
self-report nature of our questionnaire also presents a limitation, especially in regarding to 
self-reported smoking status.  Although questions related to tobacco use or exposure to 
secondhand smoke were carefully structured to avoid misclassification, we can only 
assume the individuals were truthful in their responses.  We can assume some level of 
confidence in self-reported smoking status based on measured of urinary cotinine, but non-
smoking individuals who are exposed to high levels of secondhand smoke could have 
relatively high levels of urinary cotinine, which could confound the outcomes. 
In regard to other measures that could play an important role in the development of 
CVD, although we have measures of body mass index (BMI) for the participants, we do 
not have measures of visceral adiposity or wait-to-hip ratios.  These alternate measures 
have been proposed as comparable if not better indicators of obesity than BMI (498), and 
several epidemiological studies have found significant associations between waist-to-hip 
ratios and cardiovascular events and/or cardiovascular-related death (499-501).  As obesity 




make obtaining these measures part of their protocol in order to provide a more 
comprehensive assessment of a participant’s CVD risk. 
There are also limitations in our murine studies.  First, mice are “involuntary 
smokers,” and they therefore decrease the rate and depth of their breathing in response to 
exposure to noxious compounds such as aldehydes (269); this reflex is known as the 
“respiratory braking response” (489).  Second, estimations of actual aldehyde exposure in 
mice was measured by urinary metabolites.  Because aldehydes metabolize quickly (99, 
100, 108, 109, 504), it is difficult to measure levels of these compounds in the blood, but 
levels of urinary metabolites have been shown to be proportional to and thus useful 
biomarkers of aldehyde exposure (147, 159).  Nonetheless, even at relevant exposure 
concentrations, our studies did not always show significant systemic or hematological 
changes.  This could be because the level of exposure was too low and/or the duration of 
the exposure was not sufficient to cause significant cardiovascular outcomes.  The duration 
of our exposure is also a limitation in that the time frame during which mice are exposed 
(6h/day) may be more concentrated than that of a typical tobacco product user.  That is, 
although the puff protocol used in our MCS and e-cig exposures are designed to mimic the 
episodic nature of tobacco product use (smoking or vaping for a brief session followed by 
a period of non-use before smoking or vaping again), tobacco product use in humans does 
not occur only within a six hour window in any given day; the longer window of exposure 
would likely allow for variations in metabolism and clearance greater than that seen in our 
urinary metabolite data and, thus, likely allow for a lower level of exposure to harmful 
constituents.  Therefore, although the effects induced in our exposed mice may indicate 




manifest in humans compared with mice when accounting for differences in daily exposure 
durations.  The aldehydes used in our studies are known to be carcinogenic, and it is 
possible that cancer would develop before the development of negative cardiovascular 
effects at the tested concentrations and durations. Additionally, CACs as a marker of 
vascular injury were not always measured due to limited blood available for analyses, so it 
is possible changes in CACs that could lead to subsequent CVD development were induced 
but not noted.  Similarly, we did not always perform the same exposures in both male and 
female mice, so we cannot necessarily speak to the sex-dependence of the measured 
outcomes when there was not a directly comparable study.   
D. Future Directions 
More research is still needed to explore the toxicity of traditional cigarettes and 
ENDS in both human cohorts and murine models.  Additional studies with focused 
recruitment of e-cig only users are needed in order to better understand the health effects 
attributable to e-cig use rather than effects potentially compounded from the use of both e-
cigs and traditional cigarettes.  These cohorts should also work to recruit users of more 
recent generations of e-cig devices (mechanical mods, variable voltage devices, JUUL and 
other pod-based devices) and other ENDS to better understand differences in health 
outcomes related to different ENDS, especially as more recent generations of these devices 
continue to grow in popularity among adolescents.  In regard to research using murine 
models, future studies could increase the concentration of the aldehydes used for exposure 
—although concentrations should be compared with those found in mixtures to ensure their 
real-world relevance—or the length of the exposure to test whether chronic exposures at 




systemic and vascular changes.   
Furthermore, despite looking at a number of different aldehydes, the actual 
constituent responsible for the toxicity of smoking has not been identified, so additional 
studies of different shared constituents as well as additional e-cig flavorings could help 
with this identification.  Combination studies should also be performed using individual 
aldehyde constituents and nicotine.  As users of tobacco products are exposed to aldehydes 
and nicotine simultaneously, and as nicotine alone has been shown to induce cardiovascular 
effects, a better understanding of how aldehydes and nicotine in combination affect our 
cardiovascular outcomes of interest is required, particularly if exposure to these 
compounds in combination could potentially induce outcomes varying from those seen 
with individual exposures.  Finally, as we used whole-body TRPA1-null mice in our MCS 
and unsaturated aldehyde studies, we cannot rule out a role of extra-pulmonary (neuronal) 
TRPA1 in these outcomes.  In fact, TRPA1 receptors are widely distributed in non-
neuronal sites, such as the urothelium, the heart, and the vasculature including the 
endothelium (127, 275-277, 280).  The exact location of the TRPA1 that is activated by 
inhaled MCS and MCS-related toxicants (and responsible for systemic effects) will need 
to be established in more specific models of TRPA1 deletion.  
E. Conclusions 
Overall, the work described here demonstrates the adverse systemic, hematological, 
and endothelium-related effects induced by exposure to traditional cigarettes and e-cigs 
and supports the hypothesis that much of the cardiovascular injury related to the use of 
these products is related to aldehydes, particularly the unsaturated aldehydes, through the 




Our human studies showed that e-cig or dual users were younger than other tobacco 
product use categories, as has been reported in previous cohort studies.  Relatedly, the e-
cig or dual users in our study had significantly less prevalence of CVD and of CVD-related 
medication usage.  E-cig or dual users also showed significantly increased levels of 
leukocytes—perhaps indicative of increased inflammation as seen in users of traditional 
cigarettes—as well as increased levels of CAC-3 (CD31+/CD34+/AC133+/CD45dim), which 
may be related to a persistent, low level of injury induced by some unique component of 
e-cigs or of combined e-cig and cigarette use.  Conversely, CAC-12 (CD45+) was 
significantly decreased in this group of users, but further study is needed to better 
understand this change.  Although e-cig or dual users had levels of some urinary VOC 
metabolites that were significantly lower than levels in users of traditional cigarettes alone, 
almost all measured VOC metabolite levels were still significantly higher in e-cig or dual 
users compared with both never and former smokers.  These data confirm that while e-cigs 
may be less harmful than traditional cigarettes in regard to VOC exposures, they still 
produce VOCs at levels capable of inducing adverse cardiovascular effects.   
Our murine studies indicate that short-term exposures to e-cig aerosols and PG:VG 
produce hematological changes similar to those seen with MCS exposure, as does two 
weeks of exposure to FR.  Similarly, chronic CR exposure shows dyslipidemic changes 
that could contribute to the development of CVD.  Short-term exposures to AA, however, 
produced limited systemic and hematological changes.  Only short-term exposure to JUUL 
Mango in females and two weeks of exposure to FR (5 ppm) causes significant decreases 
in CACs, indicating that endothelium dysfunction is likely not one of the early changes 




concentrations and durations tested.  The specificity of the change in CACs does also 
indicate the need for additional studies of specific e-cig flavors, as different flavors may 
cause different cardiovascular outcomes, and for the continued study of individual 
aldehyde constituents.  Additionally, these studies show the importance of the TRPA1 
receptor in the systemic and hematological changes induced by CR exposure as well as the 
sex-dependent nature of CR and, potentially, FR and e-cig aerosols.   
Future studies are required to better understand the role of tobacco products, 
particularly e-cigs, in the development of CVD and to continue working towards a better 
understanding of the mechanisms through which aldehydes contribute to the burden of 
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